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Polymeric Chloroquine: Modifying an Old Drug to
Make It a Little Sweeter
Abstract
Richard Sleightholm, Ph.D.
University of Nebraska Medical Center, 2019
Supervisor: David Oupický, Ph.D.

ABSTRACT. Hydroxyethyl starch (HES) is a clinically used polysaccharide colloidal plasma
volume expander. The goal of this study was to synthesize HES modified with hydroxychloroquine
(HCQ) as a novel polymeric drug with the ability to inhibit the invasive character of pancreatic
cancer (PC) cells. HES was conjugated with HCQ using a simple carbonyldiimidazole coupling to
prepare Chloroquine-modified HES (CQ-HES). CQ-HES with various degrees of HCQ substitution
were synthesized and characterized. In vitro studies showed CQ-HES to have a similar toxicity
profile as HCQ. Confocal microscopy revealed the propensity of CQ-HES to localize to lysosomes,
and mechanistic studies confirmed the ability of CQ-HES to inhibit autophagy in PC cells similar
to HCQ. Further studies demonstrated a greatly enhanced ability of CQ-HES to inhibit the invasion
of PC cells when compared with HCQ. No significant HCQ release from CQ-HES was observed,
which confirmed that the observed activity was due to the action of CQ-HES as a polymeric drug.
Pharmacokinetic (PK) studies showed that CQ-HES preferentially distributed to the liver and
kidney but had limited ability to alter distribution to tumors. Furthermore, levels observed in the
eyes were 2-4 times higher when administering HCQ than CQ-HES. In an orthotopic syngeneic
model of PC, the addition of CQ-HES to gemcitabine therapy reduced primary tumor growth and
prolonged survival. Additionally, mice who received HCQ showed significantly higher levels of
HCQ in the eyes compared to CQ-HES. Complete blood count and complete metabolic profiles did
not identify any organ or tissue dysfunctions in mice receiving CQ-HES. Further pathohistological
analysis confirmed the safety of CQ-HES as no microscopic indications of augmented tissue
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damage were observed. Lastly, pretreatment sensitization with CQ-HES improved survival in the
setting of stereotactic body radiation therapy. Thus, CQ-HES appears to be safe, improves
outcomes of radiation and chemotherapy, and reduces HCQ exposure to the eye, which may help
prevent retinopathy.
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Chapter 1: Introduction to Pancreatic Cancer, CXCR4, and
Hydroxychloroquine

Portions of the content covered in this chapter are the subject of published articles in Journal of
Biomacromolecules, Journal of Pharmacology & Therapeutics, and Journal of Chromatography B
by Sleightholm et al.1-3
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Pancreatic Cancer (PC)
Background
Pancreatic Ductal Adenocarcinoma (PDAC). Pancreatic ductal adenocarcinoma (PDAC) is a
malignancy that arises from exocrine cells of the pancreas and comprises nearly 90% of all
pancreatic cancer (PC) cases.4 Because a vast majority of PC cases are PDAC, the remainder of
this thesis work will use the terms interchangeably.
Development of PDAC stems from non-invasive, microscopic lesions within the ductal epithelium
known as pancreatic intraepithelial neoplasia (PanIN).5 These precursor lesions progress to
localized adenocarcinoma, also known as carcinoma in situ (CIS), and ultimately to invasive
PDAC.6,7 PanINs are graded based on cellular and architectural atypia using a scale of 1-3 with
PanIN-1 being low-grade and PanIN-3 considered high-grade.8,9 Many of the genetic alterations
seen in PanIN lesions are also observed in PDAC, which lends credence to the PanIN-to-PDAC
progression hypothesis.10 These genetic aberrations include mutations of KRAS, p16/CDKN2a,
TP53, and SMAD4, with the last two being specific to the higher grade PanIN-3 and PDAC. 11,12
Furthermore, many of the same alterations in protein expression profiles are observed in both PanIN
and PDAC including pepsinogen C, a variety of mucin proteins, COX-2, and S100 13-17 as well as
proteins thought to be associated with a stem cell-like state such as CD24, CD44, CXCR4,
ESA/EpCAM, and nestin.18
Although much has been done to study this phenomenon, limited data exist describing the rate,
both the frequency and speed, at which PanIN to PDAC progression occurs.13 It should also be
noted that PanIN studies are severely limited by a number of factors such as locating a microscopic
lesion, which is often an incidental finding or associated with a known malignancy,6,19 and
limitations in animal models to recapitulate this phenomenon.13,20,21
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Risk Factors of PC. There are several known risk factors associated with PC,22 which include the
following:
•
•
•

•
•
•
•
•
•
•
•
•
•

Smoking tobacco
Alcohol consumption, especially in those with excessive consumption
Genetic conditions
– Lynch Syndrome
– Familial melanoma and pancreatic cancer
– Peutz-Jeghers Syndrome
– Hereditary pancreatitis
– Hereditary breast and ovarian cancer syndrome
– Li-Fraumeni Syndrome
– Familial adenomatous polyposis
Increased age
Males
African American ethnicity
Ashkenazi Jewish heritage
Obesity
High fat diet
Hepatitis B
H. Pylori infection
Cirrhosis
Certain chemical exposures

Epidemiology of PC
PC is the third leading cause of cancer related mortalities and second most common gastrointestinal
cancer in the US.23-25 Despite continued research efforts to counter or slow this trend, the incidence
of PC is on the rise, which is in stark contrast to most other cancers, whose rates remain stable or
are declining.26 Moreover, PC overtook breast cancer in 2015 for the third highest annual death
rate,27 and it is predicted that by 2030, PC will become the second leading cause of cancer-related
mortalities.28 The American Cancer Society estimated that in 2019 there will be about 57,000 new
cases of PC with nearly 46,000 deaths, which equates to 80% of the incidence, underscoring the
average survival is dismal and less than 12 months.25 Mortality rates appear to vary regionally
within the US (Table 1.1) and greatly depend on stage (Figure 1.1).29 This high mortality can be
partially attributed to the fact that 80-90% of patients present with either locally advanced or
metastatic disease.25,29 The fact that most patients are diagnosed in late stage disease is due to
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multiple factors including:
•

The primary tumors of PC do not typically produce symptoms.

•

When the primary PDAC do produce symptoms, they are often vague and misdiagnosed
as some other ailment, which often is benign such as indigestion.

•

With our current technology, tumors are not readily identifiably with radiographic means
until they become large, >1-2 cm.

•

When significant symptoms arise, it is due to damaging other tissues from local invasion
or metastasis, which happens after the tumor has grown for some time.

5
29

Table 1.1 – Pancreatic cancer mortality rates by state. Estimated pancreatic cancer mortality
rates of each state grouped per 100,000. Data adopted from Siegel et al. (2018)29 and 2018 US Census

% Survival

information: https://www.census.gov/newsroom/press-kits/2018/pop-estimates-national-state.html

Figure 1.1 – Pancreatic cancer survival by stage. Suvival rates, 1-year to 5-year, presented for
each

staged.

Left:

Data

derived

from

NCDB

(1998-2002)

and

adopted

from:

http://www.aboutcancer.com/pancreas3.htm. Stage II and III were approximately equivalent, and
as such, they were combined into one group. Right: Data obtained from SEER (2008-2014). Both
sources describe similar survival for stage IV/distant disease as well as II/III for regional disease.
Stage I-IIA is locally confined to the pancreas, whereas IIB has spread regionally, and III
consititues either regional disease or local disease invading nearby structures. Given these
definitions, it is unclear why a stark difference exists between the data sources for early disease.
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Treatment Options for PC
Treatment for PC includes surgical excision, radiation, and chemotherapeutic approaches. Surgery
remains the only potentially curative intervention, yet only affords a modest improvement in 5-year
survival.23 Unfortunately, only 10-20% of patients qualify as surgical candidates due to the high
incidence of local invasion and metastatic spread prior to diagnosis.30,31 Thus, chemotherapeutic
approaches are the foundation for treatment of PC in a large majority of patients. FOLFIRINOX, a
combination of folinic acid (leucovorin), 5-fluorouracil, irinotecan, and oxaliplatin, has resulted in
the best improvement in PC patient outcomes to date, but the median survival still remains less
than a year, and the overall five-year survival is only 6%.32,33 In addition, the toxicity of
FOLFIRINOX can be so severe that most patients are forced to revert to a less toxic, but less
effective, nab-paclitaxel and gemcitabine regimen, which has a median survival of 8-9 months. 33
Tumor Micro Environment (TME)
Our inability to effectively treat PDAC stems in part from the atypical tumor microenvironment
(TME) found within these tumors (Figure 1.2).34 Whereas most cancers display abundant and
irregular networks of vasculature, the hypovascular nature of PDAC tumors reduces tissue
perfusion and mitigates delivery of chemotherapeutics to cancerous cells.35 Moreover, the dense
stromal composition of pancreatic tumors creates a physical barrier, rendering what little perfused
tumor tissue there is, impermeable to drug diffusion.36 Like most types of malignancies, poor drug
accumulation in tumors presents one of the biggest hurdles to developing new therapeutics, but this
is especially true for PC, where the unique TME prevents drug penetration and attainment of
therapeutic levels within pancreatic tumors (Figure 1.2).34,35
The desmoplastic reaction is a direct consequence of immune cell infiltration and subsequent
inflammation and is not unique to PC. However, the resulting desmoplasia in the TME of PC is one
of the most extensive of all cancers.37,38 In many cases, a majority of the mass of pancreatic tumors
is stroma, and nearly 50% of the cellular components can be accounted for by immune cells,
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including macrophages, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs),
which do more to protect cancer cells than harm them.39 Through paracrine signaling, tumorassociated macrophages (TAMs) increase levels of cytidine deaminease in PDAC cells and thus
promote gemcitabine resistance by enhancing its metabolism.40 Furthermore, TAMs along with
MDSCs and Tregs promote the evasion of tumor cells from the immune system. 41,42 The
desmoplastic reaction also recruits and enhances proliferation of non-cancerous components of the
stroma such as bone marrow-derived dendritic cells (BMDCs), cancer-associated fibroblasts
(CAFs), and pancreatic stellate cells (PSCs). These cells display a nurturing role through the
production of growth factors, chemokines, and other signaling molecules. In short, the body’s
attempts to wall off and manage the growing neoplasm create a unique environment that accelerates
tumor growth and counterproductively reduces our ability to treat PDAC.
The unique TME in PC is governed in part by reciprocal signaling networks between cancerous
and normal cells.43,44 Although many signaling molecules play a substantial role in tumor biology,
cytokines, specifically chemokines, are arguably among the most influential mediators in
establishing and maintaining the TME.45 Chemokines are responsible for the recruitment of
macrophages to the tumor, which subsequently inhibits CD8 T cell immune surveillance and
promotes tumor immunity.41 Chemokines also facilitate Treg46,47 and MDSC48 infiltration into
tumors, aiding in immune evasion. Furthermore, chemokines recruit bone-marrow-derived
fibroblasts to tumor sites.49 Upon maturation to PSCs and CAFs, these stromal cells stimulate
PDAC tumor growth and proliferation in a paracrine manner50,51 in addition to enhancing MDSC
activity48 and reducing CD8 T cell infiltration.52
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Figure 1.2 – Schematic depiction of pancreatic tumor microenvironment. PDAC tumor (blue) is
surrounded by dense stromal deposition as a result of stromal cells (orange) desmoplastic reaction (pink
lines). The desmoplastic barrier contributes to the hypovascular nature of PDAC tumors and poor ability
to deliver imaging and therapeutic agents to PDAC. A large cellular proportion of these tumors can be
accounting for by infiltrating immune cells (purple) that ultimately hinder immune-cell surveillance of
cancer cells and help to further promote tumor growth through various cytokine signaling.
Model of CXCR4 autocrine and paracrine signaling between stromal cells and tumor cells (Right).
CXCL12/CXCR4 axis increases proliferation and survival of PDAC cells via several mechanisms.
Through AKT and ERK activation, NFκβ, CREB, and β-catenin accumulate in the nucleus and lead to
transcription of oncologically relevant proteins. Additionally, phosphorylation of Bad causes its
dissociation from Bcl-2 allowing for blockade of the apoptotic pathway. CXCR4 activation also leads
to SHH production in PDAC cells, enhancing their own survival by: 1) autocrine activation of HH
pathway and 2) paracrine activation of stromal cells to enhance desmoplasia and prevent chemotherapy
diffusion. Gemcitabine (Gem in brown) permeates the stromal barrier and is transported into PDAC
cells, which causes cell killing but may also cause upregulation of CXCR4 via a reactive oxygen species
(ROS in white) mediated process.
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CXCL12/CXCR4 Chemokine Axis
Of the various chemokine signaling networks, the CXCL12/CXCR4 axis is one of the most
prominent chemokine moderators of the TME.53 The complex, and still not fully understood,
CXCL12/CXCR4 axis functions through both paracrine signaling with stromal cells such as PSC
and cancer cell autocrine signaling (Figure 1.2). The involvement of CXCR4 is not unique to PC
and has been documented in a wide array of cancer types (Table 1.2).54-67 Specific to PDAC, this
chemokine axis has been implicated in nearly every aspect of tumorigenesis, especially in the
invasive and metastatic properties of PDAC, in part through crosstalk with key oncogenic signaling
pathways including Akt, ERK, c-myc, β-catenin, NFκβ, and p53. This chemokine axis is also altered
in response to chemotherapy. Treatment with gemcitabine, one of the main chemotherapeutics used
for PDAC, upregulates CXCR4 expression in PDAC cells and induces chemoresistance, while
antagonism of CXCR4 re-sensitizes PDAC cells to gemcitabine.68 These findings suggest that
current treatments may be counterproductive and inadvertently promote a more aggressive
phenotype. The clinical significance of CXCR4 has been well-studied, and many patient-based
studies have correlated its expression with poorer outcomes and decreased overall survival. 69
Although more research is needed to fully elucidate the precise mechanisms of this pathway, it is
evident that the CXCL12/CXCR4 axis is playing a critical role in promoting the oncologic
processes of PC.
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Cancer Type
Leukemia and
lymphoma
Brain
Lung
Melanoma
Uveal melanoma
Prostate
Breast
Ovarian
Cervical
Oral squamous
cell
Esophageal
Thyroid
Gastric
Hepatocellular
carcinoma
Colorectal
Renal cell
carcinoma
Bladder
Osteosarcoma

Reference
Ahn et al. 2013, Elnaggar et al. 2014, Mannelli et al. 2014
Geminder et al. 2001, Russel et al. 2004, Bian et al. 2007,
Ma et al. 2008
Otsuka et al. 2011, Paratore et al. 2011, Wald et al. 2013,
Scala et al. 2005, Tucci et al. 2007, Franco et al. 2010
Li et al. 2008, Franco et al. 2010
Akashi et al. 2008, de Muga et al. 2012, Chen et al. 2015
Cabioglu et al. 2009, Okuyama et al. 2015, Mego et al.
2016
Popple et al. 2012, Sekiya et al. 2012, Li et al. 2014, Liu et
al. 2014
Kodama et al. 2007, Huang et al. 2013, Walentowicz et al.
2014
Uchida et al. 2007, Oliveira et al. 2008, Meng et al. 2010
Zhang et al. 2013, Wu et al. 2014, Lu et al. 2015
Gonzalez et al. 2009, Wang et al. 2013, Yun et al. 2014
He et al. 2013, Han et al. 2014, Thomaidis et al. 2014
Xiang et al. 2009, Hu et al. 2015, Neve Polimeno et al.
2015
Murakami et al. 2013, Silinsky et al. 2013, Li et al. 2015
An et al. 2014, Du et al. 2015, Cheng et al. 2016
Batsi et al. 2014, Li et al. 2014, Yang et al. 2015
Sand et al. 2015, Lu et al. 2015, Ren et al. 2016,

70-72

73-76

77-79

80-82

83,84

85-87

88-90

91-94

95-97

98-100

101-103

104-106

107-109

110-112

113-115

87,116,117

118-120

103,121,122

69

Table 1.2 – CXCR4 expression in human cancers. CXCR4 is one of the most ubiquitously
overexpressed chemokine receptors in cancer and has been shown to play a role in a variety of
different malignancies. See Zhao et al. meta-analysis for comprehensive cancer expression profile
of CXCR4.69
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Autophagy
Autophagy is the catabolic process of breaking down macromolecules and organelles to
conserve/recycle energy,123,124 and several lines of evidence also suggest that autophagy is just as
important in PC, from malignant transformation to growth, survival, and metastasis as the
CXCL12/CXCR4 axis.125-128 Additionally, the ability of stromal cells to perform autophagy appear
to be just as crucial in PC as the breakdown of macromolecules in stromal cells and subsequent
release into the TME are capable of fueling the cancer cells.125 However, some lines of evidence
suggest that autophagy itself may be inhibitory to cancer, or at least some cancer types, though
most literature appears support a nurturing role in the context of PC.129
CXCL12/CXCR4 Axis in PC – A Thorough Discussion
Overview of Chemokines and CXCR4
Chemokines. Chemokines are a subfamily of cytokines that contain approximately 50 different
signaling proteins. These signaling molecules are generally 8-10 kDa and are classified based on
the location of conserved cysteine residues that are crucial for proper 3-dimensional conformation:
C, CC, CXC, CX3C.41 Roughly twenty different chemokine receptors have been identified to date,
all belonging to the G-protein coupled receptor family, and named according to the respective
chemokine to which they bind.41 Similar to other cytokines, such as interferons, interleukins,
lymphokines, and tumor necrosis factors, chemokines influence cellular behavior through both
autocrine and paracrine signaling. Although chemokines participate in a wide array of functions,
their principle role is to serve as moderators of migration via a concentration gradient-dependent
manner termed chemotaxis.
Chemokines in Cancer. Chemokine systems contribute to cancer development and progression
through a number of mechanisms. For example, chemokines and their receptors modulate the
trafficking of cells into and out of the TME.41 These signaling systems recruit immunosuppressive
cells and deter infiltration of lymphocytes that possess anti-tumor activity,130-132 contributing to
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evasion of immune surveillance and reducing effectiveness of tumor immune responses. The
tumor-chemokine network also participates in angiogenesis and generation of the stroma by direct
and indirect stimulation of endothelial cells, PSCs, and CAFs. 133,134 Perhaps due in part to their
embryonic origins,135 PC cells acquire expression of chemokine receptors distinct from normal cell
counterparts enabling paracrine signaling from stromal components to enhance growth,
proliferation, and survival of the cancer cells.136
Chemokines and Metastasis. Additionally, chemokines and their respective receptors are directly
involved in the molecular control of cancer metastasis and govern organ-specific homing of
metastatic cancer cells.137 Sites of metastasis are neither random nor determined solely by the
characteristics of the cancer cells, but also by whether the microenvironment in specific organs can
support cancer cell localization and subsequent tumor proliferation.138 Corresponding chemokines
expressed in select tissues provide chemotactic signals that guide trafficking of tumor cells to
distant organ sites and provide survival signals allowing for growth after implantation.139 Although
different types of cancer have different expression profiles of chemokine receptors, the 352 amino
acid C-X-C receptor 4 (CXCR4, also known as CD184) is the most widely expressed chemokine
receptor in human cancers (Table 1.2).139
The C-X-C Receptor 4. CXCR4 plays a role in a number of different cellular processes through
interaction with its ligand CXCL12 (also known as stromal derived factor-1, SDF-1),55 though other
factors are believed to activate this receptor including: macrophage migration inhibitory factor
(MIF),140 pancreatic adenocarcinoma upregulated factor (PAUF),141 and ubiquitin.142 Very little is
known about the interactions of CXCR4 with the other ligands, but upon binding with CXCL12,
CXCR4 transduces its signal to an assortment of different pathways known to be responsible for
apoptosis, proliferation, survival, and differentiation.143-145 A concentration gradient of CXCL12
drives chemotaxis in a number of different cell types,55 and this migratory role is crucial for proper
immune system function146-148 as well as embryonic development,149 especially in that of the
pancreas.135 Binding of high mobility group box 1 (HMGB1) with CXCL12 enhances the signaling
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ability of CXCL12.150
Additionally, CXCR7 competes with CXCL12 for binding to CXCR4. Initially it was thought that
CXCR7 acted as a passive decoy receptor.151 However, further studies have shown that CXCR7
possesses an active binding function. In fact, CXCR7 homodimerizes with itself and
heterodimerizes with CXCR4 in response to CXCL12 binding to actively moderate cellular
signaling,152 although the exact purpose and interplay of CXCR7 with CXCR4 in PDAC remains
to be determined.153,154
Anomalies in the CXCL12/CXCR4 axis contribute to the pathogenesis of a variety of different
diseases including neurological, cardiovascular, angiogenic, immunologic (WHIMS syndrome),
and myeloid precursor deficiencies.155 Although CXCR4 is expressed in a variety of
malignancies,69 its exact function in cancer is still not clear. However in PDAC, the axis behaves
in a manner similar to that of normal pancreatic ductal epithelium during embryologic
development.135
The Roles of the CXCL12/CXCR4 Axis in PC Development
PanIN To PDAC Progression. Development of PDAC stems from non-invasive, microscopic
lesions within the ductal epithelium known as pancreatic intraepithelial neoplasia (PanIN). 5 These
precursor lesions progress to localized adenocarcinoma, also known as carcinoma in situ (CIS), and
ultimately to invasive PDAC.6,7. PanINs are graded based on cellular and architectural atypia using
a scale of 1-3 with PanIN-1 being low-grade and PanIN-3 considered high-grade. 9 Many of the
genetic alterations seen in PanIN lesions are also observed in PDAC, which lends credence to the
PanIN-to-PDAC progression hypothesis.10 These genetic aberrations include mutations of KRAS,
p16/CDKN2a, TP53, and SMAD4, with the last two being specific to the higher grade PanIN-3
and PDAC.11,12 Furthermore, many of the same alterations in protein expression profiles are
observed in both PanIN and PDAC including pepsinogen C, a variety of mucin proteins, COX-2,
and S10013-17 as well as proteins thought to be associated with a stem cell-like state such as CD24,

15

CD44, CXCR4, ESA/EpCAM, and nestin.18

Although much has been done to study this

phenomenon, limited data exist describing the rate, both the frequency and speed, at which PanIN
to PDAC progression occurs.13 It should also be noted that PanIN studies are severely limited by a
number of factors such as locating a microscopic lesion, which is often an incidental finding or
associated with a known malignancy,6,19 and limitations in animal models to recapitulate this
phenomenon.13,20,21
CXCR4 in PanIN Progression. PanIN progression is accompanied by alterations in chemokine
and chemokine receptor expression including CCR9156 and CCR7157; however, the
CXCL12/CXCR4 axis may be a critical component in the malignant transformation of PanIN
lesions.158 CXCR4 expression increases through PanIN progression and PDAC transformation both
in human and murine models.18,159 Increasing CXCL12 levels are also directly associated with
increasing PanIN grade.159 High expression of CXCL12 and CXCR4 receptor activation in tumors
enhance growth and restrict immune surveillance in the tumor via local autocrine and paracrine
mechanisms.160-167 Through intracellular crosstalk, this axis also promotes epithelial-mesenchymal
transition (EMT)168 and increases the invasive phenotype of PDAC cells.169 These intrusive
characteristics are augmented by the co-expression and direct enhancement of matrix
metalloproteinase (MMPs) expression.170-172 Moreover, CXCL12/CXCR4 interactions facilitate
metastatic spread to sites of high CXCL12 expression (e.g., lung, liver, bone marrow, and brain)
by providing chemotactic, survival, and proliferative signals that guide implantation and support
growth in these tissues.160-167,173-175 This is one mechanism by which the tissue at potential metastatic
sites is playing a pivotal role in the metastasis of many cancers including PDAC (Table 1.2). 176-180
The ability of neoplastic cells to invade surrounding tissues and metastasize to distant locations is
a distinguishing characteristic between malignancy and benignancy.181 Thus, the CXCL12/CXCR4
axis may be driving PanIN to PDAC transformation via a positive feedback-dependent, autocrine
mechanism.159,182
CXCR4 as a Predictor of Poor Outcomes. In regards to disease management and patient
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outcomes, high levels of CXCR4 expression correlate with poor prognosis.183 Blood vessel density
and perineural invasion are prognostic markers in PC,184 both of which correlate strongly with
CXCR4 levels.172,185 Lymph node involvement186-189 as well as distant organ metastasis189-191 are
also poor prognostic markers associated with CXCR4 expression. Furthermore, increasing levels
of CXCR4 correspond with advancing stage67,161,185,186 as well as survival in PC.67,189,191-193 Recent
evidence suggests that this axis may also play a role in delaying symptomatic presentation of PC
through reduced pain sensation, thus delaying diagnosis.194 These findings illustrate the complex
role the CXCL12/CXCR4 axis plays throughout PDAC development and progression into later
phases of malignancy as well as the clinical relevance of CXCR4 overexpression (Table 1.3).
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#

Reference Year Number
of
Patients
Koshiba 2000
52
Sato
2006
87

Study Methods

Conclusion
NC
NC

2006
2008
2008
2008
2009
2009
2009
2011
2011
2012
2012
2012
2013
2013

103
80
10
48
30
71
15
30
249
471
88
30
65
78

17
18
19
20

Wehler
Maede
Thomas
Wang Z
Fei
Marechal
Welsch
Cui
Gebauer
Bachet
Park
Zhong
Guo
Van Den
Broeck
Wang Z
Mizukami
Wang
Xu

IHC
Methylation status of
CXCR4
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC, mRNA
IHC, mRNA
mRNA

2013
2014
2014
2014

48
28
36
78

IHC
IHC
Genetic profile
IHC
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Jiang

2014

51

IHC

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Stage, mets
NC
PanIN grade
OS, stage, mets
mets
OS, mets, recurrence
NC
Stage, mets
NC
OS, mets, recurrence
NC
mets
NC
OS
OS, stage, mets
mets
mets
Stage, mets, vascular
invasion.
Perineural invasion

Table 1.3 – Overview of patient studies on CXCR4 in PC. CXCR4 has been examined in
numerous PC patient studies with a majority finding a correlation with outcomes. IHC =
Immunohistochemical analysis; NC=No Correlation observed in outcomes; OS=overall survival;
mets=lymph node or distant metastasis.
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The CXCL12/CXCR Axis Contributes to The Hallmarks of Cancer
Upon CXCL12 binding, CXCR4 transduces a signal in a classical G-protein manner, and through
crosstalk with several intracellular signaling pathways, promotes cancer cell proliferation,
migration, invasion, angiogenesis, and metastasis.143,151,195,196 In fact, CXCL12/CXCR4 impacts
several hallmarks of cancer that include sustaining proliferative signals, resisting cell death,
evading growth suppression, inducing angiogenesis, enabling replicative immortality, and
activating invasion and metastasis, thus revealing a pivotal role for CXCL12/CXCR4 in
establishing and maintaining tumors (Figure 1.3).181 Additionally, CXCL12/CXCR4 signaling
contributes to positive autocrine and paracrine feedback loops between both tumor and stromal
cells that promote protumorigenic effects increase expression of the receptor-ligand pair.
CXCR4 in Sustaining Proliferative Signaling. Sustained proliferative signaling can be achieved
via several different mechanisms 181. The CXCL12/CXCR4 axis promotes tumor cell proliferation
through direct activation of MAPK, PI3K, Wnt, and Sonic Hedgehog197 signaling pathways as well
as autocrine and paracrine signaling that coordinates tumor-stromal interactions. CXCR4 activation
promotes the expression of EGFR,198 activation of the Ras and PI3K signaling pathways that
ultimately activate ERK and Akt,66,68,182,198-200 and activation of the Wnt pathway increasing βcatenin expression and nuclear accumulation and transcription of Wnt target genes, 161,201 which
collectively promote increased cancer cell proliferation (Figure 1.3). Additionally, ERK and Akt
activation promotes the phosphorylation and degradation of Iκβ-α, which leads to the nuclear
accumulation of NFκβ and increased SHH signaling.200 SHH signaling exerts a paracrine effect on
the surrounding stromal cells to promote a desmoplastic response and induce additional CXCL12
expression and extracellular release to complete a positive pro-proliferative feedback loop.
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Figure 1.3 – CXCR4 crosstalk & the hallmarks of cancer. The CXCl12/CXCR4 axis is involved
in multiple pathways that lead to tumor development and is directly and indirectly, through
crosstalk with several key signaling cascades, involved with various molecular and cellular
processes that play a pertinent role in tumorigenesis of PDAC. CXCR4 appears to be most directly
involved with invasion and metastasis, arguably the most important of all the hallmark
characteristics of cancer.
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CXCR4 in Resisting Cell Death. Resistance to cell death pathways can occur through dysfunction
in the external apoptotic pathway or through malfunctions in the intrinsic apoptotic pathway, with
the latter mechanism contributing more to tumorigenesis. 181 182 182 182 182181 As mentioned previously,
the CXCL12/CXCR4 axis activates ERK and Akt, and in a cooperative manner, ERK and Akt
promote the nuclear accumulation of β-catenin161 and NFκβ,200 which lead to the expression of prosurvival proteins.177 Similarly, Akt phosphorylates CREB at S133, which then recruits its
coactivator CBP to promote the transcription and increases expression of several target genes,
including Bcl-2.202 ERK phosphorylates Bad on S112 leading to inactivation and sequestration by
14-3-3 proteins ultimately causing its dissociation from Bcl-2. Bim is also phosphorylated by ERK,
which causes its dissociation from other anti-apoptotic proteins including Bcl-2 and Mcl-1. This
frees Bcl-2 and Mcl-1 to bind Bax and inhibit its pro-apoptotic effects.203 Additionally, the
Raf/MEK/ERK and Akt pathways have been shown to be significantly intertwined with p53
signaling; however, the results of these interactions are variable and highly tissue and context
specific suggesting the CXCL12/CXCR4 signaling in certain situations may exploit these
interactions to avoid cell death.203
CXCR4 in Evading Growth Suppression. Evading growth suppression is another hallmark of
cancer that involves cell cycle regulation, which is most commonly regulated through the Rb or
p53 pathways.181 Wildtype p53 expression, but not the dominant negative mutant (V143A) or
commonly occurring cancer mutants (R175H or R280K), suppresses CXCR4 expression due to
p53 binding and transcriptional repression via a GFI-1 binding site in the proximal enhancer region
of the CXCR4 gene.204,205 P53 rescue drugs (PRIMA-1, CP-31398) restore this suppression of
CXCR4 transcription in cells with mutant p53. This suggests that in cancer, which is commonly
characterized by loss of functional p53, this suppression is lost and is one mechanism by which
CXCR4 is upregulated. However, the potential for feedback inhibition exists as activated CXCR4
has been shown to activate p53 in neurons.206 Conversely, the CXCL12/CXCR4 axis promotes the
expression of pro-survival proteins MDM-2 and NFκβ through Akt activation.207 Specifically,
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MDM-2 phosphorylation of p53 directly leads to its degradation through ubiquitin-dependent
proteolysis. However, the relationship between p53 and the CXCL12/CXCR4 axis is complex and
convoluted, and the complete mechanisms controlling these relationships have not been fully
elucidated.
CXCR4 in Angiogenesis. Substantial and rapid neoangiogenesis within tumors results in the
development of abnormal and atypical blood vasculature. Hanahan and Weinberg’s descriptive
portrayal characterizes the anomalous nature of tumor vasculature as possessing “precocious
capillary sprouting, convoluted and excessive vessel branching, distorted and enlarged vessels,
erratic blood flow, micro-hemorrhaging, leakiness, and abnormal levels of endothelial cell
proliferation and apoptosis.”181 The induction of angiogenesis to provide tumors with additional
access to nutrients can be initiated and advanced via increased vascular endothelial growth factor
(VEGF) production and signaling or through the presence of proteases, notably MMP-9, which are
capable of releasing and activating VEGF that has been sequestered in the extracellular matrix. 208
In response to hypoxia, HIF-1α promotes the expression of CXCR4,209 and through increased ERK
and Akt signaling, the CXCL12/CXCR4 axis not only enhances production of VEGF, but also
matrix metalloproteases, which synergistically promote angiogenesis.66,169,182,198,210,211 Additionally,
in an ERK-dependent manner, CXCL12/CXCR4 signaling increased endothelial cell migration and
capillary tube formation.66 The effects of CXCL12/CXCR4 on angiogenesis have been seen in a
subcutaneous gastrointestinal tumor mouse model, where CXCR4 inhibition reduced intratumor
CD31+ capillaries, blood flow, and tumor growth in vivo.210,212
Although angiogenesis is a hallmark of cancer, PDAC seems to be an exception, despite studies
demonstrating the increase in vascular-promoting factors in response to CXCR4 stimulation. 66,198
In fact, extensive desmoplasia and prominent stromal contributions to the tumor with little-to-no
vascularity are common traits of PDAC. These traits arise in part from positive feedback of
autocrine and paracrine signaling through several mechanisms, including CXCL12/CXCR4, which
in turn promote a desmoplastic response. Specifically, stromal-derived CXCL12 activates CXCR4

22

in PDAC cells. This leads to increased expression of Smoothened, Gli1, EMT markers (increasing
vimentin and decreasing E-cadherin),168 and CXCR4.49,213 Additionally, CXCR4 activation
promotes the production and release of SHH to potentiate paracrine signaling interactions with
stromal cells.168,200 The secretion of SHH activates PSCs, which increases the desmoplastic
response and promotes additional secretion of CXCL12.200 This CXCR4 and SHH interaction
contributes to extensive stromal deposition and creates a physical barrier that may explain the lack
of vasculature in PDAC tumors even with the increased expression of VEGF.
CXCR4 in Replicative Immortality. Through the cross-talk between CXCR4 and SHH discussed
above, there exists a potential role for CXCR4 in promoting replicative immortality in cancer cells.
As discussed previously, CXCR4 can induce SHH signaling, and SHH signaling is known to
promote human telomerase reverse transcriptase (hTERT) expression.214 Thus, CXCR4 may
indirectly modulate telomerase activity and help foster replicative immortality; however, this
association is purely theoretical at this point. To demonstrate this relationship in vitro would be
difficult and require cells that are not already immortalized using hTERT.
CXCR4 in Invasion and Metastasis. Multiple genetic sequencing studies investigating clonal
progression in cancer suggest that invasion and metastasis are the last hallmark to be acquired by
many but not all215 tumor types, including PDAC.216,217 This attribute remains the definitive trait to
distinguish benign versus malignant neoplasms, and arises from a multitude of different
mechanisms.181 The CXCL12/CXCR4 axis promotes chemotaxis and invasion in normal cells, and
substantial evidence has demonstrated that this axis is a key component promoting cellular invasion
and the development of cancer metastasis in cellular and animal models, and patient-based
studies.151,183 First, increased signaling through the SHH signaling pathway, as a direct consequence
of CXCL12/CXCR4 activation, has been associated with EMT, loss of cell adhesion, and increased
cancer progression and metastasis.168,200,205 Wnt signaling has also been shown to promote EMT
through increased expression of Wnt targets, vimentin and slug.161 Further, CXCL12 induces shape
changes in pancreatic cancer cells that are consistent with those of migrating cells and increases
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cell migration in vitro.66 CXCL12 also increases the expression of MMP-2, MMP-9, and uPA,
which contributes to an increase in cell invasion.168,169,211 The evidence supporting the role of
CXCL12/CXCR4 in invasion and metastasis is substantial. To date, at least 60 publications have
described this association in PC, and of the accumulated knowledge, the facilitation of invasion
and metastasis appears to be the feature integrally associated with the CXCL12/CXCR4 axis.
The CXCL12/CXCR Axis in Cancer Stem Cells

Cancer stem cells (CSCs), also known as cancer initiating cells, represent a biologically
distinct population of cells identified in an increasing number of cancer types, including
PDAC.218-220 Cancer stem cells are capable of self-renewal and differentation into any cell
type in the tumor population to continuously drive the expansion of malignant cells. 221-223
In PDAC, two different stem cell populations have been described: CD44 +CD24+EpCAM+
224

and CD133+CXCR4+.176 Although the former was highly tumorigenic and formed

tumors with very few transplanted cells in xenograft mice models, the CD133 +CXCR4+
subpopulation was found to be the migrating CSCs contributing to the invasive and
metastatic profile of PDAC.163 Although CD133+ cells produced tumors, CXCR4 coexpression was essential for producing metastasis. 176 Pancreatic progenitor cells also
express CXCR4 during embryogenesis, which is crucial for survival and proliferation. 225
Reversion of ductal epithelium during carcinogenesis to a dedifferentiated state with more
of a stem cell-like phenotype may permit re-expression of CXCR4 and promote cancer cell
survival in addition to increasing the invasive and metastatic traits associated with
increased CXCR4 activity.
CSCs are highly resistant to chemotherapeutics and often trigger disease relapse following
treatment of PC.190,223,226 Stem-like PDAC cells with high self-renewing capacity,
chemotherapeutic resistance, and metastatic potential express high levels of
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CXCR4.198,227,228 Thus these CSCs represent a small subpopulation of PC cells that are a
desirable target for novel therapies. However, there remains a great deal of complexity and
controversy over these unique PDAC cell populations. 163
The CXCL12/CXCR4 Axis Promotes Chemoresistance
CXCR4-mediated Chemoresistance in PC Cells. Much of the difficulty in treating PDAC arises
from the highly chemoresistant nature of PDAC that is a result of the complex TME and survivalsustaining crosstalk between normal and cancerous cells. Stromal cells within the TME secrete
CXCL12200 activating CXCR4 on PDAC cells to induce a highly drug resistant phenotype via
crosstalk with several well-known pathways of survival, proliferation, tumorigenesis, and EMT. 229.
Through downstream activation of β-catenin and NFκβ, CXCR4 mediates transcription of prosurvival and anti-apoptotic proteins including survivin, Bcl-2, Bcl-xL, Notch1, which confers
resistance to gemcitabine treatment, one of the main therapies for PC.229 Activation of CXCR4 also
leads to the expression of SHH. In an autocrine fashion, SHH promotes EMT and a more stem
cell-like state of PDAC cells, thus further enhancing the anti-apoptotic, proliferative, and
chemoresistant signature of the tumor.200 In a paracrine manner, secreted SHH also modifies the
behavior of PSCs in the stroma that also acts as a positive feedback system to bolster tumor growth.
CXCL12/CXCR4 Axis Remodeling of TME Promotes Chemoresistance. Not only does the
TME produce anti-apoptotic and pro-survival signals that contribute to drug resistance, but the
physical organization of the tumor itself also presents a problem for drug delivery. CXCR4-induced
expression of SHH stimulates stromal deposition.200 This paracrine SHH signaling also enhances
CXCL12 production from PSCs that assist in further recruitment of fibroblasts and could explain
why the stromal component of the tumor becomes so disproportionate. Moreover, the large stromato-vasculature ratio creates a poorly perfused environment within PDAC tumors,35 which in turn
further reduces levels of drugs delivered into PDAC tumors because of the physical desmoplastic
barrier .36
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CXCR4 Recruitment of Immune Cells Further Enhances Chemoresistance. To complicate
matters further, the CXCL12/CXCR4 axis interacts with other cytokine pathways to establish both
autocrine and paracrine signaling mechanisms that enhance chemoresistance. CXCL12 stimulation
augments IL-6 production and secretion via Akt and ERK pathways. The resulting IL-6 autocrine
signaling reinforces resistance to gemcitabine.230 Indirect recruitment of tumor associated
macrophage (TAMs) via CXCL12-induced IL-6 production leads to an upregulation of cytidine
deaminase in PDAC cells, which enhances gemcitabine metabolism.40 Recruitment and activation
of mast cells to pancreatic tumors occurs in a CXCR4 dependent manner.166 Once integrated into
the tumor network, activated mast cells release IL-13 that activate PSCs and further stimulate
PDAC growth and survival. In other cancers, infiltrating immune cells have also been shown to
promote IFNγ-mediated CXCR4 surface expression.231 This leads to the possibility of a positive
feedback loop where CXCR4 activation promotes immune cell recruitment and activation, which
can then in turn increase CXCR4 activation. Although these are just three examples, they clearly
illustrate the contributions of the CXCL12/CXCR4 axis to the complex network of cytokine
signaling within tumors that drive chemoresistance.
Chemotherapy Effects And The CXCL12/CXCR4 Axis. Intriguingly, gemcitabine enhances
CXCL12/CXCR4 signaling, which inadvertently promotes a more chemoresistant phenotype in
PDAC tumors. Administration of this nucleoside analog increases the levels of reactive oxygen
species (ROS) in PDAC cells, which causes activation of the Akt and ERK pathways. The
combined effect of these pathways lead to the nuclear accumulation of NFκβ and HIF-1α, and upon
direct binding to the promoter region of the CXCR4 gene, these transcription factors promote the
expression of CXCR4 68. These findings illustrate the potential concern with gemcitabine-based
therapies and suggest that our current treatment regimens may be contributing to the chemoresistant
nature of PDAC on a cellular level through the CXCL12/CXCR4 axis.
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Therapeutic Targeting of The CXCL12/CXCR4 Axis in PC
CXCR4 overexpression is associated with poor overall prognosis (Table 1.3). Treatment options
such as gemcitabine that increase CXCR4 expression may unintentionally enhance the aggressive
and metastatic potential of PDAC tumors.68,175,229,232 In particular, treatments that promote a more
hypoxic environment increase CXCR4 expression through HIF-1α activation.233-235 Current
evidence supports the potential of improving chemotherapy and radiotherapy through combination
therapies with CXCR4 antagonists.229,233,236-238 Animal models of PC show that CXCR4 antagonists
inhibit macrophage infiltration, reduce tumor growth, induce apoptosis, and suppress metastatic
spread.65,159,173,210,213,239
AMD3100 in PC. AMD3100 (Plerixafor), the first CXCR4 antagonist, received FDA approval in
2008 for mobilization of hematopoietic stem cells in bone marrow transplantation procedures. 240
However, as early as 2004 Marchesi et al. recognized that the administration of AMD3100 could
abrogate an autocrine stimulatory loop and decrease proliferation of PC cells.144 Gao et al. later
went on to demonstrate that PSCs producing CXCL12 stimulate proliferation and migration of
cancer cells and that the treatment with AMD3100 abolished this effect. Later studies with
combination therapies showed chemosensitization of PDAC cells via AMD3100 antagonism of
CXCR4.229 The activation of the CXCL12/CXCR4 axis confers resistance to gemcitabine via Fak,
ERK, and Akt-mediated increases in survival proteins, and the nullification of these signaling
pathways demonstrate the benefits of co-administrating a CXCR4 antagonist like AMD3100 with
convention chemotherapeutics such as gemcitabine.
Feig et al. extended this concept to include immunotherapeutic antibodies241 and demonstrated that
co-administration of AMD3100 with α-CTLA-4 and α-PD-L1 eliminated stromal-cancer cell
interactions and allowed for enhanced T cell infiltration into the tumor and a greater anticancer
response. Similarly, AMD3100 displayed the ability to reduce tumor burden and increase survival
by modulating another component of the immune niche in PDAC tumor microenvironment, mast
cell infiltration.166 This may be of added benefit as IL-13 release from mast cells enhances
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proliferation of PSCs that support and cultivate the growth of PDAC cells. It should be noted
though, that AMD3100 administration may impact muscle atrophy in the setting of cachexia,
although more studies are needed to validate these findings.242 Alternatively, chloroquine, an
aminoquinoline used in the management of autoimmune disease, was shown to possess CXCR4
antagonistic properties.239 Although it possesses inhibitory properties for autophagy as well,
combination therapy with chloroquine demonstrated enhanced sensitivity towards gemcitabine
treatment through CXCR4 antagonism and reduction of the stromal-cancer cell paracrine HH
signaling.238
Novel CXCR4 Therapeutics. Many researchers have investigated novel ways to target cancers
expressing CXCR4: neutralizing antibody immunotherapy in colorectal cancer,243 copolymer drug
incorporating BKT140, a small molecule inhibitor for targeting prostate cancer,244 polymeric
AMD3100 nanoparticles for siRNA delivery in melanoma,245 LFC131 peptide inhibitor conjugated
PGLA nanoparticles for drug delivery in lung cancer,246 and HPMA block copolymer of
hydroxychloroquine for reducing lung metastasis in breast cancer.247 The translational significance
has been recognized, and a few clinical trials have been started to investigate CXCR4 as a drug
target including a trial for pancreatic cancer imaging using a copper-64 chelated AMD3100 and
another for safety testing of AMD3100 in advanced pancreatic, ovarian, and colorectal cancer.
Additionally, there have been numerous early phase trials with suspected CXCR4 inhibitor
chloroquine,248-254 but the effects of this drug extend beyond CXCR4 antagonism and include
inhibition of autophagy and cholesterol biosynthesis.255,256 Despite the evidence that CXCR4 is a
valuable therapeutic target for the treatment of cancer, there have been no new inhibitors approved
by the FDA since 2008 and aside from the few combination therapies mentioned above, no further
studies have investigated the therapeutic targeting of CXCR4 in PC.
Potential Alternative Strategies for Targeting CXCR4. The CXCL12/CXCR4 axis is modulated
directly and indirectly by several mechanisms, which may serve as potential alternative strategies
for abrogating the pro-cancerous effects of CXCR4 signaling. For example, CXCL14 has been
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shown to be a natural antagonist of the CXCR4 receptor.257 Systemic administration of CXCL14,
a peptidomimetic, or a synthetic derivative could have potential anti-cancer benefits. However, the
antagonistic properties of CXCL14 towards CXCR4 are not universal over all cell types, 258 and it
has been debated whether these antagonistic properties arise from direct antagonism of the receptor
or an alternative mechanism.259 Another modifier of the CXCL12/CXCR4 axis, HMGB1 binds to
CXCL12 and enhances CXCR4 activation.150 Therapies directed towards inactivating HMGB1 or
creating derivatives that retain the heterodimerizing function with CXCL12 but lack interaction
with CXCR4 could serve to minimize CXCR4 activation and thus produce anti-cancer effects.
Although these mechanisms comprise viable alternative strategies for mitigating CXCL12/CXCR4
signaling, they remain unexplored in the setting of PDAC.
Autophagy in PC – A Thorough Discussion
Autophagy, Greek for “self eating” or “eating of self”, is a process normal, healthy cells employ to
breakdown dysfunctional or unnecessary intracellular macromolecules and organelles. It is
currently believed that the two main roles of autophagy are to: 1) conserve/recycle energy in the
event of nutrient starvation AND 2) destroy and recycle the components of damaged organelles
and proteins as a preventative means to reduce further damage/erroneous processes.260 Though
three different forms of autophagy exist (macroautophagy, microautophagy, and chaperonemediated autophagy), macroautophagy is the most well-characterized, compromises the majority
of autophagy, and is simply referred to as autophagy out of convention.261 The remainder of this
thesis will discuss macroautophagy and use the term autophagy for simplicity. Like most biological
processes, autophagy is quite complex but can be thought of as the sequence of three individual
tasks: 1) recognizing cellular components to be degraded; 2) forming a double membrane around
said components, autophagosome; AND 3) merging autophagosomes with lysosomes to form the
autophagolysosomes, wherein the components become degraded by enzymes that were present in
the lysosomes.260
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Autophagy in The Development of PC
Autophagy may be important for development of mutated KRAS-driven PDAC tumors, 262,263 which
comprised 60-90% of PDAC cases.264-266 Genomic studies of PC patient samples demonstrated an
association of poor outcome to autophagy.267 Further, mouse studies showing loss of ATG proteins
halted PanIN to PDAC progression,268 and use of chloroquine to inhibit autophagy prolonged
survival in xenograft models of PDAC.126
Autophagy in The TME
Because the stroma and TME play such an impactful role in tumor progression of PC, many have
sought to understand the role that autophagy plays in the stromal cells.269,270 One such theory
suggests that cancer cells can induce autophagy in CAFs via paracrine signaling mechanisms. The
resulting abundance of cellular building blocks and energy molecules are extruded into the stroma
to fuel neighboring cancer cells.271 Though these initials studies were done in breast cancer models,
further studies have shown that a similar mechanism of metabolic coupling could exist in PC, 272 as
well as in a variety of other cancers.273 Of note, the work by Sousa et al. showed that alanine rather
than glutamine or glucose-derived sources were being utilized by PC cells to fuel the TCA cycle
suggesting a wide variety of carbon sources could serve as energy sources in transformed cells.
Thus, autophagy, not only in the cancer cell themselves, but also in the neighboring stromal cells
of the TME may be playing a very large role in tumorigenesis, sustained proliferation, and
ultimately local and distant spread of PC. In this regards, targeting autophagy in the tumor as a
whole, and not just cancer cells, may be a novel and potentially promising approach to treating PC.
Hydroxychloroquine (HCQ)
Background
Chloroquine (CQ) and HCQ are 4-aminoquinoline derivatives that were synthesized nearly 80
years ago as antimalarial agents. Specifically, hydroxychloroquine (HCQ) was first synthesized in
1946 as an alternative to avoid toxicities from chloroquine (CQ) in the treatment of malaria. 274 The
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4-aminoquinoline derivative quickly found a niche in the management of rheumatoid arthritis and
has remained in clinical use ever since.275 Over the years, HCQ has also shown beneficial effects
in other chronic autoimmune disorders such as lupus
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and Q-fever.277 Only a few drugs have

remained in clinical use as long as these two compounds, which is due to their favorable safety
profiles, efficacy, and powerful immune-modulating properties.275
Mechanisms of Action
The predominate effect of HCQ has long been attributed to its unique pKa and ability to inhibit
autophagy. However, recent evidence has emerged that suggests HCQ may possess multiple
mechanisms of action, several of which may have detrimental effects on cancer cell proliferation
and survival.
Autophagy Inhibition. HCQ is a weakly basic compound, but the unprotonated form of HCQ is
highly lipophilic and freely permeates cellular membranes. Once inside the acidic environment of
lysosomes, it readily protonated in these acidic vacuoles and leads to the neutralization of lysosomal
pH.275 Once protonated, the charged HCQ species can no longer freely permeate membranes and
results in accumulation in lysosomes. The overall buffering effect of HCQ prevents the fusion of
the lysosome with the autophagosome and has additional consequences on lysosomal proteins that
require acidic conditions to perform their catalytic function. The net effect is disruption of
endolysosomal trafficking and autophagy, which have been one of the main reasons for renewed
interest in these compounds as adjuncts in chemotherapy regimens.129 This has an interesting effect
of disrupting pinocytosis and receptor recycling, which may impart a global disruption of cellular
functioning.278 In the setting of PC, this inhibition of autophagy has been shown to play a pivotal
role in potentiating the effects of gemcitabine therapy and reducing stem cell activity.256 Also,
stromal cells such as CAF may be undergoing high rates of autophagy and subsequently secreting
the molecules into the stroma fueling neighboring cancer cells, a mechanism that may be occurring
due to paracrine signaling from the PC cells themselves. Thus, HCQ therapy may be beneficial in
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PC treatment in both that it is affecting cancer cells as well as stromal cells to alter the metabolic
activity of rapidly growing and dividing PC cells.125
CXCR4 Antagonism. HCQ was shown to possess CXCR4 antagonistic properties.239 Although it
possesses inhibitory properties for autophagy as well, combination therapy with chloroquine
demonstrated enhances sensitivity towards gemcitabine treatment through CXCR4 antagonism and
reduction of the stromal-cancer cell paracrine HH signaling (Figure 1.2).238
Cholesterol Biosynthesis Inhibition. As early as the 1970’s, it was recognized that HCQ could
impact cholesterol hemostasis, what was a consequence of autophagy disruption.279 Later, HCQ
was shown to impede the cholesterol biosynthesis pathway via inhibiting squalene epoxidase (AKA
squalene monooxygenase) preventing cyclization to lanosterol. 255 Regardless of the exact
mechanism, many reports of lowered lipid panels in RA patients taking CQ/HCQ have supported
the clinical relevance of this association.280-282 Through disrupting cholesterol metabolism, HCQ
was shown to synergistically improve mTOR-directed therapies, although this was performed in
bladder cancer models.283
Renewed Interest in HCQ as Adjunct Chemotherapeutic
Because autophagy was found to be critically important for cancer cell survival,284 especially
pancreatic cancer, research and clinicians alike have become re-interested in the anticancer activity
of CQ and HCQ, investigating the agents at both a preclinical and clinical level. In addition, HCQ
has been shown to sensitize cancer cells to radiation and chemotherapy. 285,286 There have been
numerous phase trials initiated and/or completed using CQ/HCQ as an adjuvant to chemotherapy
or radiation.248-254,287 However, CQ/HCQ have one of the largest volumes of distribution, and high
and/or prolonged regimens of CQ/HCQ can lead to off-target effects, which may be severe and/or
permanent such as retinopathy.275,288-290
Thus, a drug delivery system for chloroquine that could reduce the distribution to the eye and brain
while maximizing levels in the tumors could be of great utility as an adjunct therapy in many types
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of cancers. This rationale is the premise of my thesis work, which will explore the creation of a
polymeric version of HCQ in an attempt to improve the pharmacokinetic (PK) profile of HCQ
without disrupting the biological activity. The goal is to demonstrate that this altered formulation
may be beneficial in sensitizing PC to chemotherapeutics and radiation therapy, not only in vitro at
the cellular level but also in vivo, where the TME plays a substantial role in aiding growth and
proliferation of PC cells.
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Chapter 2: Synthesis and Characterization of Polymeric HCQ
(CQ-HES)

Portions of the content covered in this chapter are the subject of a published
article in Journal of Biomacromolecules by Sleightholm et al.3
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Introduction
Modified polysaccharides have shown great promise in the biomedical field.291-298 A few nonsynthetic and semi-synthetic formulations of glucans such as dextran and hydroxyethyl starch
(HES) have been used clinically for the past few decades,299,300 and their biocompatibility,
biodegradability, low immunogenicity, and ability to be readily modified by various functional
moieties make them attractive starting materials in the field of drug delivery.301-309 Modification
with hydrophobic moieties such as cholesterol or hydrophobic drugs allows for assembly of the
polysaccharides into nanoparticles that may improve the efficacy and safety of drug delivery. 310,311
For example, modifying HES with fatty acids allowed for assembly of HES micelles, 312 and
subsequently it was shown that propylating starch facilitates the assembly of large nanoparticles
for encapsulation of docetaxel.313 Using pentadecylphenol-modified dextran, Pramod et al.
synthesized a dual delivery nanovesicle of camptothecin and doxorubicin, which displayed
synergistic improvement in anticancer activity.314 Similarly, Wasiak et al. used dodecylamine to
drive assembly of a dextran-based polymeric doxorubicin-conjugate.315 Senanayake et al. showed
that modifying dextrin with both cholesterol and fluorouracil produced a polymer-drug nanogel
conjugate that demonstrated sustained drug release and improved anticancer activity. 316
In tumor delivery applications, these nanoparticle systems take advantage of the unique tumor
biology through the enhanced permeability and retention (EPR) effect and allow for improved
tumor accumulation.303-305 For most types of malignancies, poor tumor accumulation presents one
of the biggest hurdles to developing new therapeutics. This is especially true for pancreatic cancer
(PC), where the unique tumor microenvironment prevents drug penetration and attainment of
therapeutic levels within pancreatic tumors.34,35 In this sense, readily modifiable and biocompatible,
polysaccharide-based

drug

delivery

systems

can

improve

tumor

accumulation

of

chemotherapeutics without the concerns of eliciting immunogenic responses.317-319 Thus, there is
an ongoing need to develop polysaccharide-based drug delivery systems that can provide
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meaningful improvements in survival and/or reductions in systemic toxicities for patients with
difficult to treat malignancies where drug delivery or tumor accumulation is an issue.
HES is a modified polysaccharide consisting of approximately 20% amylose, a linear α-1,4-glucose
polymer, and 80% amylopectin, a branched glucose polymer with both α-1,4- and α-1,6-glycosidic
linkages. HES is prepared from natural sources like waxy maize starch by chemical modification
with ethylene oxide. The hydroxyethylation increases the solubility and reduces enzymatic
degradation of starch by serum amylases, thereby extending its plasma half-life.320 This increase in
biostability is dependent on the average substitution per anhydroglucose unit (AGU) as well as the
ratio between C2 and C6 substitution.321 Optimization of these substitutions has resulted in
sufficiently prolonged plasma half-lives that have allowed for translation of HES into the clinical
setting as a colloidal blood volume expander.301 Multiple HES formulations are available
commercially that differ in their molecular weight and degree of hydroxyethylation.
HES lacks any known drug interactions, shows very low rates of hypersensitivity, and has very few
known side effects.301,302 These favorable properties make HES an attractive alternative to nondegradable polymers like polyethylene glycol (PEG) in the design of drug delivery systems.
Modifying HES with hydrophobic moieties allows for assembly into nanoparticles that are capable
of drug encapsulation and delivery.312,322,323 Using a hydrophobic drug to drive the assembly of
polysaccharides and to enable encapsulation of another drug for combination therapy is an
underappreciated approach to designing drug delivery systems.
Herein, we explore this concept by proposing to use hydroxychloroquine (HCQ) as an HES
modifier to create a polysaccharide delivery system with therapeutic benefits imparted by the
known biological activity of HCQ described in Chapter 1 of this thesis. The weak electrolyte nature
of HCQ may also allow for pH-controlled assembly of polymers modified with HCQ, while also
providing the therapeutic benefits associated with autophagy inhibition. Multiple cancers, including
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PC, exhibit a strong dependence upon autophagy for growth and proliferation. 126,256 Thus, this work
centers upon creating a biologically active polymeric version of HCQ that through the EPR effect
and multivalency effect augment the biological activity of HCQ. Thus, this work extends the use
of HCQ to polysaccharide modification by presenting the synthesis of HCQ-modified HES (CQHES), which displays significant inhibition of autophagy in PC cells and demonstrates a new use
for the well-established and safe drug HCQ as an assembling moiety in drug delivery systems.
Materials & Methods
Materials. HES (200 kDa, degree of substation 0.5) was purchased from Serumwerk Bernburg,
Germany. Hydroxychloroquine (HCQ) sulfate was purchased from Sigma Aldrich. All other
reagents, chemicals, and materials were obtained from Fisher Scientific.
Synthesis of CQ-HES. HCQ sulfate was first converted to its free base form. The HCQ sulfate salt
(6 g, 13.8 mmol) was dissolved in 10 mL of deionized water. While stirring, a 30% NH4OH aqueous
solution (5 mL, 38.2 mmol) was added dropwise to precipitate the free base HCQ, which was then
isolated by extraction with 20 mL dichloromethane (DCM). The organic layer was dried with
anhydrous Na2SO4 and the solvent was evaporated to produce HCQ as a colorless viscous
solid. The synthesis of CQ-HES was performed using CDI coupling with slight alterations to a
previously described method.324 Under nitrogen atmosphere, 389 mg (2.4 mmol) of carbonyl
diimidazole (CDI) was added to a dry Schlenk tube, and 3 mL of dry dimethylformamide (DMF) was then transferred to the tube via syringe to dissolve the CDI. In a separate
dried vessel, HCQ free base (200 mg, 0.6 mmol) was dissolved in 1 mL of dry DMF and transferred
via syringe to the stirring CDI solution. The reaction mixture was stirred for 4 h at room
temperature, and HCQ activation was monitored by thin layer chromatography (TLC) (1:1 DCM:
ethyl acetate). Once complete, the solution was diluted with 5 mL DCM, and 2 mL of water was
added to quench any unreacted CDI. The activated HCQ was extracted to DCM (20 mL), washed
with water (10 mL x 2) then brine, and dried over Na2SO4. DCM removal in a rotary evaporator
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produced 220 mg (75%) of activated HCQ (HCQ-CI) as a colorless solid. 1H NMR (499 MHz,
Chloroform-d) δ 8.43 (d, J = 5.8 Hz, 1H), 8.14 (d, J = 1.1 Hz, 1H), 8.08 – 7.94 (m, 3H), 7.41 (t, J
= 1.4 Hz, 1H), 7.35 (dd, J = 9.0, 2.2 Hz, 1H), 7.09 – 7.02 (m, 1H), 6.45 (d, J = 5.9 Hz, 1H), 4.47
(t, J = 6.0 Hz, 2H), 3.76 (p, J = 6.6 Hz, 1H), 2.85 (t, J = 6.0 Hz, 2H), 2.64 – 2.51 (m, 4H), 1.80
(ddd, J = 16.2, 9.8, 6.6 Hz, 1H), 1.72 – 1.54 (m, 4H), 1.36 (d, J = 6.4 Hz, 3H), 1.04 (t, J = 7.1 Hz,
3H).
HES (300 mg, 1.8 mmol glucose units) was dried for 2 h at 105°C in a dried Schlenk tube. Then, 3
mL of DMF was added to the Schlenk tube under nitrogen atmosphere, and the mixture was heated
to 60oC while stirring to dissolve the HES, followed by addition of various amount of HCQ-CI
intermediate (see Table 2.1) in 2 mL of DMF. The resulting solution was stirred at room
temperature for 4 days. The CQ-HES product was collected by precipitation with 500mL of acetone
and further purified by dissolving in DMF and precipitated two more times to give the final
product. NMR and elemental analysis were used to calculate degree of HES substitution with HCQ.
1

H NMR (499 MHz, D2O) δ 8.68 (d, J = 6.2 Hz, 1H), 8.40 (d, J = 9.1 Hz, 1H), 8.16 (d, J = 2.2 Hz,

1H), 7.02 (d, J = 6.3 Hz, 1H), 5.83 (d, J = 123.5 Hz, 5H), 4.51 – 3.71 (m, 35H), 3.55 – 3.37 (m,
5H), 2.59 – 2.48 (m, 1H), 2.10 (d, J = 6.9 Hz, 4H), 1.68 (d, J = 6.5 Hz, 3H), 1.51 (td, J = 7.4, 2.4
Hz, 3H). All NMR spectra can be found in the supporting information (Figures 2S1-2S3).
Fluorescently labelled CQ-HES (fCQ-HES) was synthesized by using CQ-HES20 produced by the
above procedure. Fluorescein (665 mg, 2 mmol) and CDI (389 mg, 2.4 mmol) were dissolved in
DMF (4 mL) and stirred for 4 h at room temperature. TLC showed the formation of the intermediate
and the unreacted fluorescein. Water (10 mL) was added to terminate the reaction after the mixture
was stirred for 4 h. The fluorescein intermediate was extracted by DCM (50 mL) and washed by
brine (10 mL). After evaporation, the intermediate (560 mg, 66 %) was obtained and used for the
next step without further purification. To conjugate fluorescein to CQ-HES20, conditions were
maintained in a similar fashion as described above with a few exceptions. CQ-HES20 was used
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instead of HES and was dried under vacuum for 3 days at room temperature. A ratio of 1:100
fluorescein-CI:AGU was used for the second step of the reaction, and the final fCQ-HES product
was precipitate with methanol instead of acetone.
Polymer analysis. 1H NMR spectroscopy was performed using the Bruker Avance-III HD 500
MHz NMR;

13

C NMR spectroscopy was performed using the Bruker Avance-III HD 600 MHz

NMR unless otherwise specified. Data was analyzed with Bruker TopSpin software
(v3.5pl7). Approximately 10 mg samples were dissolved into 700 µL of either CDCl 3 for HCQ and
HCQ-CI or d6-DMSO for HCQ, HES, and CQ-HES unless otherwise specified. All CQ-HES were
analyzed for carbon, nitrogen, hydrogen, and chlorine content using elemental analysis (Atlantic
Micro Labs, Atlanta, Georgia). The molecular weight of CQ-HES was determined by gel
permeation chromatography (GPC). The Agilent 1260 Infinity LC system was operated at a flow
rate of 0.5 mL/min using a 0.1 M sodium acetate buffer (pH 5.0) with a TSKgel G3000PWXL-CP
column (Part No. 0021873, Tosoh Bioscience LLC, King of Prussia, PA), miniDAWN TREOS
multi-angle light scattering (MALS) detector, and an Optilab T-rEX refractive index detector from
Wyatt Technology (Santa Barbara, CA). Data was analyzed using Astra 6.1 software. HPLC was
used to assess the presence of unreacted HCQ or HCQ-CI in CQ-HES. The polymers were
dissolved in acetate buffer (pH 5.0) at 5 mg/mL, the solutions were then filtered with 0.2 μm filter
and analyzed on an Eclipse Plus C18 column (5 µm, 4.6×150mm) at a flow rate of 1 mL/min using
a gradient mobile phase composed of 5-95% gradient of acetonitrile (0.01% trifluoroacetic acid)
and HPLC grade water with 0.01% trifluoroacetic acid.
Hydrolytic stability of CQ-HES. CQ-HES solutions were prepared by slowly adding 200 µL of
stock CQ-HES (50 mg/mL in DMSO) to a 2 mL stirring solution of 0.01 N HCl, water, PBS, or
acetate buffer (pH 5.0) producing a final concentration of 5 mg/mL. A 200 µL aliquot was sampled
at the following time points: 0, 24, 48, 72, and 168 hours. CQ-HES of similar concentrations were
subjected to acid hydrolysis, 1 N HCl at 100ºC for 4 hours, and subsequently neutralized with equal
parts 1 N NaOH.325 Samples were filtered with 0.2 micron filters and analyzed for free HCQ content
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using HPLC and polymer size using GPC.
Physical Size Analysis - Dynamic Light Scattering (DLS). CQ-HES solutions were prepared by
slowly adding 200 µL of stock CQ-HES (50 mg/mL in DMSO) to a 2 mL stirring solution of water,
PBS, or acetate buffer (pH 5.0) producing a final concentration of 5 mg/mL. After preparation,
solutions were then subjected to dialysis (Thermo Scientific, 3,500 MWCO snakeskin dialysis
tubing) for 24 hours using the same solutions they were initially diluted in as dialysis media (water,
PBS, or acetate buffer respectively). The solutions were analyzed on a Zetasizer Nano ZS (Malvern
Instruments Ltd., UK) using a 633 nm laser at 25ºC. All samples were analyzed using the
backscattering angle of 173º. Overall average particle size, distribution, and polydispersity indexes
were obtained using the manufacturer provided DTS software.
Physical Size Analysis - Atomic force microscopy (AFM). AFM samples were prepared as
described in the previous sections and diluted 500-fold in the respective media (10 µg/mL). A
droplet of each sample (5-10 μL) was immediately deposited on freshly cut mica for total
incubation time of 2 min. Samples were rinsed carefully with water and dried under a flow of argon.
AFM images in air were acquired using MultiMode AFM NanoScope IV system (Bruker
Instruments, Santa Barbara, CA) operating in tapping mode with 1.5 Hz scanning rate. TESPA
probes from Bruker were used for tapping mode imaging. The probes had a spring constant of about
40 N/m and a resonance frequency between 300 and 320 kHz. Particle sizes were analyzed using
ImageJ and plotted with GraphPad Prism 5.
Results
Synthesis and Characterization of CQ-HES
Because of the abundant hydroxyl groups, many linker chemistries can be implemented to
conjugate a drug or hydrophobic group to HES.326,327 HCQ contains a primary hydroxyl group that
is a prime target for conjugation. The secondary alkyl-aryl amine also present in the HCQ structure
is not a suitable site for conjugation due to its low reactivity and its importance for binding to the
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CXCR4 receptor.328 Although hydroxyethylation increases the stability of HES, the polysaccharide
remains susceptible to degradation in extreme pH conditions. Multiple previous reports have used
mild carbodiimide and CDI chemistries for polysaccharide modifications.322,324 Conjugation of
HCQ to HES required a linker chemistry suitable for conjugating two hydroxyls. Thus, we selected
the two-step CDI approach, which not only allowed mild conditions for conjugation of HCQ to
HES, but it also resulted in the formation of a potentially biodegradable carbonate bond. In the first
step of this procedure, the hydroxyl of HCQ was activated with CDI to produce an HCQ-CI
intermediate, which was then used in the subsequent step to react with HES to afford CQ-HES
(Figure 2.1). Adjusting the ratio of HCQ-CI with HES allowed us to control the degree of HES
substitution with HCQ (Table 2.1).

Figure 2.1 – Synthetic scheme of CQ-HES
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Table 2.1 – Physical characterization of CQ-HES.
HCQCI:AGUa

MWb

%Cl
(w/w%)c
0.25
0.94
1.35

%HCQ
(w/w%)d
2.4
8.8
12.6

HCQ:AGUe

yield, %

HES
1.480 ×105
5
1:69/ND
61.3
CQ-HES2.5
1:23
1.614 ×10
1:17/1:15
72.9
CQ-HES8.5
1:15
2.079 ×105
CQ1:11/1:17
76.6
1:9
1.627 ×106
HES12.5
CQ1.88
17.6
1:8/1:11
79.5
1:8
1.707 ×106
HES17.5
2.25
20.9
CQ-HES20
1:3.3
2.935 ×106
1:6/1:4.7
68.4
5
3.39
31.2
1:3.5/1:4.1
81.7
CQ-HES30
1:1.7
2.862 ×10
a
CQ-HES# represents a formulation of CQ-HES with approximate HCQ w% = #. ratio of HCQCI:AGU used in step 2 of synthesis (scheme 2), HCQ-CI = hydroxychloroquinecarbonylimidazole intermediate, AGU = anhydrous glucose unit. bMW = molecular weight of
CQ-HES as determined by gel permeation chromatography. c%Cl (w/w%) = weight percent of
chlorine in CQ-HES determined by elemental analysis. d%HCQ (w/w%) = weight percent
hydroxychloroquine based on elemental analysis data. eHCQ:AGU = molecular ratio of
hydroxychloroquine to anhydrous glucose unit based on elemental analysis/NMR.
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NMR analysis of CQ-HES demonstrated the presence of the characteristic aromatic signal of HCQ
at 7.5-8.5 ppm, as well as the presence of complex signal signature from the HES at 2-6 ppm (Figure
2.2). Furthermore, CQ-HES displayed the unique presence of a carbonyl group at 155 ppm with
long-range coupling solely to the protons adjacent to the former hydroxyl groups, which were found
to have shifted from 3.5 to 4.1 ppm. The remaining coupling relationships of HCQ in CQ-HES
were preserved as seen from the 1D and 2D NMR spectra and validated the proposed linkage
between the hydroxyls and no side-reactions occurring through the amine groups (Figures 2.3 and
2.4). Lastly, no starting materials or intermediate species, i.e. CDI or imidazole, were apparent in
the NMR spectra of CQ-HES. HPLC further confirmed the absence of any small molecule
impurities in the CQ-HES samples. The degree of substitution of HES and content of HCQ was
first calculated from the NMR spectra using the ratio of the anomeric C1 proton (* at 5-6 ppm) in
HES to one of the aromatic protons (** at 8.43 ppm) in HCQ (Figure 2.2). The content of HCQ
was then validated using elemental analysis (Table 2.1).
As shown in Table 2.1, by varying the HCQ:HES ratio (HCQ-CI:AGU) from ~1:20 to 1:2, we were
able to synthesize CQ-HES with HCQ content ranging from 2.4 to 32 w%. The corresponding
degree of substitution of the glucose units in HES with HCQ ranged from 1:69 to 1:3.5. Because
of the HCQ substitution, the molecular weight of CQ-HES increased with increasing degree of
HCQ substitution in the HES chain (Table 2.1).
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*

Figure 2.2 – 1H-NMR spectrum of CQ-HES. Inset shows the structure of CQ-HES. For
complete peak assignments, see following figures (Figures 2.3 and 2.4).
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Figure 2.3 – Overlapping spectra of HCQ and HCQ-intermediate at 500 Hz, 1H-NMR (top)
and 13C-NMR (bottom). Protons are assigned from most shifted, proton (A), to least shifted,
proton (Q), while carbons are labeled chronologically, C1-C18, in accordance with chemical shift.
Shifting of protons (A) and (B) illustrate activation of HCQ with carbonyl-imidazole and formation
of the intermediate species. Carbons are assigned numerically by increasing shift values. The
shifting of carbon-9, C9, and the addition on the carbonyl group (C22) further validate the
formation of the activated HCQ-intermediate. Additionally, no change in protons (E), (C), and (D)
and no changes in carbons C5, C6, and C7 demonstrate that no unwanted side reactions occurred
with the amine groups.
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Figure 2.4 – Overlapping NMR spectra of HCQ, HES, and CQ-HES: 1H-NMR (top) and
13C-NMR (bottom) spectra at 600 Hz (DMSO-d6). The ratio of H1 signals (*) to (**) allows for
approximate measurement for degree of substitution. Proton (G) becomes more shifted after
conjugation, 3.5 to 4.1 ppm, and integrating the signals show that proton (G) increase in signal
intensity from two to four protons. The symmetry of the newly formed carbonate bond results in
degenerate signals from both sets of proximal protons, one set from HCQ [protons (G)] and another
set from HES [protons (G’)], to the oxygens involved in the carbonate linker. Thus, the increase in
signal intensity occurs due to the overlay of protons (G) and (G’). Furthermore, the shifting of C9
of HCQ in the 13C-NMR of CQ-HES along with the presence of C22 carbonyl demonstrate the
effective conjugation of the carbonate linker via the hydroxyl of HCQ.
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Solubility and Particle Formation
All CQ-HES readily dissolved in DMF and DMSO up to 200 mg/mL. However, dissolving CQHES directly in water or aqueous buffers proved difficult even with extensive sonication and the
solubility was found to be dependent upon the HCQ content and pH of the solvent. In PBS, only
CQ-HES2.5 and CQ-HES8.5 (HCQ w% ~ 2.5% and 8.5%, respectively) were soluble. In water,
CQ-HES17.5 was soluble up to 5 mg/mL. In the acidic pH of the acetate buffer, the amines in HCQ
become protonated affording an increase the solubility, and as a result all CQ-HES formulations
were soluble at 5 mg/mL (see supporting information – Table S1). Solubility of CQ-HES was
further evaluated in acetate buffer, water, or PBS. Solutions prepared using CQ-HES20 and CQHES30 were initially soluble in water or PBS at 1.5 mg/mL, but aggregated and precipitated within
one hour of preparation. All other lower HCQ-containing CQ-HES remained soluble up to 20
mg/mL with no signs of aggregation or precipitation.
CQ-HES20 had high HCQ content and substantial aqueous solubility and was thus selected for
further study of its physical and biological properties. We first analyzed the hydrodynamic size of
CQ-HES by DLS. Control HES dissolved in acetate buffer, water, or PBS revealed hydrodynamic
sizes of ~20 nm. CQ-HES20 showed a slight increase in hydrodynamic size to ~30 nm in all three
solutions (see supporting information – Table 2S2). Using the empirical calculator in the Zetasizer
software, HES (200 kDa) showed a predicted size of 16-26 nm, while conservative estimates for
CQ-HES (250-300 kDa) were 17-33 nm. AFM was then used to directly visualize possible
formation of nanoparticles. In water and acetate buffer, CQ-HES20 displayed irregularly shaped
nanostructures indicative of single molecule arrangements with a few interspersed thin-film
aggregates (Figure 2.5). However, images of CQ-HES20 formulated in PBS revealed the formation
of well-defined nanoparticles. Analysis of the formed particles described a normally distributed
population with an average diameter of 15 nm (range 2-30 nm) (Figure 2.5).
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Figure 2.5 - AFM and corresponding size distribution of CQ-HES. Polymeric chloroquine
depicted is CQ-HES20 in acetate buffer (left) and PBS (right).
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Hydrolytic Stability of CQ-HES
Hydrolytic stability of the HES backbone and of the carbonate linker between HCQ and HES were
assessed. CQ-HES20 was incubated in 0.01 N HCl, acetate buffer, water, or PBS (pH 2, 5.0, 7.0,
or 7.4 respectively) for 72 h at 37ºC. No release of free HCQ or any changes in the molecular
weight of CQ-HES were observed during the experiment using HPLC and GPC, suggesting relative
stability of the carbonate linker. However, hydrolytic cleavage of CQ-HES20 and release of HCQ
was observed after incubation in 1 M HCl for 4 h. These pieces of evidence validate the success of
the conjugation, efficiency of the purification procedure, and the stability of CQ-HES.
Discussion
Use of CDI chemistry employs and easy and reasonably quick chemistry to conjugate HCQ and
HES via the hydroxyl groups on each compound. The result is the desired CQ-HES, which
possesses a carbonate linker to adjoin the two compounds. HCQ and CQ show a similar propensity
to inhibit autophagy. This characteristic is a result of the unique pKa’s of the compounds’
secondary and tertiary amines. In docking studies, the hydroxyl of HCQ was found not be a
significant contributor to the antagonism of CXCR4.239 Therefore, use of the hydroxyl to adjoin
HCQ with HES should result in minimal, if any, changes to the biological effects of HCQ as a
polymeric drug, an assumption that will later be validated in the subsequent chapters. The
preservation of biological activity when in the polymeric form distinguishes polymeric drug versus
a polymer-drug conjugate, which requires release of the drug from the polymer to be active. In the
event that the biological activity is disrupted in the polymeric form, either partially or completely,
CQ-HES should behave as polymer-drug conjugate at the least as the linker in CQ-HES
decomposes to produce HCQ, HES, and CO2, leaving no residual chemical modifications to either
starting compound.
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CDI chemistry was also beneficially in allowing the control of the conjugation ratio. Adjusting the
intermediate to AGU in the final step produced a reasonable control of the final CQ-HES
substitution, as described in Table 2.1. CQ-HES30% (30% wt/wt%) was the highest degree of
substitution (DOS) obtained, which corresponded to approximately 1 HCQ:4 AGU. It should be
clarified that the DOS refers to the average number of conjugated HCQ per anhydrous glucose units
in CQ-HES, while percent HCQ refers to the actual percent weight (wt/w%) of HCQ in the total
CQ-HES polymer, often denoted as CQ-HESx% for any given CQ-HES formulation with x
wt/wt%. It is acknowledged that these two terms describe two different physical traits of CQ-HES.
Because their proportionality, these terms may be used interchangeably in future proceedings for
simplicity to refer to general HCQ content in the polymer, especially when comparing two different
CQ-HES formulations. Due to solubility issues with wt/wt% above 20%, no further optimizations
were attempted to achieve a higher DOS. This chemistry also resulted in good yields, 60 – 80%.
Lastly, the reaction conditions were scaled up to gram quantities with similar yields, which allowed
for the possibility of large-scale and multiple in vivo studies. These characteristics along with the
linker properties discussed above made the CDI chemistry ideal for CQ-HES synthesis.
The carbonate linker of CQ-HES is typically stable. However, it is an ester-like bond and is subject
to acid or base hydrolysis. Thus, the stability of CQ-HES needed to be tested. Typical physiological
pH’s that CQ-HES would experience after IV injection would range from pH 5 – 8. Buffer systems
were implemented to emulate these conditions over the course of 72 hours, and there were no
observable increases in HCQ signal as demonstrated on GPC. Further use of harsher conditions
(pH 2) were also tested, which demonstrated a similar lack of release of free HCQ. HCQ elicits a
moderate signal with the fluorescent detector of the GPC system used, but overall, the sensitivity
of GPC compared to other more advanced analytical techniques is poor. So, it is not unreasonable
to assume a portion of CQ-HES decomposed to release a small, undetectable degree of HCQ.

53

However, what may have decomposed should be reasonably minute, and these studies still illustrate
the stability of CQ-HES in solutions that would be used for in vivo applications is sufficient for
solvation and storage at ambient conditions until administered to mice.
It was initially hypothesized that the carbonate linker could decompose under conditions presented
in the previous paragraph. The stability observed was promising for in vivo applications, but
ultimately, a compound that would degrade was desirable. Use of 1 M HCl revealed degradation
of CQ-HES, which resulted in significant hydrolysis at only four hours. However, there are many
conditions and enzyme systems that cannot be tested in vitro that would occur in vivo. Blood and
liver esterases, as well as many other enzymes, could act to degrade CQ-HES. Therefore, it was
reasonable to assume that, though the compound demonstrates stability in vitro, CQ-HES could
and would degrade once administered to mice.
To understand the effects of conjugating HCQ to HES on the molecular structure, both DLS and
AFM were used. DLS described a corresponding increase in hydrodynamic size of HES from ~20
nm to CQ-HES with a size of ~30 nm. These sizes are in accordance with previous reports of HESmodified compounds,312,322. Furthermore, the empirical size calculator of the Zetasizer software
estimated the size of HES, a 200 kDa polysaccharide, to be 16-26 nm depending on branching
status. Conservative calculations for CQ-HES20 of 250-300 kDa estimated a size of 17-33 nm. It
should be emphasized that these calculations describe the hydrodynamic sizes of the molecules.
Furthermore, data obtained from DLS may be misleading, and a complementary method to validate
nanoparticle formation and assess morphology should always be included.
Thus to further characterize any particle formation, AFM was used. Although HES displayed a
hydrodynamic sizes of ~20 nm via DLS, AFM failed to demonstrate any nanoparticle formation
irrespective of pH conditions (supporting information Figure 2S3). On the other hand, CQ-HES
assembled into nanoparticles in a pH-dependent manner. In acidic aqueous conditions, only
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amorphous and linear structures were observed, while 15 nm diameter particles with well-defined
spherical shapes and a narrow size distribution were observed when CQ-HES was formulated in
PBS. The well-defined nanoparticle distribution and sizes of CQ-HES defined by AFM is in
contrast to the sizes and PDI obtained from DLS. The discrepancies between DLS and AFM data
could be derived from a number of factors including the difference in hydration status for aqueous
samples used in DLS and lack thereof after drying for visualization with AFM.
Overall, these findings suggested CQ-HES possesses pH-dependent assembling properties. This is
thought to be a result of the amphiphilic nature of HCQ, and CQ-HES displayed the propensity to
assemble into nanoparticles that appeared to be driven by the content of CQ within the polymer
(the degree of substitution, DOS) in addition to the pH of the solution. The higher the DOS, the
more readily the polymer seemed to intramolecularly self-assemble, folding into finite
nanoparticles. It is also believed that intermolecular assembly/aggregation may be occurring and
competing simultaneously in CQ-HES, a relationship that is complicated by the DOS,
concentration of polymer, and solvent system being utilized. Moreover, the images described herein
were taken from optimized conditions, which were done at very low concentrations of the polymer.
At higher concentrations it stands to reason that aggregation would be an issue, one that is often
prevalent in polymer-based nanoformulations.
Moreover, how CQ-HES behaves under in vivo applications may be even more complicated as
blood and fluid within tissues possess proteins, electrolytes/ions, buffering solutes, and other
biologically relevant constituents. It is potentially impossible to predict how this polymer would
behave, whether it be as a simple macromolecule of indefinite, amorphous shape much like the
observed AFM images of HES or as finite nanoparticles. Perhaps there would be some generalized
globular shape to each molecule of CQ-HES, and in an in vivo study, the concentration would likely
be low enough that intermolecular aggregation would not occur to any significant extent. However,
these are not the rigid nanoparticles like those of gold or even stable polymer-based formulations
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people commonly reference in the field of drug delivery, and they are most likely behaving as a
“soft” nanoparticle. In conclusion, it is uncertain if these nanoparticles are stable enough to survive
in vivo applications or if their morphology even matters with respects to producing anticancer
effects in animal models.
Conclusion
The goal of this study was to synthesize a polysaccharide-based polymeric drug of HCQ, which
retained the biological activity of HCQ and secondarily demonstrated nanoparticle assembling
characteristics. a system composed of HES modified with CDI linker chemistry was chosen
because of its biocompatibility and biodegradability, which represents a novel class of
multifunctional, biocompatible drug delivery systems. The methods presented herein provide a
means to conjugate HCQ to HES while also controlling the degree of substitution and preserving
the biological activity of HCQ, autophagy inhibition, and CXCR4 antagonism (see subsequent
Chapter 3 on in vitro characterization). Future studies will investigate the in vivo properties of CQHES, i.e. assess the effects on the pharmacokinetics of HCQ, determine the release profile of HCQ
from CQ-HES, etc. Due to its propensity to readily form nanoparticles in a pH-dependent manner,
the use of CQ-HES as a multifunctional drug delivery vehicle for targeting and reducing local
invasion and metastasis of aggressive malignancies like PC will be explored.
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Supporting Information
Figure 2S1 - 1H-NMR & 13C-NMR spectra of HCQ and HCQ-CI
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Figure 2S1 – Overlapping NMR spectra of HCQ and HCQ-intermediate at 500 Hz:
1

H-NMR (top) and 13C-NMR (bottom, zoomed in areas of importance just below spectra).

Protons are assigned from most shifted, proton (A), to least shifted, proton (Q), while
carbons are labeled chronologically, C1-C18, in accordance with chemical shift. Shifting
of protons (A) and (B) illustrate activation of HCQ with carbonyl-imidazole and formation
of the intermediate species. Carbons are assigned numerically by increasing shift values.
The shifting of carbon-9, C9, and the addition of the carbonyl group (C22) and aromatic
carbonS (C19-C21) further validate the formation of the activated HCQ-intermediate.
Additionally, no change in protons (E), (C), and (D) and no changes in carbons C5, C6,
and C7 demonstrate that no unwanted side reactions occurred with the amine groups.
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Figure 2S2 - 1H-NMR & 13C-NMR spectra of HCQ, HES, and CQ-HES
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Figure 2S2 – Overlapping NMR spectra of HCQ, HES, and CQ-HES at 600 Hz
(DMSO-d6): 1H-NMR (top) and 13C-NMR (bottom). The ratio of H1 signals (*) to (**)
allows for approximate measurement for degree of substitution. Proton (G) becomes more
shifted after conjugation, 3.5 to 4.1 ppm, and integrating the signals show that proton (G)
increase in signal intensity from two to four protons. The symmetry of the newly formed
carbonate bond results in degenerate signals from both sets of proximal protons, one set
from HCQ [protons (G)] and another set from HES [protons (G’)], to the oxygens involved
in the carbonate linker. Thus, the increase in signal intensity occurs due to the overlay of
protons (G) and (G’). Furthermore, the shifting of C9 of HCQ in the 13C-NMR of CQ-HES
along with the presence of C22 carbonyl demonstrate the effective conjugation of the
carbonate linker via the hydroxyl of HCQ.
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Figure 2S3 - 2D NMR spectra of HES and CQ-HES
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Carbonyl C22
coupling
with protons (G)
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Figure 2S3 – 2D NMRs of HCQ and CQ-HES: Overlapping Correlation spectroscopy
(COSY) 1H-NMR (top); side-by-side heteronuclear single quantum coherence
(HSCQ) and heteronuclear multiple bond correlation (HMBC) overlaid spectra for
13C-NMR (middle); and overlapping HMBC spectra for 15N-NMR (bottom) of HCQ
and CQ-HES at 600 Hz (DMSO-d6). 1H COSY data is displayed in the top subfigure
with HCQ in blue and CQ-HES in red. In the middle subfigure on the left, carbon-proton
coupling, HSCQ (blue) and HMBC (teal), is presented for HCQ, which taken with the
COSY data validates the proposed carbon and proton assignments for HCQ in
supplementary figures 1 and 2. Carbon-proton coupling, HSCQ (red) and HMBC (violet),
data for CQ-HES shows that the carbonyl carbon (C22) is coupled with the four proton
signature of proton (G). The bottom subfigure illustrates the nitrogen-proton coupling for
HCQ (blue) and CQ-HES (red). The nitrogen coupling relationships are upheld in CQHES, and taken with the previous 1D and 2D NMR spectra confirms that (1) the carbonate
linker is occurring in the proposed manner between the hydroxyls of HCQ and HES AND
(2) no side-reactions occurred with any of the three amine groups.
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Table 2S1 - Solubility of CQ-HES

DMSO

Acetate
Buffer
(pH 5)

DI

PBS

(pH 7)

(pH 7.4)

CQ-HES2.5

500mg/mL

>5mg/mL

>5mg/mL >5mg/mL

CQ-HES8.5

500mg/mL

>5mg/mL

>5mg/mL >5mg/mL

CQ-HES12.5 500mg/mL

>5mg/mL

>5mg/mL Insoluble

CQ-HES17.5 500mg/mL

>5mg/mL

>5mg/mL Insoluble

CQ-HES20

500mg/mL

>5mg/mL

Insoluble Insoluble

CQ-HES30

500mg/mL

>5mg/mL

Insoluble Insoluble

Table 2S1 – Solubility of CQ-HES. In both acetate buffer (pH 5.0) and PBS (pH 7.4), HES (200
kDa) can be seen as both individual polymers (~6-7 nm) and aggregated, amorphous clusters.
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Table S2 - Dynamic light scattering of HES and CQ-HES

HES

CQ-HES20

Size
(nm)

±SD

PDI

kcps

±SD

ABS

21.5

0.5

0.214

490.1

4.7

DI

20

0.16

0.21

491.2

1.5

PBS

20.9

0.06

0.196

462.1

2

ABS

31.3

0.2

0.263

633.8

2.5

DI

32.7

3.2

0.301

612.1

9.1

PBS

29.4

0.7

0.304

605.4

11.4

Table 2S2 – Dynamic Light Scattering of HES and CQ-HES. Approximate size estimates using
the empirical size calculator in the Zetasizer software predict HES to be 16-26 nm, while
conservative estimates of CQ-HES predict a size of 20-40 nm.
SD – Standard deviation
PDI – Polydispersity index
kcps – kilocounts per second
ABS – Acetate buffer solution (pH 5.0)
DI – de-ionized water
PBS – Phosphate buffer saline (pH 7.4)
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Figure 2S4 - AFM of HES
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Figure 2S4 – Atomic Force Microscopy of HES in acetate buffer (top) and PBS
(bottom). In both acetate buffer (pH 5.0) and PBS (pH 7.4), HES (200 kDa) can be seen
as both individual polymers (~6-7 nm) and aggregated, amorphous clusters.
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Chapter 3: in vitro Characterization of CQ-HES

Portions of the content covered in this chapter are the subject of a published
article in Journal of Biomacromolecules by Sleightholm et al.3
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Introduction
Now that we have synthesized CQ-HES and done so via a hydrolytic linker on thee hydroxyl
functional group, the polymeric HCQ should retain its biological activity of inhibiting autophagy
and/or degrade within lysosomes to the free HCQ and starch. This is based on the assumption that
the pKa’s of the amines, which act to absorb protons under acidic conditions imbuing HCQ with
its autophagy inhibitory property, have not be overtly altered as a result of the conjugation to starch.
Additionally, the affinity of HCQ towards CXCR4 could be altered despite the hydroxyl end
appearing to play an insignificant role in binding given previously published QSAR and docking
studies. Conversely, the multiplicity of CQ-HES may enhance the polymer’s overall avidity
towards CXCR4 expressing cells due to the multivalency effect. Regardless of the theoretical
soundness of each argument, these assumptions must be tested. Thus, this chapter is dedicated to
testing the biological activity and in vitro properties of CQ-HES, and the results contained herein
have been previously published in conjunction with the chemical synthesis and characterization
presented in chapter 2.3
Materials & Methods
Materials. Fetal bovine serum (FBS) was from Atlanta Biologicals. Mia Paca-1, Mia Paca-2, and
AsPC-1 cell lines were kind gifts from Dr. Surinder Batra. CellTiter Blue was from Promega.
Laemmli Sample Buffer, nitrocellulose membranes, 1x TBS with 1% casein, and Precision Plus
Protein WesternC Standard were from Bio-Rad. 10% Tris-glycine Midi Protein gels were from
Invitrogen. The following antibodies were used to manufacturer’s specifications: LC3B (Cell
Signaling Technology, 2775S), Akt/ERK (Cell Signaling Technology, 12651s), GAPDH (Cell
Signaling Technology, 2118S), and anti-rabbit (Cell Signaling Technology 7074S). Immun-Star TM
AP Chemiluminescence Kit was from Bio-Rad. All other reagents, chemicals, and cell culture
materials were obtained from Fisher Scientific.
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Cell Culture. AsPC-1, MiaPaca-1, and MiaPaca-2 cells were cultured in DMEM high glucose
medium supplemented with 10% FBS. U2OS cells stably expressing functional EGFP-CXCR4
fusion protein (Fisher Scientific) were cultured in DMEM high glucose supplemented with 10%
FBS, 2 mM L-glutamine, 1% Pen-Strep, and 0.5 mg/mL G418. All cell lines were maintained at
37°C with 5% CO2. All cell lines were grown to 70-80% confluency before subculturing using
trypsin, 0.05% for U2OS and 0.25% for PC cell lines.
Cytotoxicity. Cytotoxicity studies were performed using the CellTiter-Blue viability assay. Cells
were seeded at 2,000-3,000 cells/well in a 96 well plate. The medium was replaced after 24 h with
medium containing 10% FBS and different concentration of CQ-HES or HCQ. The cells were
incubated for 72 hours, and afterwards, the medium was aspirated and replaced with 100 µL of
the CellTiter-Blue solution. The cells were left to incubate for one hour, and the fluorescence was
measured using a SpectraMax M5. The cell viability was calculated as a relative percentage,
[A]sample/[A]untreated ×100%.

Dose

response

curves

were

constructed

and

analyzed

using GraphPad Prism 5. IC50 values were calculated as the CQ-HES or HCQ concentration
required to achieve 50% growth inhibition relative to untreated cells.
Western Blot. Cells were treated in a 6-well plate and harvested with ice cold RIPA lysis buffer
containing protease and phosphatase inhibitors. Samples were centrifuged for 10 minutes at 14,000
RPM, cellular supernatant was collected, and the amount of protein in each sample was analyzed
using BCA protein assay kit. Sample protein levels were adjusted with RIPA buffer, diluted with
equal parts of 2x Laemmli Sample Buffer containing 5% 2-mercaptoethanol, and heated for 10
minutes at 90°C. Samples (20 µg) were electrophoresed (10% Tris-Glycine Midi Protein Gels) and
transferred to nitrocellulose membranes. Membranes were blocked for 1 hour at room temperature
using 1x TBS (1% casein). Primary antibodies were run overnight at 4°C in 1x TBS (1% casein) to
manufacturer’s specifications. Afterwards, membranes were washed thrice with TBS and incubated
for 1 hour at room temperature with secondary antibody at manufacturer’s specifications.
Chemiluminescence was initiated using the Immun-StarTM AP Chemiluminescence Kitand
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subjected to LucentBlue X-ray films. Western blots were analyzed using Image Studio Lite (LICOR).
Confocal microscopy. The LSM 510 Zeiss confocal microscope was used to image intracellular
trafficking of fCQ-HES (5 μM HCQ, 490/520 exc/em) in Mia Paca-1 cells. LysoTracker Red DND99 (577/590 exc/em) was used to fluorescently label lysosomes.
Cell migration. Cell migration was assessed using a wound healing assay as previously
described.329 Briefly, the cells were seeded in 12-well plates. Upon growing to near confluence, a
sterile 200 µL pipette tip was used to create a wound. The cells were then washed twice with PBS,
and media containing 10% FBS and respective HCQ, CQ-HES, or control was added to the wells.
Using an AMG EVOS XL Core Imaging System, the cells were then imaged at regular time
intervals: 0, 6, 12, and 24 hours. Wound healing was assessed as the percent of wound closure (±
standard deviation) compared to time zero measured as the distance between wound borders with
10 measurements being taken for each biological replicate at each time point.
Cell invasion. Cell invasion was performed as previously described.330 Briefly, Matrigel was
thawed on ice and then diluted 1:4 with serum free medium. A final volume of 40 uL of
the Matrigel solution was placed into cell culture inserts and incubated for 2 hours at 37°C in 24
well plates. Cells were harvested using AccutaseTM cell detachment solution and re-suspended in
serum-free medium. Cells were diluted with serum-free medium to their respective drug (HCQ or
CQ-HES) or vehicle concentration and a final concentration of 200,000 cells per insert. Medium
with 10% FBS was then added to the lower chamber of the wells, and the cells were allowed to
incubate overnight at 37°C. Cells were fixed in 100% methanol, stained with 0.2% Crystal Violet,
and imaged using AMG EVOS XL Core Imaging System. Invasion was assessed as the average
cells/area imaged ± standard deviation. Invasion was also assessed in an SDF-1 dependent manner
using U2OS cells constitutively expressing CXCR4. The method was similar to the above
except for following changes: 1) cell density – 100,000 cells/insert; 2) DMEM supplemented with
2 mM L-glutamine; and 3) SDF-1 (100 ng/mL) in serum free media in the lower well instead of
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serum-containing media.
Results
Cytotoxicity
The presence of HCQ provides CQ-HES with a weak polycationic character. It was important to
first assess whether this results in any unexpected cytotoxicity. To address this issue, we tested the
cytotoxic effects of CQ-HES20 in three different PC cell lines, AsPC-1, MiaPaca-1, and MiaPaca2. We found no difference in the cytotoxicity of CQ-HES and parent HCQ (see supporting
information – Figure 3S1). Repeating these cytotoxicity studies at densities (6×105 cells/cm2) used
in the migration, invasion, and cellular signaling studies described below, showed no discernable
toxicity of either CQ-HES or HCQ until 300 µM (Supporting Figure 3S1). Thus, we selected 100
µM concentrations of HCQ and CQ-HES to be used in the subsequent studies as the cytotoxic
effects should be of little consequence in the modifications of cellular behaviors addressed below.
Inhibition of Autophagy and Intracellular Trafficking of CQ-HES
Because the amines in HCQ act as proton acceptors, sufficiently high concentrations of HCQ can
neutralize the acidic lysosome and inhibit protease activity and autophagosomal fusion, effectively
inhibiting autophagy.331 Using CDI chemistry, we aimed to conjugate HCQ to HES through the
hydroxyl group of HCQ so that the amines remain unaltered and retain the biological activity of
HCQ. However, the conjugation of HCQ with HES could have unanticipated effects on the ability
of CQ-HES to inhibit autophagy. To investigate this assertion, we determined the buffering ability
of CQ-HES (supporting information – Figure 3S2). CQ-HES displayed a comparable buffering
capacity to HCQ within physiological ranges of pH 3.6-7.9. This buffering capacity was solely the
result of the HCQ in CQ-HES as HES lacked any buffering ability by itself. Thus, CQ-HES
appeared to retain the buffering capacity of HCQ even after conjugation.
HCQ readily permeates cellular membranes, and once in the lysosome, it becomes protonated and
buffers the lysosomal environment. This buffering neutralizes the acidity and directly and indirectly
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leads to autophagy inhibition. In CQ-HES, the HCQ is tethered to the very large modified starch
HES. Therefore, CQ-HES must undergo a phagocytic and subsequent intracellular trafficking
process to reach to the lysosome. To understand the cellular localization of CQ-HES, live cell
imaging studies and observed the cellular trafficking of CQ-HES were performed using confocal
microscopy. Lysosomes were stained with LysoTracker Red, and the cells were incubated with
fluorescein-labeled CQ-HES (fCQ-HES). FCQ-HES displayed a rapid internalization with ultimate
localization and retention in lysosomes as evident by co-localization with the LysoTracker signal
(Figure 3.1). After substantial accumulation of CQ-HES in the lysosomes, the fluorescence of the
LysoTracker Red decreased suggesting a neutralization of the acidic pH in the lysosomes. Thus,
CQ-HES appears to be internalized and traffic to the lysosome where it may impart a buffering
ability to neutralize the acidic environment of the lysosome.
Thus far, the data suggest CQ-HES retains the physical properties, ability to localize to lysosomes,
and the propensity to neutralize the acidic environment therein, characteristics necessary for HCQ
to properly inhibit autophagy. However, the ability of CQ-HES to truly inhibit autophagy needs to
be substantiated. Thus, the difference in biological activity for autophagy inhibition between CQHES20 and HCQ was assessed by measuring intracellular levels of the autophagosome marker
LC3B in three PC cells. All three PC cell lines showed an increase in both LC3B-I and II after
treatment with CQ-HES20 (Figure 3.2). These increased levels were comparable to those see in
cells that were administered free HCQ. indicating a preservation of the autophagy inhibitory
activity of HCQ in CQ-HES. This evidence taken together with the acid-base titration data indicates
that the functionality of HCQ in CQ-HES is preserved and the localization of HCQ to the lysosomes
is maintained in CQ-HES, although the mechanism by which this occurs may be different.
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Figure 3.1 – Cellular localization of CQ-HES using live cell imaging using Mia PaCa
cells. Transmitted light (top left), LysoTracker Red (top middle), fluorescein-labeled CQ-HES (top
right), colocalization (bottom left), and colocalization of an individual cell (bottom right).

Figure 3.2 – Effects of CQ-HES on Autophagy. Autophagy was analyzed by western
blot analysis of LC3 levels.
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Effect of CQ-HES on the Migration and Invasion of PC Cells
Following the successful demonstration of the strong autophagy inhibition of CQ-HES, the other
potential HCQ target in cancer, the CXCR4 chemokine receptor, was explored by evaluating the
related effects of CQ-HES on the motility of cancer cells assessed first by a wound healing assay
(Figure 3.3). Twenty-four hours after creating the wound, the untreated control group showed ~5060% wound closure in all three PC cell lines. In contrast, a considerable inhibition of the wound
closure was observed in cells treated with CQ-HES. This inhibitory effect of CQ-HES was observed
in all three PC cell lines even at the lowest concentration used (10 µM). The highest CQ-HES
concentration (100 µM) showed ~80% inhibition over the control group, while the 10 µM
concentration still displayed significant migration inhibition of ~40-60% over control. In contrast,
the effects of CQ-HES on wound healing substantially exceeded the effects of HCQ alone, as HCQ
did not reach significant inhibition until doses of approximately 50 μM.
Next, the ability of CQ-HES to inhibit cancer cell invasion was examined using a Boyden chamber
Matrigel invasion assay with 10% FBS media as the source of chemotactic signals (Figure 3.4).
Negative controls lacking FBS demonstrated a minimal degree of random invasion, while the
positive controls containing FBS showed a strong ability to drive invasion in all three cell lines
through the Matrigel. As in the wound healing assay, CQ-HES demonstrated a greatly enhanced
ability to inhibit PC cell invasion when compared with equivalent concentrations of HCQ. At 1
μM, CQ-HES was able to reduce invasion by ~80% in AsPC-1 cells and ~70% in MiaPaca-2 cells,
but only a modest reduction of ~10% was observed in MiaPaca-1 cells. Increasing the concentration
to 50 μM achieved a nearly complete inhibition of cell invasion in all three cell lines. In contrast,
there was no significant effect on invasion with 1 µM HCQ in any of the cell lines tested. Regardless
of cell type or concentration, the effects of CQ-HES were substantially greater than that of
comparable levels of HCQ.
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Figure 3.3 – Effect of CQ-HES20 on PC cell migration determined by wound healing assay at
24 hours with representative figures from Mia Paca-2 cells displayed above.
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Effect of CQ-HES on CXCR4 Signaling
Through QSAR modeling, direct competition binding assays, and through effects on downstream
activation components, HCQ has been identified as an antagonist of the CXCR4 receptor. 238,328 It
has been previously shown that chloroquine-containing HPMA copolymers inhibited CXCR4mediated breast cancer cell invasion and decreased lung metastasis in vivo. Thus, the involvement
of CXCR4 antagonism in the ability of CQ-HES to inhibit PC cell migration and invasion was
investigated. First, using U2OS cells overexpressing CXCR4-EGFP fusion protein, it was found
that CQ-HES inhibited CXCR4-mediated cell invasion to a similar extent as HCQ at equivalent
concentrations that was similar to AMD3100 (300 nM), a potent CXCR4 antagonist (Figure 3.5).
We then determined cellular localization of the CXCR4 receptor (see supporting information –
Figure 3S5) after 1 h activation with its ligand SDF-1 (100 ng/mL). CXCR4 readily translocated
from the cell surface to focalized points within the cytosol after SDF-1 activation, indicating rapid
receptor activation and internalization. Treatment with both HCQ and CQ-HES displayed modest
decreases in CXCR4 internalization following SDF-1 stimulation, indicating partial antagonism.
To understand the effect of CQ-HES on CXCR4 signaling at the molecular level, two downstream
pathways (Akt, ERK) affected by CXCR4 activation with SDF-1 were examined. The ability of
CQ-HES to inhibit phosphorylation of Akt and ERK was assessed using Western blot to measure
the ratio of phosphorylated Akt and ERK to the total cellular content of the corresponding protein.
Treatment of U2OS cells with 100 ng/mL SDF-1 for 1 h induced phosphorylation of both Akt and
ERK (Figure 3.6). The phosphorylation of both proteins was inhibited significantly by CQ-HES
treatment. HCQ treatment showed substantially lower inhibitory activity than CQ-HES as did
treatment with the commercial CXCR4 antagonist, AMD3100. Thus, the ability of CQ-HES to
inhibit downstream signaling pathways of CXCR4 involved in cell motility may explain its
enhanced effects on migration and invasion.
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Figure 3.5 – Effect of CQ-HES on SDF-1-mediated invasion. Specifically, CQ-HES20 was
assessed for its effects on SDF-1-driven cellular invasion at 24 hours of U2OS constitutively
expressing CXCR4.
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Figure 3.6 – Effect of CQ-HES on downstream signaling of CXCR4. Antagonistic effects of
AMD3100, HCQ, and CQ-HES on CXCR4 downstream signaling after SDF-1 stimulation. Levels
of pAkt:Akt and pERK:ERK are presented as percentage ratios to control group that did not receive
SDF-1.
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Discussion/Conclusions
In the previous chapter, chemical synthesis and physical characterization of CQ-HES was
described. In this chapter, the biological activity of CQ-HES was assessed, especially in regards to
comparable levels of free HCQ and the effects on cytotoxicity and autophagy. In general, creating
a polymeric drug conjugate often reduces the biological activity as the drug must be released in
order for it to be active. In polymeric drugs, the drug is active even in the polymer state. However,
it is common for that drug to be less cytotoxic, given the main mechanism of action (MOA) is not
cytotoxicity. This is certainly the case for another student in our lab who synthesized a different
polymeric drug analog of HCQ.332 Using block copolymerization and HPMA, this polymeric HCQ
was similarly produced through conjugation chemistry utilizing the hydroxyl group. Despite this,
the ability of this polymer to inhibit autophagy was severely hampered, though it displayed other
effects. Conversely, CQ-HES showed a similar ability to inhibit autophagy as well as a similar
cytotoxicity profile. So although many polymeric drug formulations display reduced cytotoxicity,
even those of HCQ from our own lab, the effects of CQ-HES were quite similar to the parent
compound (unmodified/unconjugated/free HCQ) underscoring the importance of all three
components of the polymeric drug: the drug itself, the linker, and the polymer backbone.
Because HCQ readily permeated membranes and localizes to lysosomes solely based on the fact
that the acidic environment protonates the amines and the now charged HCQ can no longer pass
through a phospholipid bilayer, the creation of a polymeric formulation of HCQ would undoubtedly
alter its cellular trafficking. The confocal microscopy experiments presented herein demonstrate
that CQ-HES is readily taken up by cells and eventually transported to lysosomes. So although
HCQ, with a molecule of 336 daltons and possesses the ability to readily permeate membranes,
was attached to HES (200 kDa) increasing its molecular weight nearly 1000 fold and nullifying its
capacity to permeate membranes, the ability of CQ-HES to ultimately reach the lysosomes still
occurs. Unquestionably, this is due to a different mechanism, one that relies on the phagocytic
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activity and intracellular vesicular transportation of the cell.

CQ-HES inhibited CXCR4 signaling to a greater extent than HCQ. The explanation for the
improved CQ-HES activity is likely through increased a combination of antagonism of the
receptor at the cellular surface and retention of the receptor in the endosome. Once the
CXCR4 receptor is stimulated by SDF-1, it becomes internalized at which point it is either
recycled or degraded.333,334 HCQ interferes with the receptor trafficking by preventing
recycling and decreasing the surface receptor concentration, thus minimizing long-term
activation of the pathway.278,335 In the case of CQ-HES, where multiple HCQ molecules
reside on a single chain of HES, the overall avidity is substantially enhanced in comparison
to the affinity of HCQ due to the multivalency effect.336 Thus, CQ-HES may preferentially
serve a dual function of not only antagonizing CXCR4, but also may act to prevent receptor
recycling following internalization through a receptor mediated process further
diminishing CXCR4 signaling.
The combination of these mechanisms may also help to explain the enhanced effects on
migration and invasion. Antagonism of surface receptors and the prevention of receptor
recycling could lead to a synergistic reduction in chemotactic-mediated migration or
invasion. These data suggest, however, that these effects are not limited to CXCR4 and
that other receptors could also be sequestered, leading to a general reduction in receptor
presentation on the cell surface. The fact that CQ-HES decreased invasion when either
SDF-1 or FBS was used as chemoattractants, informed us that it is most likely a
combination of both receptor antagonism and intracellular sequestration, in addition to
autophagy inhibition, that leads to decreased invasion and motility seen in cells treated
with CQ-HES.
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In the case of the cell migration assay, further inhibition of autophagy may reduce a cell’s
ability to proliferate and migrate. Increased proliferation and artificial inflation of cell
invasion is always a concern in invasion assays. Limiting the duration of the assay helps to
prevent this, but disruptions in autophagy would be highly impactful on invasion in the
short-term. After some time, the cell may compensate by re-acidifying its lysosomes and
degrading HCQ. CQ-HES on the other hand may be more resistant to degradation due to
steric hindrance from HES. So while the cell may re-acidic its lysosomal compartments,
the buildup of CQ-HES may also be impactful and lead to disruptions in overall functioning
of the cell. Thus, there may be several mechanisms by which CQ-HES is inadvertently
leading to a more profound reduction in migration and invasion over comparable levels of
HCQ.
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Supporting Information

83

Figure 3S1 - Additional Cytotoxicity Studies

Figure 3S1 – Additional cytotoxicity studies of CQ-HES. Cytotoxicity was examined at
cell densities comparable to those run for invasion and wound healing studies to confirm
that cytotoxicity was not a factor in altering these cellular behaviors.
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Figure 3S2 - Titration Curves of HES, HCQ, and CQ-HES
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Figure 3S2 – Acid-base titration of HES, HCQ, and CQ-HES. Approximately 5 ml of
0.15 M aqueous NaCl solution containing 10 mg CQ-HES20 (w/w% = 20% HCQ), 2 mg
HCQ, or 8 mg HES was adjusted to an initial pH of 10.3 by 0.1 M NaOH and then titrated
using 0.1 M HCl until the pH declined to 3. The pH of all solutions was measured by a pH
meter after each addition of 0.1 M HCl (50 μl). As a control, a solution of 0.15 M NaCl
was titrated in similar fashion, and its pH profile was obtained.
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Figure 3S3 - Additional Wound Healing Assays of AsPC-1 and Mia Paca-1 Cells

Figure 3S3 – Effects of CQ-HES on wound healing in AsPC-1 and Mia Paca-1, top
and bottom respectively. Representative images are shown for each treatment group at
24-hour time points. Average width values are presented below each figure with respective
red-dashed lines approximating the wound borders within each image.
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Figure 3S4 – Effects of CQ-HES on Invasion
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Figure 3S4 – Effects of CQ-HES on invasion. Representative images of FBS-mediated
invasion assays in AsPC-1, Mia Paca-1, and Mia Paca-2 cells and SDF-mediated
invasion assay in U2OS cells.
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Figure 3S5 – CXCR4 Redistribution Assays
CQ-HES

SDF

100
80
60
40
20

nm
10
0

10

1

M

M

0
10
0

Relative CXCR4 Activation

CQ-HES+SDF

CQ-HES on CXCR4 activation

M

Relative CXCR4 Activation

CQ-HES+AMD+SDF

HCQ
HCQ+AMD+SDF
HCQ+SDF
SDF

HCQ on CXCR4 activation
100
80
60
40
20
0

100 M

10 M

1 M

Figure 3S5 – CXCR4 antagonistic effects of CQ-HES. CXCR4 inhibition was assessed
using CXCR4 Redistribution Assay as previously described. AMD3100 was used as a
control, and relative CXCR4 was assessed relative to SDF alone (100%) and AMD3100
(0%).
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Chapter 4: Preliminary Toxicity & Efficacy Studies
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Introduction
Because the in vitro results thus far have been positive and CQ-HES appears to retain the biological
activity of HCQ, it was decided to test the anticancer activity of CQ-HES in vivo. Before this could
be done, the maximum tolerated dose (MTD), a viable dose for multiple administrations, and
subsequently the pharmacokinetic (PK) profile of CQ-HES needed to be determined in order to
establish a proper dosing regimen to implement in future in vivo efficacy studies. This chapter will
present findings supporting the MTD of three different degree of substitution CQ-HES
formulations as well as a pilot study comparing the anticancer activity and side effect profile of
CQ-HES to that of comparable levels of free HCQ. Positive results from these studies were required
in order to proceed with a large-scale, costly, in-depth evaluation of the PKs of CQ-HES, which
will be presented in a subsequent chapter.
Methods
Materials. Fetal bovine serum (FBS) was purchased from Atlanta Biologicals. The Colo357 cell
line was a gift from Dr. Rakesh Singh. All other reagents, chemicals, and cell culture materials
were obtained from Fisher Scientific.
Cell Culture. Colo357 cells were cultured in DMEM high glucose medium supplemented with
10% FBS and maintained at 37°C with 5% CO2. All cell lines were grown to 70-80% confluency
before subculturing using 0.25% trypsin.
HEPES-buffered Glucose. For in vivo administration of CQ-HES, HEPES-buffered glucose
(HBG) was used to formulate CQ-HES at appropriate concentrations. Briefly, 5% glucose (w/v%)
was added to 20 mM HEPES buffer and stirred until dissolved. The resulting solution was adjusted
to pH 7.4 using 1.0 M NaOH and HCl. Prior to creating a fresh solution of CQ-HES, HBG was
filtered using 0.2 micron syringe-fitted filters.
Mice. BALB/c mice and athymic NU/NU (nude) mice were purchased from Charles River
Laboratories.
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Maximum tolerated dose (MTD) assessment. MTD was performed in BALB/c mice (n=3) using
a modified Fibonacci scheme of dose escalation (100%, 65%, 52%, 40%, 33%, 33%, 33%) given
every third day starting at 5 mg/kg of total compound and was repeated in a second cohort. The
study was continued until mice displayed signs concerning for acute toxicity including altered
behavior, body weight decrease of >10%, severe injection site reaction, or death. Three different
CQ-HES compounds differing in HCQ content (8%, 16%, and 20%) were investigated. All animal
work was approved by the IACUC at the University of Nebraska Medical Center.
Orthotopic xenograft mouse model of PDAC. Colo357 cells were grown in cell culture as
described above until they were needed. Cells were grown to ~50-70% confluency in T150 flasks
before using. Briefly, cells were washed 1x with 10 mL of PBS, and then released with 1 mL of
TrypLE. Cells were then spun and rinsed 3x with 10 mL PBS. Final stock solution of cells was ~20
x 106 cells/mL and stored on ice until injected. To expose the pancreas for injection, a modification
to a previously describe surgical approach was used.337 Briefly, approximately 350 µL of a sterile
ketamine (8.0 mg/mL)/xylazine (0.5 mg/mL) mixture suspended in PBS was used to anesthetize
each mouse. Nair was used to remove any hair on the abdomen as needed, allowing visualization
of the spleen through the skin. Each mouse was positioned on its right side exposing its left
abdomen, which was sterilized with iodine and alcohol. A 0.5 cm transverse incision was made
exposing the spleen and pancreas. Slight pressure applied in a pinching fashion protruded the spleen
and pancreas from the abdominal cavity. Holding the pancreas with slight pressure, a syringe was
carefully inserted into the body of the pancreas, and approximately 50 µL of cell suspension (1 x
106 cells) was injected into the body of the pancreas producing a small, visible bubble. The syringe
was kept in the pancreas momentarily following injection after which it was carefully withdrawn.
The pancreas was carefully repositioned back into the abdomen. The incision was closed using 13 sutures for the abdominal wall and staples for the skin.
Mice were housed under normal conditions for 4-5 days until the staples were removed. Once
palpable tumors were identified, mice were assigned to treatment groups. Treatments were given
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every third day. The study continued for a total of thirty days or until the number remaining in a
single one group was less than or equal to one half of the original starting number. Primary tumor
growth was the main end point with survival and metastasis being secondary assessments of
interest. Tumors were followed daily using external calipers to measure growth. The shortest and
longest physical diameter measurements were averaged and used to calculate volumes. Mice were
followed until they died of natural causes or were severely lethargic or fully obtunded at which
point they were euthanized. Similarly, if tumors exceeded 2 cm in diameter, mice were euthanized.
Upon termination of the study, all organs were inspected for signs of metastasis. GraphPad Prism
7 was used for all graphing and statistical calculations. Tumor volume were presented as averages
± standard error of mean, and average growth patterns of each cohort were plotted accordingly.
Results
Maximum Tolerated Dose (MTD)
In performing the MTD for CQ-HES, three different CQ-HES formulations were used that varied
by %weight of HCQ: CQ-HES8%, CQ-HES16%, and CQ-HES20%. The higher HCQ content
polymers were more difficult to dissolve in HBG. Moreover, CQ-HES20% induced an unknown
fatal event at 50 mg/kg, while lethargy and tachypnea, concerning for a serious adverse event, were
observed in CQ-HES16% at this dose. Conversely, CQ-HES8% was dosed up to 100 mg/kg without
any apparent issues. Thus, the MTD was concluded to reside at 40 mg/kg for both CQ-HES20%
and CQ-HES16%, and CQ-HES8% was considered to be generally safe at reasonable doses that
would be applicable for an efficacy study.
Efficacy in Xenograft Model (Colo357)
Because CQ-HES16% appeared to possess acute toxicity that CQ-HES8% did not and the two
formulations were conveniently double/half, we decided to use these two formulations in a pilot
study to determine if the formulations themselves possessed anticancer activity and if they were
superior to administered free HCQ of comparable doses. Given that multiple doses would be used,
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we opted to use a 25% dose reduction from the MTD of CQ-HES16% or 30 mg/kg. Thus, 30 mg/kg
of CQ-HES8% and CQ-HES16% were used and compared against HCQ at 2.4 and 4.8 mg/kg.
Overall, only two mice died in the HCQ 4.8 mg/kg group, while the other treatment groups only
experienced one death each. On the other hand, the control group experienced three deaths
throughout the study with an additional four mice requiring premature euthanasia and early
termination of the study. Thus, no difference in survival was appreciated (data not shown).
Tumor volumes for each mouse were followed longitudinally (Figure 4.1). HCQ alone reduced
tumor growth by approximately 20% and 40% for 2.4 and 4.8 mg/kg respectively. Additionally,
both CQ-HES formulations appeared to decrease tumor volume to a degree that appeared greater
than 4.8 mg/kg of free HCQ. The final tumor sizes between the CQ-HES8%, CQ-HES16%, and
HCQ high (comparable to CQ-HES16%) cohorts were indiscriminant. However, the overall
exponential growth curves were statistically different between CQ-HES and HCQ, p = 0.003, but
growth kinetics appeared to be similar between the two CQ-HES cohorts.
Gross examination of necropsied mice at the termination of the study showed differential patterns
of liver metastasis (Figure 4.2). Rates of metastasis in mice administered 2.4 mg/kg HCQ showed
rates comparable to the control group, ~50%. However, increasing the dose to 4.8 mg/kg reduced
this rate to 20%, though not statistically significant. A similar metastasis rate (18%) was seen in
CQ-HES16%, while no mouse in CQ-HES8% displayed signs of liver metastasis. Comparing CQHES8% to the comparable dose of free HCQ, there was a statistically significant difference in liver
metastasis between the cohorts (56% v 0%, p = 0.008), but no difference was appreciated between
CQ-HES formulations (18 v 0%, p = 0. 48).

94

Figure 4.1 – Effects of CQ-HES on tumor growth in xenograft model. The anticancer effects
of CQ-HES versus HCQ were tested in athymic mice bearing human orthotopic PC tumors derived

Percent of Mice

from Colo357 cells in terms of primary tumor growth (average ± SEM).

Figure 4.2 – Effects of CQ-HES on liver metastasis in xenograft model. The antimetastatic
effects of CQ-HES versus HCQ were tested in athymic mice bearing human orthotopic PC tumors
derived from Colo357 cells.
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Discussion
From the MTD studies, CQ-HES with higher degree of substitution (DOS), specifically CQHES20%, appeared to impart greater toxicity with acute side effects being altered mental status,
tachypnea, and death. Additionally, these higher DOS formulations were more difficult to dissolve
at concentrations and pH’s suitable for intravenous administration. Specifically, CQ-HES20%
proved very difficult to produce high concentrations suitable for efficacy studies. The pH of the
solutions were double checked prior to administration, and extensive efforts were made to ensure
proper pH of administered solutions. However, there are concerns that this still may have been an
issue as higher content HCQ polymers had difficulty dissolving in solution, and the side effects
incurred by the mice were similar to that of acid-base disturbances of the blood. Because of the
solubility and MTD issues, CQ-HES16% was selected over CQ-HES20% for further studies and
was compared to a formulation with half the DOS, CQ-HES8%.
The pilot efficacy study presented in this chapter could have been performed in two different ways
with regards to comparing formulations and drug concentrations: 1) holding the total HCQ
administered constant OR 2) holding the total drug administered constant. First, the total amount
of HCQ administered could have been held constant by administering twice as much of CQHES8% compared to CQ-HES16%. In doing so, only one theoretical control group for HCQ would
have been needed. Conversely, the amount of overall polymer would have varied between the
groups. Colloidal plasma volume expanders such as HES have been shown to improve tumor
uptake of drug. Moreover, the pharmacokinetic-pharmacodynamic (PK-PD) relationship has not
been studied for this compound. So, it is unclear what level of drug reaches the tumor and what
level is needed to impart a therapeutic effect. This relationship will be further explored in Chapters
6 & 7, and this study was meant to determine if any therapeutic efficacy could have been observed
using the polymer alone at the highest, but safest, concentration administrable.
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It was decided that the second approach, holding total amount of CQ-HES polymer administered
at a constant mg per kg basis, was preferable. In doing so, two different amounts of total HCQ
would be used. In previous chapters, the linker stability (Chapter 2), buffering capacity (Chapter
3), and in vitro biological activity (Chapter 3) were described. Although carbonate linkers are
subject to acid or base hydrolysis, it was shown that CQ-HES was fairly stable under these
conditions, and the biological activity seemed to mirror similar concentrations of free HCQ.
However, it was unknown how CQ-HES would behave in vivo. There was a potential that the linker
would break down and release free HCQ, which may occur very rapidly. If this was the case,
administering CQ-HES would be very similar to administering free HCQ. Thus, two different HCQ
cohorts, one comparable to CQ-HES8% (2.4 mg/kg) and another comparable to CQ-HES16% (4.8
m/kg), would be implemented in order to control for this situation.
Looking at the in vivo anticancer profile of the two different formulations of CQ-HES tested (Figure
4.1), a higher DOS did not translate into improved efficacy. Both CQ-HES8% and CQ-HES16%
appeared to slow primary tumor growth to a similar degree. In fact, both formulations were
markedly better than giving free HCQ at 2.4 mg/kg but only modestly better than free HCQ at 4.8
mg/kg, with approximately a 10-15% decrease in final volumes at the conclusion of the study. So
despite a difference in total HCQ administered, both polymeric formulations appeared to perform
equally as well. Since little is known of the PK-PD relationship of these polymers, it is not
unimaginable to reason that the doses administered were above the threshold to induce biological
effects, slowing primary tumor growth.
Another metric of anticancer activity is the ability to prevent metastasis, which ultimately dictates
survival in humans. High doses of HCQ (4.8 mg/kg) appeared to reduce the metastatic rate by
almost one half, ~40% v 20%. In mice administered a comparable amount of polymeric HCQ (CQHES16%), a similar rate was observed (18%). However, these comparisons were not significantly
different, which is partly due to the sheer low number of mice in this study. Conversely, comparing
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CQ-HES8% to the control group (no treatment) or low dose HCQ group revealed a significant
reduction in liver metastasis, p = 0.04 and p = 0.008, respectively. It should be noted that these
statistical figures are derived from single Fisher’s exact tests, and no adjustments for pairwise
comparisons were performed. Performing such an operation, although statistical sound, would
inadvertently prevent the identification of any true positive results as this study was not designed
nor powered for such multiple comparisons. Moreover, the number of mice remaining at the end
of the study were much fewer in the control cohort. Mice with extensive liver metastasis could, and
probably would, die much sooner than mice un-afflicted by metastasis. This survival bias may have
artificially led to the lower liver metastasis rate observed compared to HCQ at 2.4 mg/kg. Thus,
the true significance, repeatability, and external validity of comparing the metastatic rates between
cohorts are questionable. Rather, the findings from this pilot study suggest that a potential
relationship exists, and exploration of this concept in a future study may be fruitful. Additionally,
knowing the approximate rates of metastasis will help in guiding the design of the future study so
as to ensure it is properly powered if this outcome is to be investigated.
Though the xenograft model is not perfect, it served as a valuable preliminary efficacy model for
understanding the anticancer activity of CQ-HES and HCQ alone. However, these mice lack an
immune system, which contributes greatly to the TME of PC. Advances in PC mouse models have
yielded two better models that use C57BL/6 mice, colloquially known as black6 mice: 1) the
spontaneous “KPC” model using genetically modified C57BL/6 mice harboring KrasLSL.G12D/+;
p53R172H/+; PdxCretg/+ mutations; AND 2) orthotopic implantation of cell lines derived from
cultured tumor cells from KPC mice. Because of the intact immune systems, these models are
superior to the xenograft models as they are more readily able to recapitulate the TME observed in
human PC. Both of these models are available to our lab through collaborations with Dr.
Hollingsworth, but the orthotopic transplant version is much more desirable for our studies due to
the lower logistical constraints but similar tumor compositions. So while our preliminary evaluation
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of CQ-HES yielded positive results in terms of anticancer activity, additional studies are needed to
confirm these findings. Rather, the results support the fact that multiple doses of CQ-HES are
tolerable, side effects are limited, and CQ-HES and HCQ may possess appreciable anticancer
activity by themselves. Thus, these studies served more of a role in helping to establish a proper
dose to use in a future efficacy study combining CQ-HES with a chemotherapeutic like oxaliplatin,
paclitaxel, gemcitabine, etc. within the orthotopic KPC model as well as identify potential side
effects associated with the administration of multiple doses of CQ-HES.
Conclusions
The lower dose formulation (CQ-HES8%) possessed a better balance of reducing primary tumor
growth and preventing metastasis to the liver. Conversely, the higher CQ-HES16% can deliver a
higher payload of HCQ per mg of compound, and thus may be better suited for use in combinations
with radiation or a chemotherapeutic. Overall, both formulations appeared to impact primary tumor
growth and may have the potential to reduce liver metastasis. What still remains to be determined
is if the different formulations result in different PK profiles, how dose affects response (i.e. if
giving more CQ-HES produces a larger tumor response/reduces metastatic spread), if giving CQHES in combination with a chemotherapeutic or with radiation is beneficial, or if there are any
unobserved, masked, or long-term toxicities. So before proceeding to a full-scale in vivo efficacy
study, the effects of varying the DOS in CQ-HES on tissue distribution and tumor uptake in a KPC
model must be determined. Ultimately, this would not only help determine the best formulation to
test in an efficacy study but will also influence the dosing intervals implemented (see Chapter 6).
Clearly, these studies served a pivotal role in helping to guide the design of future experiments, and
the subsequent chapters build upon these findings so that we may answer these question and better
understand what translational potential CQ-HES may possess in the treatment of PC.
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Chapter 5: LC-MS/MS Method for Quantitation of HCQ in
Mouse Blood and Tissue

Portions of the content covered in this chapter are the subject of a published
article in Journal of Chromatography B by Chhonker & Sleightholm et al.2
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Introduction
While there appears to be benefits of using HCQ in cancer treatments (see Chapter 1), there is little
preclinical data illustrating optimal dosing regimens and tissue concentrations for HCQ. Current
studies dose HCQ to achieve the highest blood concentrations with the thought that this will achieve
the highest tumor concentrations. However, there is little evidence in the literature correlating blood
concentrations of HCQ to tumor concentrations.
The lack of evidence describing the pharmacokinetic (PK) profile of HCQ as it relates to tumor
uptake and accumulation is partially due to the inability to detect low drug concentrations.
Following intravenous (i.v.) administration, HCQ readily redistributes from blood into tissues,
dropping blood concentrations below the limit of detection for traditional analytical methods. In
addition, the amount of viable blood and tissue available in small animal studies can be low,
especially in mice. These factors make designing small animal PK studies for HCQ very
challenging.
HCQ

is

metabolized

into

three

major

metabolites,

desethylchloroquine

(DCQ),

bisdesethylchloroquine (BDCQ), and monodesethylhydroxychloroquine (Cletoquine; DHCQ).
The respective contributions of each metabolite to the efficacy and toxicity of HCQ treatment
remain poorly understood. DHCQ appears to be the only active metabolite with some evidence
suggesting its therapeutic index is higher than HCQ itself.338 However, in patients with rheumatoid
arthritis, gastrointestinal side effects and ocular toxicity are related to blood concentrations of HCQ
and BDCQ, while clinical improvement is related to the blood concentrations of DHCQ. 338 Brocks
et al. showed that HCQ concentrations in plasma were appreciably lower and more variable than
those in whole blood suggesting whole blood is a better matrix for therapeutic drug monitoring
(TDM) of HCQ.339
Various techniques have been employed for the separation, detection, and quantification of HCQ
from biological samples. A majority of these methods have relied on fluorescent detection systems
used in conjunction with high performance liquid chromatography (HPLC) to analyze HCQ
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concentrations. Only a few methods have been developed to simultaneously quantitate HCQ and
its major metabolites.340-343 These methods have the disadvantage of being labor intensive,
expensive, and time-consuming as well as requiring large sample volumes. The high sensitivity and
selectivity of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) has
allowed for the analysis of picogram drug quantities, establishing itself as a major tool for
bioanalysis.344,345 Despite the relatively high sensitivity of LC-MS/MS, methods for drug extraction
from tissue need to be refined and experimental parameters optimized on a drug-by-drug basis to
produce reproducible methods capable of analyzing low drug concentrations.
Although LC–MS/MS methods have been developed and validated for the quantitation of HCQ, 346349

limitations in these methods still preclude their implementation in PK studies involving mice.

Soichot et al. provided a method for the quantitation of HCQ with all three of its major metabolites
in whole blood (LLOQ; 25 ng/mL).348 Hong-Wei Fan et al. later developed a more sensitive method
of HCQ quantitation using plasma with a LLOQ of 0.2 ng/mL, but did not explore the method’s
potential for metabolite analysis or HCQ analysis from tissue.349 Furthermore, using plasma may
not be ideal for HCQ quantitation for two reasons. First, the plasma partition coefficient
(Kblood/plasma) concentration in whole blood to concentration in plasma is ≥ 1 for HCQ and its
metabolites. Thus, HCQ has a high affinity toward RBC, and whole blood is better suited for
quantitation of HCQ compared to plasma.350 Secondly, analyzing plasma requires a greater volume
of blood. For studies involving mice, only small amounts of blood should be sampled per time point
from each individual mouse in order to avoid compromising the integrity of blood composition.
Therefore, we have developed a simultaneous LC–MS/MS method for the quantiﬁcation of HCQ
and its three major metabolites from whole blood and tissues with a LLOQ of 1 ng/mL for all
analytes that is more suited for small animal studies. The validated bioanalytical method was
successfully applied to the quantitative analysis of HCQ (5 mg/kg intravenously) administered to
BALB/c mice for blood and tissue determinations of HCQ, DCQ, BDCQ, and DHCQ. Thus, this
method serves as a platform for the subsequent pharmacokinetic (PK) evaluation of CQ-HES as a
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sensitive and reliable method for quantitating free and total HCQ (polymeric + free) levels in blood
and tissue.
Materials & Methods
Chemicals and materials. HCQ, DCQ, BDCQ, DHCQ and HCQ-d4 (Figure 5.1) of
pharmaceutical grade were purchased from Sigma-Aldrich (St Louis, MO). HPLC-grade methanol
(MeOH), acetonitrile (ACN), diethyl ether (ether), zinc sulfate (ZnSO4), sodium hydroxide
(NaOH), and formic acid (FA) were obtained from Fisher Scientific (Fair Lawn, NJ). Centrifuge
tube filters were purchases from Corning Co. (Corning, NY). Ultrapure water was obtained from a
water purification system (ThermoFisher Scientific). All other reagents used in the study were of
analytical grade or higher and procured from standard chemical suppliers.
Liquid chromatographic and mass spectrometric conditions. A Shimadzu, Nexera UPLC
system equipped with a binary pump system (LC‐30 AD), column oven (CTO‐30AS) and an auto‐
sampler (SIL‐30AC) was used. Mass spectrometric detection was performed on an LC-MS/MS
8060 system (Shimadzu Scientific Instruments, Columbia, MD), equipped with a dual ion source
(DUIS) in positive electrospray ionization mode. The MS/MS system was operated at unit
resolution in the multiple reaction monitoring (MRM) mode. All chromatographic separations
were performed with a Thermo Aquasil C18 (50 × 4.6mm, 3µ) column equipped with a C18 guard
column (Thermo Scientific Inc).
The mobile phase consisted of 0.2% formic acid (FA) in water (mobile phase A) and 0.1% FA in
MeOH (mobile phase B), at total flow rate of 0.5 mL/min with a column temperature of 40 ℃. The
chromatographic separation was achieved using 7.5-minute gradient elution. The gradient was:
20% B from 0.0-2.0 min, 20-70% B from 2.0-6.0 min, 70-90% B from 6.0-7.0, 90-20% B from
7.0-7.1 min, and 20% B from 7.1-7.5 min. The injection volume of all samples was 10 μL.
The compound dependent mass spectrometer parameters, such as temperature, voltage, gas
pressure, etc., were optimized by the auto optimization method as included in the software package
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via product ion search for each analyte and the internal standard (IS) using a 1 µg/mL solution in
methanol. All analytes were more readily detected in positive ionization mode. The following
mass spectrometer source settings were utilized: nebulizer gas: 2.0 L/min; heating gas: 10 L/min;
drying gas: 10 L/min; interface temperature: 300 ℃; desolvation line temperature: 250 ℃; heat
block temperature: 400 ℃. The multiple reaction monitoring (MRM) transitions for each analyte
and IS, as well as their respective optimum MS parameters, such as voltage potential (Q1, Q3), and
collision energy (CE), are shown in Table 1. Data acquisition and quantitation were performed by
using LabSolutions LCMS Ver.5.6 (Shimadzu Scientific, Inc.).
Preparation of stock, calibration standards and quality control samples. Individual stock
solutions of 1 mg/mL of HCQ, DCQ, BDCQ, DHCQ and HCQ-d4 were prepared in 50:50
MeOH:H2O. The stock solutions were diluted with methanol to make working standard solutions,
which were further diluted to prepare the calibration standards (CCs) and quality control samples
(QCs). CCs were prepared by spiking 10 µL of mixed working standard solution into 100 µL of
blood (4x diluted) or tissue homogenate to obtain a concentration range of 1–2000 ng/mL for all
analytes. The obtained CCs concentrations were 1, 2, 5, 10, 50, 100, 500, 1000, 1700 and 2000
ng/mL in matrix. QCs at four different concentrations including the lower limit of quantification
(LLOQ; 1 ng/mL), low quality control (LQC; 6 ng/mL), middle quality control (MQC; 200 ng/mL)
and high quality control (HQC; 1500 ng/mL), were prepared separately in five replicates,
independent of CCs. All the main stocks, intermediate stocks, spiking calibration, and QCs stock
solutions were kept at -20 °C.
Blood and tissues sample preparation for free HCQ – acetonitrile liquid-liquid extraction
(LLE). All analytes were extracted from CCs, QCs, mouse blood, and tissue samples by simple
protein precipitation extraction method (PPT) using ACN. Briefly, 25 µL of mouse blood or 100
µL tissue homogenate of study samples were added into a 1.5 mL polypropylene (PP) tube and
spiked with 10 µL of IS working solution (HCQ-d4 solution 500 ng/mL). The solution was vortexed
for 30 seconds, followed by dilution with 100 µL of 1% FA and vortexed once more. Subsequently,
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1 mL of ice-cold ACN was added to initiate simple protein precipitation in the sample. The mixture
was vigorously vortexed for 2 minutes, followed by centrifugation at 17,950 x g for 20 minutes at
4ºC. Thereafter, 950 µL of the supernatant was transferred to another 1.5 mL PP centrifuge tube
and evaporated under vacuum at 50ºC. The dried residue was reconstituted with 100 μL of 0.1%
FA:MeOH (60:40), vortexed for 30 sec and centrifuged again at 17950 x g for 10 minutes at 4ºC.
The supernatant was transferred to an autosampler vial and 10 µL was injected.
Blood and tissues sample preparation for CQ-HES – diethyl ether liquid-liquid extraction
(LLE). Prior to extracting HCQ, remaining polymeric drug in the form of CQ-HES needed to be
cleaved from HES. Hydrolysis of CQ-HES was performed using base-mediated cleavage of the
carbonate bond. Initially, CQ-HES was prepared in 100 µL mouse plasma or tissue homogenate in
6 mL glass tubes and spiked with 10 µL of IS (HCQ-d4 solution 500 ng/mL). Aqueous NaOH (400
µL of 1 M) was slowly added, and the solution was vortexed for 30 seconds. Samples were then
covered and allowed to incubate at 50°C for 2 hours under gentle shaking. Samples prepared up to
this point will be referred to here on out as “hydrolyzed samples” for convenience.
HCQ was extracted from mouse plasma or tissue hydrolyzed samples (as described above) by
simple PPT using ZnSO4 instead of ACN. Briefly, 1 mL of ZnSO4 (1 M) was carefully added to
room temperatures samples prepared as described above. Diethyl ether (4 mL) was then added, and
the samples were vigorously vortexed for 5 minutes. After vortexing, samples were allowed to sit
until layers separated. The aqueous layer was then frozen using liquid nitrogen. Carefully, the
organic layer was transferred into another 6 mL glass tube, and the samples were dried under
nitrogen at 50°C. Final extracted samples were reconstituted with 100 μL of aqueous

methanol (40%) containing 0.06% FA. Samples were then vortexed for 30 sec and
centrifuged (17950 x g, 4ºC) for 10 minutes. The resulting supernatant (70 µL) was
transferred to a 96-well autosampler plate. Final samples were injected into LC–MS/MS
using 10 µL.
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Assay Validation. The developed LC-MS/MS method was fully validated according to the
Guidance for Industry: Bioanalytical Method Validation of USFDA (FDA, 2001). 351
Assay selectivity and specificity was determined by comparing the chromatogram of six different
blank mouse blood or tissue homogenate samples with that of HCQ, DCQ, BDCQ, DHCQ and ISspiked blood or tissue homogenate samples.
The sensitivity of the method was determined from the signal-to-noise ratio (S/N) of the analyte
response in the calibration standards. The S/N ratio was required to be greater than three for the
LOD and greater than ten for the LLOQ.
The calibration curves were established by plotting the peak area ratio (analyte/IS) versus
concentration for all analytes. Each calibration curve consisted of a blank sample, a zero sample
(blank + IS), and ten non-zero concentrations. The acceptance criteria for each back calculated
standard concentration were ± 15% standard deviation (SD) from the nominal value except at
LLOQ which was set at ± 20%.
Carry-over was checked by injecting two zero samples directly after injecting an HQC sample. The
response of the first zero sample was required to be < 20% of the response of a processed LLOQ
sample.
Accuracy and precision (intra- and inter-day) were determined by analyzing five replicates of QC
samples at four different levels (LLOQ, LQC, MQC, and HQC) in mouse blood or tissue
homogenate for three consecutive days. The acceptance criteria for all the QCs were ± 15% SD
from the nominal values with a precision of ± 15% relative standard deviation (RSD), except for
LLOQ, where the limit is ± 20% of SD.
Recovery and matrix effect. The extraction recoveries at three different QC levels (i.e. LQC,
MQC and HQC) were determined by comparing the peak area of HCQ, DCQ, BDCQ, and DHCQ
in extracted samples with those obtained by equivalent concentration of pure authentic standards
for each analyte in methanol. Recovery of IS was determined in the same way.
The matrix effect was evaluated at three QC levels for each matrix. Blank mouse blood and tissues
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from six different animals were processed. After extraction, the dry extract was spiked with analyte
prepared equivalent to QCs. Mean peak area of the analytes spiked in the blank matrix was
compared with QCs prepared in the methanol.
Dilution integrity. Dilution integrity was performed using two- and five-fold dilutions of the HQC
sample. Six replicates of each concentration (3000 ng/mL and 7500 ng/mL) were prepared in the
corresponding matrixes, diluted to 1500 ng/mL, and analyzed against the fresh calibration curve.
Stability. The stability of HCQ, DCQ, BDCQ, and DHCQ in blood samples following three freeze–
thaw cycles (room temperature to -80 ℃ to room temperature), long-term sample storage (−80 °C
for 60 days) and bench-top storage (20 ℃ for 8 h) was assessed by determining at LQC, MQC and
HQC concentrations (n = 3). Auto-sampler stability of extracted samples was evaluated at 4 °C for
36 h.
Animals, drug administration and sampling. All studies were approved by the Institutional
Animal Ethics Committee (protocol number 17-020-04-FC). Male BALB/c mice, weight ranging
from 20–25 grams were obtained from the Jackson Laboratory. Animals were housed in the
University of Nebraska Medical Center animal facility at a temperature of 23–25 ℃, relative
humidity of 50–70% and 12/12 hour light/dark cycles for one week prior to the experiments in
order to acclimatize the animals to the laboratory conditions. Pharmacokinetic studies and the tissue
distribution of HCQ and metabolites were conducted. Prior to dosing, the mice were fasted
overnight (12 hours) with free access to water and standard mice food was given 2 hours post dose.
Mice were divided into four groups of five mice each. The HCQ was administered intravenously
(i.v.) at a dose of 5 mg/kg of body weight. The dose was selected based on previous
pharmacological reports in mice. The i.v. dose was prepared in isotonic saline and administered via
the tail vein. Approximately 50 µL of whole blood was collected at 0.083, 0.25, 0.5, 0.75, 1, 2, 4,
6, 8, 24, 48 and 72 hours post dose into heparinized microcentrifuge tubes. Three blood time points
with one terminal time point were collected from every mouse. Blood samples (25 uL) were
transferred to a polypropylene tube and stored at -80 ℃ until analysis.
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Tissues (liver, lungs, heart, kidney, and spleen) were collected at 6, 24 and 72 hours following the
dosing. Tissue samples were rinsed thoroughly with phosphate buffered saline to remove blood and
then blotted with filter paper. After weighing, each tissue sample was individually homogenized
with deionized water (1:3, w/v) using a TissueLyserII (Qiagen Science, KY) and subsequently
stored at -80 ℃ until analysis. Blood concentration (ng/mL) and tissue concentration (ng/g) were
determined for each mouse. Drug accumulation in tissue was assessed by calculating a tissue to
blood concentration ratio (Kp) for each tissue. When the Kp value is greater than 1, it indicates the
tissue concentration is greater than the blood concentration, suggesting drug accumulation in the
tissue.
The pharmacokinetic parameters of HCQ and its metabolites in blood were calculated using noncompartmental analysis with Phoenix WinNonlin 6.3 (Pharsight Corporation, Mountain view, CA).
The maximum concentration (Cmax) and time to Cmax (Tmax) was obtained from the
concentration time plot. The maximum concentration (C0) at time zero was extrapolated. The area
under the curve (AUC0-∞) was estimated using the linear trapezoidal method from 0-tlast and
extrapolation from last time point to infinity based on the observed concentration at the last time
point divided by the terminal elimination rate constant (k). The elimination half-life (t 1/2) was
calculate using the formula of 0.693/k. For intravenous administration, clearance (CL) and the
apparent volume of distribution of the elimination phase (Vd) were calculated as dose/AUC0-∞ and
dose/k*AUC0-∞, respectively. The tissue to blood (Kp) ratio was calculated by using the following
formula:
Kp = Concentration in Tissue/ Concentration in Blood
Results
Chromatographic and mass spectrometric conditions optimization. To optimize MS conditions
for detection of HCQ and its metabolites, ESI and atmospheric pressure chemical ionization (APCI)
conditions were tested. It was found that the signal intensity of all analytes and the IS was higher
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by using the ESI source in positive mode compared to the APCI probe. During method
optimization, the mass spectra for HCQ, DCQ, BDCQ, HDCQ and IS revealed peaks at m/z 336.4,
292.4, 264.4, 308.5 and 340.4, respectively as protonated molecular ions, [M + H] +. The
fragmentation of analytes and IS were auto-optimized via precursor ion search of approximately
1000 ng/mL of stock solution for each analyte. The most abundant precursor > product ions with
the highest sensitivity for HCQ, DCQ, BDCQ, DHCQ and HCQ-d4 were found to be m/z
336.40>247.35, 292.30>114.45, 264.40>179.30, 308.50>179.30 and 340.40>251.40, respectively
(Figure 5.2). The compound dependent parameters such as voltage potential Q1 (V) and Q3 (V),
and collision energy (CE) were also optimized to obtain the highest signal intensity for all the
analytes and IS (Table 1).
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Figure 5.1 – HCQ and its metabolites: DCQ, BDCQ, DHCQ, and D4-HCQ1

Figure 5.2 –MS/MS Product ion spectra HCQ and its metabolites in positive mode: (a) HCQ,
(b) DCQ, (c) BDCQ, (d) DHCQ and HCQ-d4 (IS).

HCQ

MRM
transition m/z
(Q1→Q3)
336.40>247.35

DCQ

292.30>114.45

-10

-21

-12

4.6

BDCQ

264.40>179.30

-11

-22

-13

3.8

DHCQ

308.50>179.30

-19

-25

-13

4.0

HCQ-d4

340.40>251.40

-12

-22

-18

4.6

Analytes

Q1
(V)

CE
(V)

Q3
(V)

Retention
time

-11

-21

-18

4.7

Table 5.1 – Summary of MS/MS parameters: precursor ion, fragment ions, voltage potential
(Q1), collision energy (CE) and voltage potential (Q3) for analytes.
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In order to achieve a higher peak resolution and shorter chromatographic times for the all analytes,
various chromatographic conditions, such as different analytical columns, different mobile phases
(i.e. acetonitrile, methanol and water) and additives (i.e. formic acid, acetic acid, ammonium acetate
and ammonia) were tested. Complete and rapid chromatographic resolution of analytes and IS was
achieved with a gradient elution of the mobile phase on Thermo Aquasil C18 (50 × 4.6mm, 3µ)
column equipped with a C18 guard column, with no significant interference from the biomatrix or
endogenous compounds. Overall, 0.2% FA and 0.1% FA in MeOH as a mobile phase, at a ﬂow
rate of 0.5 mL/minute with a column temperature of 40 ℃, produced the best peak shape for all the
analytes. The retention times for HCQ, DCQ, BDCQ, DHCQ, and HCQ-d4 were 4.7, 4.6, 3.8, 4.0,
and 4.6 min, respectively. HCQ-d4 was selected as the IS because it had similar chromatographic
behavior without prolonging the analysis time and similar ionization response to that of the
analytes. Typical representative overlay chromatograms with blank plasma indicated no
interference of endogenous compounds at the retention time of HCQ, DCQ, BDCQ, DHCQ and
HCQ-d4, for samples spiked at the LQC concentration (Figure 5.3). Further, the reproducibility
(%CV) in the measurement of retention time for the analytes was 0.5% for 100 injections (data not
shown).
Assay validation - Specificity and selectivity. The specificity of the method was evaluated by
analyzing blank blood or tissue homogenate samples from six different animals to investigate
potential interferences at the retention time of all analytes and IS. No co-eluting peaks that were >
20% of the analytes area at LLOQ level and no co-eluting peaks > 5% of the area of IS were
observed. The representative UPLC overlay chromatogram with blank plasma, samples spiked at
LQC concentration is shown in Figure 5.3. The retention time for HCQ, DCQ, BDCQ, DHCQ and
HCQ-d4 were 4.7, 4.6, 3.8, 4.0, and 4.6 min, respectively. Analytes and IS peak showed less
variability with a RSD well within the acceptable limit of ± 5%.
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Figure 5.3 – Representative MRM ion-overlay chromatograms of HCQ (a), DCQ (b),
BDCQ (c), DHCQ (d), and HCQ-d4 (e) in blank plasma spiked at LQC level.
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Assay validation - Calibration curve and linearity. The method exhibited a linear response over
the of concentration range from 1 to 2000 ng/mL for all analytes, with a coefficient of determination
of 0.998 or better. The results were fitted using linear regression with the use of 1/x 2 weighting.
The lowest concentration with RSD <20% was taken as LLOQ and was found to be 1.0 ng/ml.
Assay validation - Carry-over. The analytes showed no significant peak (< 20% of the LLOQ) in
zero samples injected after the HQC samples. Thus, there was no significant carry over effect.
Assay validation - Accuracy and precision. The inter-day accuracy and precision results for the
detection of HCQ and metabolites in mouse blood and tissue samples at four different
concentrations are presented in Table 5.2. The RSD of precision values ranged from 2.3 to 12.9%,
indicating acceptable assay precision. The accuracy of the quantitative analysis of the compounds
was within the acceptance limits at all concentration levels.
Recovery and matrix effect. The recovery of analytes was calculated from the spiked blood and
tissue samples at the LQC, MQC and HQC concentrations. The absolute mean recoveries are
provided in Table 5.3 for HCQ, DCQ, BDCQ, and DHCQ, respectively. In addition, the extraction
recovery of HCQ-d4 was 81.5 ± 7.3%. The matrix effects for all the biological samples ranged
from 93.45 to 105.26%.
Dilution integrity. The dilution integrity was confirmed for samples that exceeded the upper limit
of the standard calibration curve.
Stability. Table 5.4 summarizes the data from stability experiments, where the mean concentration
(expressed as percentage accuracy from nominal concentration) at each level is presented together
with SD. In the different stability studies, analytes were found to be within ± 15% of the actual
concentration at the LQC, MQC and HQC concentrations.
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Heart

Spleen

Kidney

Lungs

Liver

Blood

Bio- Analyte LLOQ (1 ng/mL) LQC (6 ng/mL)
MQC (200 ng/mL) HQC (1500 ng/mL)
Matrix
Accuracy % RSD Accuracy % RSD Accuracy % RSD Accuracy % RSD
HCQ

112.5

5.7

110.1

6.1

98.3

8.4

112.5

6.6

DCQ

102.3

2.5

107.2

4.2

97.8

8.2

102.3

3.2

BDCQ

104.6

3.4

108.4

3.7

96.9

5.4

105.6

4.8

DHCQ

100.7

7.5

112.7

1.3

96.7

1.3

100.7

3.8

HCQ

99.2

5.6

98.1

3.7

97.8

10

87.3

1.8

DCQ

100.7

6

112.7

4.3

96.7

1.3

105.3

5.8

BDCQ

104.6

1.4

108.4

3.7

96.9

5.4

107.5

4.8

DHCQ

104.5

1.4

114.5

3.3

87.1

5.6

91.1

3.2

HCQ

90.5

5.5

114.7

7.8

92.1

10.8

84.7

4.3

DCQ

109.9

2.9

100.4

0.9

103.1

10.3
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5.4

BDCQ

112.5

11.9

112.1

7.1

96.3

12.4

102.8

6.6

DHCQ

102.3

2.5

107.2

2.2

97.8

11.2

90.2

3.2

HCQ

102.9

14.3

106.7

2.3

105.8

10.2

107.3

1.4

DCQ

112.2

10.6

103.3

2.3

103.9

9.1

108.3

4.5

BDCQ

100.2

4.3

114.4

3.1

100.6

9.1

101.1

55

DHCQ

101.3

2.5

107.5

5.8

101.9

11.2

98.3

2.7

HCQ

90.9

5.1

95.5

4.6

107.6

9.2

107.7

6.1

DCQ

109.6

7.1

105.3

2.7

90.1

11.7

106.5

4.6

BDCQ

104.3

4.3

109.9

9.7

104.7

5.4

107.8

8.9

DHCQ

90.1

7.1

106.1

2.9

101.5

9.2

109.1

8.9

HCQ

116.6

4.2

105.7

2.4

101.4

10.2

108.7

7.1

DCQ

110.8

3.8

99.9

4.7

102.5

9.1

95.7

5.5

BDCQ

103.2

5.1

115.1

3.2

92.2

10

108.1

7.2

DHCQ

101.7

4.4

109.6

5.4

100.5

7.4

90.5

4.7

Table 5.2 – Accuracy and precision (% RSD) of LC-MS/MS method for HCQ, DCQ, BDCQ
and DHCQ in mouse blood and tissues.
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Analyte

% Extraction recoveries (Mean ± SD, n=5)
Lungs

Liver

Kidney

Spleen

Heart

HCQ

Blood
84.1±12.9

89.4 ± 9.2

91.1 ± 7.9 75.1 ± 10.2 78.1 ± 13.5 81.5 ± 9.9

DCQ

73.8 ± 7.0

69.5 ± 6.5

74.8 ± 5.4 67.8 ± 10.5 69.2 ± 11.0 64.8 ± 7.0

BDCQ 68.5 ± 12.4 71.2 ± 8.5 72.3 ± 11.5 64.5 ± 7.4 75.5 ± 12.4 68.5 ± 8.7
DHCQ 72.5 ± 7.6 75.0 ± 11.2 68.7 ± 9.8

69.5 ± 8.4 62.5 ± 10.3 74.8 ± 9.6

Table 5.3 – Mean extraction recoveries of the HCQ, DCQ, BDCQ and DHCQ from mouse blood
and tissues.

% Stability recoveries (Mean ± SD)
Freeze-thaw
Analyte (–80 ± 5 ℃
after three cycle)

Long-term (–80 ± 5
Auto-sampler (4 ℃, Bench-top (20 ℃,
℃, 60 days)
36 hrs)
8 hrs)

HCQ

90.7 ± 4.2

91.4 ± 7.8

103.4 ± 8.6

107.3 ± 7.8

DCQ

95.2 ± 6.5

96.2 ± 10.5

98.5 ± 9.6

10.3.5 ± 8.7

103.4 ± 11.2

107.2 ± 10.7

109.4 ± 1.6

95.4 ± 8.7

103.5 ± 7.8

102.2 ± 8.8

BDCQ 105.3 ± 4.3
DHCQ 107.2 ± 7.9

Table 5.4 – Mean stability recoveries of the HCQ, DCQ, BDCQ and DHCQ at different storage
conditions in blood.
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Applications of the method for PK studies. The developed and validated LC-MS/MS method
was successfully applied to the determination of HCQ pharmacokinetics and tissue distribution
following a single i.v. dose of HCQ (5 mg/kg) in mice. The blood concentration vs. time profile for
the HCQ and its metabolites is shown in Figure 5.4. The pharmacokinetic parameters of HCQ and
DCQ in mice are summarized in Table 5.5. The compound reached a maximum concentration (C0)
1747 ± 329 ng/mL of HCQ and (Cmax) 36.1 ± 11.2 ng/mL of DCQ in blood. The area under the
curve (AUC0–∞ ) were determined to be 5578 ± 882 and 384 ± 83 hr×ng/mL for HCQ and DCQ,
respectively. The apparent volume of distribution and clearance of HCQ was found to be 17 ± 4
L/kg and 0.9 ± 0.2 L/hr/kg, respectively. The plasma elimination half-life (t1/2 ) was 13 ± 1 hrs and
14 ± 6 hrs for HCQ and DCQ, respectively. Both HCQ and DCQ were detected in plasma up to
72 hrs, which was the last time point monitored. The percentage extrapolation of AUC from the
last measured time point to infinity was less than 5%.
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Figure 5.4 – Blood Concentration-Time profile of HCQ, DCQ, BDCQ, and DHCQ after 5
mg/kg intravenous administration of HCQ (Mean ± SD, n=5).

Parameters

Estimates (mean ± SD)
HCQ

DCQ

1746.9 ± 329.0

-

NA

36.1 ± 11.2

12.7 ± 1.1

13.7 ± 5.6

AUC0- ∞(hr×ng/mL)

5577.8 ± 881.8

383.9 ± 83.2

AUC0-last (hr×ng/mL)

5490.6 ± 890.0

369.3 ± 74.3

Vd (L/kg)

17.0 ± 4.3

NA

Cl (L/hr/kg)

0.9 ± 0.2

NA

C0
Cmax (ng/ml)
t1/2 (hr)

Table 5.5 – Pharmacokinetic parameters of HCQ and DCQ after 5 mg/kg intravenous
administration of HCQ (Mean ± SD, n=5).
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Discussion
Concentrations of HCQ and all three major metabolites were detected in all studied tissues (Table
5.6). In addition, our data show that the tissue to blood concentration ratio (Kp) is ≥1, significantly
high (Table 5.6), indicating high affinity to tissues. The Kp ratios for HCQ were observed in the
descending order of lungs>kidney>spleen>liver>heart, whereas for HDCQ, DCQ, and BDCQ it
was liver>kidney>lungs>spleen>heart. Higher concentrations in different tissues suggest that
further toxicological studies are required to investigate the relation between drug concentration and
effect, both therapeutic and toxic, after repeated dosing. With multiple lines of evidence suggesting
the metabolites of HCQ are active and at least partially related to HCQ efficacy and toxicity, this
method will allow for the characterization of exceedingly low concentrations of HCQ and its
metabolites in small animal studies. Furthermore, the results presented in this chapter demonstrate
that both free and polymeric drug levels of HCQ can be quantified using these two methods. In the
latter though, the same sample must be analyzed using the two methods, free and total, and the
difference between those values would describe the amount still remaining in the polymeric
version, CQ-HES.
The two methods differ greatly in terms of extraction due to the pH differences. To obtain free
HCQ levels, formic acid creates a slightly acidic environment after which ACN is used for LLE.
Several iterations were attempted to degrade the carbonate bond to release HCQ, and initially acidic
conditions were employed. However, these failed to degrade the polymeric compound. Basic pH
cleavage using NaOH was then attempted, which appeared more promising, but subsequent
extraction using acidic conditions proved problematic. First, it was somewhat difficult to add
precise amounts of an HCl solution to neutralize the sample due to slight differences in volumes
added that occur at the high throughput level. Second, HCQ acts as a buffer, and varying
concentrations of the drug produced issues that also precluded the use of pH neutralization at a high
throughput level.
To circumvent this issue, a stronger organic solvent LLE was implemented, which takes advantage
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of the basic conditions of the biological samples as HCQ in its deprotonated form is much more
lipophilic. Initial runs using this method seemed to give highly variable results, and it was
concluded that ether extraction of phospholipids could be to blame. Thus, the addition of ZnSO 4
after the cleavage step was explored to resolve this issue. Concomitantly this doubled as a means
of protein precipitation aiding in extraction. This was ultimately found to be a satisfactory
approach, and further conditions were optimized to yield the best extraction possible while
balancing time per sample to facilitate adaption to the large-scale level for a future PK study, i.e.
involving multiple mice, tissues, and time points. For cleavage, a three-hour incubation was not
superior to two in further cleaving HCQ from CQ-HES, and two LLE extractions was not any better
than just one. Use of liquid nitrogen to freeze of the aqueous layer allowed for simple and fast
transferring of the extracted HCQ. Even the appropriate ratio of ZnSO4 to NaOH was studied and
optimized.

Blood Conc.
(ng/mL)

131.2 ±24.0
58.6±26.3
4.7±1.2

24.5±3.9
12.7±6.3
1.3±1.3

2.1±0.7
2.1±0.8
1.4±0.7

10.1±2.4
10.3±3.1
5.6±2.9

Time
(hr)

6
24
72

6
24
72

6
24
72

6
24
72

HCQ

DCQ

BDCQ

HDCQ

15.2±4.0
39.4±18.9
55.7±5.4
24.4±5.4

29.0±2.9
25.6±11.0
29.5±6.4
16.5±5.0

Lungs (Kp)

212.4±37.7
178.3±120.5
61.9±13.6

73.8±19.9
64.0±53.4
31.7±9.6

417.0±92.4
277.7±177.6
50.4±10

3,395.9±611.4
1,739.3±1214.6
147.5±72.9

Lungs Conc.
(ng/g)

6.9±0.9
8.1±3.6
11.2±0.2
5.5±1.2

Heart (Kp)

66.3±20.4
58.6±28.8
22.9±2.21

22.9±7.3
23.7±12.6
15.7±3.3

121.6±32.9
92.2±48.4
15.9±2.7

816.11±279.4
461.18±288.4
31.1±11.8

Heart Conc.
(ng/g)

Abbreviation: Kp: Tissue to blood concentration ratio, NA: Not applicable.

(top) and tissue to blood concentration ratio (bottom) after 5 mg/kg intravenous administration of HCQ (mean ± SD, n=5).

Table 5.6 – Tissue distribution profile of intravenous HCQ administration. HCQ, DCQ, BDCQ and DHCQ blood and tissues concentration

10.8±4.6
43.2±9.6
195.4±110.1
114.3±73.1

11.6±2.9
14.6±3.6
17.7±5.8
19.3±9.1

NA
NA
NA
NA

HCQ
DCQ
BDCQ
HDCQ

6 to 72
6 to 72
6 to 72
6 to 72

Spleen (Kp)

50.6±6.9
31.6±16.1
19.1±14.3

340.0±17.9
144.5±74.8
24.5±18.5

1,899.9±103.1
673.1±350.5
41.0±37.8

Spleen Conc.
(ng/g)

Tissue to blood concentration ratio (Kp) Mean ± SD
Kidney (Kp)
Time
Liver (Kp)
(hr)

116.4±25.1
128.7±71.8
69.9±28.2

530.7 ±160.6
473.8 ±297.4
78.7 ±33.7

1,465.4±441.5
887.7±541.0
89.8 ±46.4

Kidney Conc.
(ng/g)

298.7±19
163.6±86.7
69.0±74.3

1,957.5±315.2
1,021.2±560.5
277.9±83.1

671.8±135.6
294.4±148.9
173.3±103.9

1,322.4±143.6
453.4±196.4
53.1±26.7

1,918.3±130.3
700.6±347.1
26.8±41.6

Liver Conc.
(ng/g)

254.7±149.6
302.5±186.1
103.6±38.1

Analytes
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Conclusion
This chapter describes two analytical methods that will allow for the quantitation of free and
polymeric HCQ in blood and tissue. Preclinical studies investigating the therapeutic effects of HCQ
have empirically used blood concentrations following the administration of the maximum tolerated
dose (MTD). There is a lack of information regarding tissue distribution of HCQ, and even less
information regarding metabolite concentrations accumulating in tissues and tumors. To evaluate
the effects of combination therapy on tumor response and drug toxicity, it is critical to quantitate
drug concentrations in tissues and tumors. Moreover, several of the metabolites of HCQ are active,
and the relationship between metabolite concentration and efficacy or toxicity remains unclear.
Developing an enhanced understanding the PKs of HCQ and its metabolites in animal models, and
their interaction with other therapies are crucial in characterizing and further optimizing
combination therapies involving HCQ. In regards to CQ-HES, it will be imperative to know how,
if at all, varying the degree of substation (DOS) in this polymeric drug affects its tissue distribution,
especially within the tumor. Performing a thorough PK evaluation of CQ-HES, selecting a
formulation with an optimal DOS, and establishing an appropriate dosing regimen will ensure a
proper in vivo assessment of the anticancer activity of CQ-HES. Thus, the analytical methods
developed in this chapter will be critical in guiding future in vivo studies of CQ-HES as well as
other similar polymeric formulations of HCQ.
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Chapter 6: Pharmacokinetics of CQ-HES

Portions of the content covered in this chapter are the subject of a published
article in Journal of Chromatography B by Chhonker & Sleightholm et al.2
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Introduction
HCQ has one of the largest volumes of distribution. This is due to a few unique characteristics of
HCQ. First, the amines in HCQ have a pKa which at blood-relevant pH is neutral giving HCQ a
high lipophilic profile. At more acidic pHs, such as those found intracellularly within lysosomes or
in certain tissues, the amines become protonated imbuing HCQ with a positive charge and causing
its retention within that environment, or at least preventing its ability to readily permeate through
cellular membranes compared to its uncharged state. This facilitates the wide and nearly ubiquitous
distribution of HCQ to all tissues. Some reports suggest that HCQ more preferentially deposits in
highly pigmented areas. One may deduce that the highly pigmented areas are more abundant in
lipophilic compounds and thus contribute to greater lipophilic drug deposition. One may also
speculate that this accusation was largely a result of studies investigating retinopathy associated
with HCQ administration, and that pigmented epithelium of the eye are damaged by HCQ
accumulation. Thus, the association of pigmented cells and HCQ accumulation was made.
Additional studies supporting and refuting this claim have been similarly published ranging from
different pigmented mouse breeds to darker pigmented humans showing variable HCQ levels.
Regardless of the reason for wide-spread tissue distribution and variability due to pigment, creating
a polymeric version of HCQ would undoubtedly alter the tissue distribution and PK profile of HCQ.
Thus, in our exploration of an improved formulation of HCQ via polymeric formulation, we sought
to determine the altered PK profile and how it may impact the overall efficacy of CQ as a sensitizing
agent for the in vivo anticancer effects of certain chemotherapeutics and radiation.
Materials & Methods
Materials. For all cell culture-related reagents and materials, please refer to Chapter 3. For all
reagents and materials associated with LC-MS/MS, please refer to Chapter 5.
Cell Culture. KPC-derived cancer cells (KPC 8060), a kind gift of Dr. Hollingsworth, were
harvested from spontaneous KPC mice and grown in culture until ready for use. Cells were cultured
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under previously describe conditions found in Chapter 3. Cells were grown to ~50-70% confluency
before using.
Orthotopic Syngeneic Mouse model of PDAC. All animal work was approved by the University
of Nebraska Medical Center and conducted according to IACUC protocol 17-020. C57BL/6 mice,
termed Black6, were purchased from Charles River Labs. A more thorough description of the
surgical procedure used to orthotopically inject cells into the pancreas can be found in Chapter 4.
Briefly, cells were washed 1x with 10 mL of PBS, and then released with 1 mL of TrypLE. Cells
were then spun and rinsed 3x with 10 mL PBS. Final stock solution of cells was ~1 x 10 6 cells/mL
and stored on ice until injected. Approximately, 50 µL of cell solution was injected in the body of
the pancreas. Mice were housed under normal conditions throughout the entirety of the study.
Approximately four to five days after surgery, staples were removed, and mice were assigned to
treatment groups on day 7, when the respective drug was administered.
Drug Administration. CQ-HES was prepared as previously described. Briefly, stock CQ-HES
was dissolved in DMSO and further diluted using HEPES-buffered glucose solution when needed.
Solution pH was doubled checked prior to administration to ensure no buffering occurred due to
CQ. Mice were injected via tail vein using approximately 200 µL, which was corrected for each
mouse per its respective weight (w), 200*w/20.
Collection of blood and tissue. After drug administration, blood and tissues were collected at
specified time points as previously described in Chapter 5.
Quantitation of HCQ from blood and tissue. Methods for quantitation of free and total HCQ
were described in Chapter 5. HCQ persisting as CQ-HES in the polymeric form was determined to
be the difference between total and free amounts in any given sample. GraphPad Prism 7 was used
to graph all data, which is presented as mean ± standard deviation. Exponential decay functions
were used to plot trend lines for blood PK results.
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Results
Effects of HCQ Content on CQ-HES Tissue Distribution
Five different CQ-HES polymers with varying degree of substitution (DOS) were tested. Their
corresponding wt/wt% of HCQ is as follows: 3% – CQ-HES3%, 6% – CQ-HES6%, 9% – CQHES9%, 18% – CQ-HES18%, AND 24% – CQ-HES24%. Their tumor and liver distribution at 24
hours is displayed in Figure 6.1. CQ-HES displayed a higher propensity to distribute to the liver
over free HCQ. Moreover, increasing the DOS was found to increase the HCQ distribution to the
liver, and the level to which CQ-HES deposited in the liver was directly proportional to the degree
of substitution, R2 = 0.986 (Figure 6.1). Conversely, there was no observable difference in tumor
uptake between the different CQ-HES formulations. Lastly, all polymeric formulations showed
relatively similarly levels of distribution to the eyes, which were 2-3 fold lower than in mice
administered free HCQ (Figure 6.2).
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Figure 6.1 – Effect of HCQ content on CQ-HES Liver and Tumor Distribution. All
CQ-HES formulations were administered at 5 mg/kg and compared to free HCQ at 24 hours. Tissue
levels were described as total HCQ content within the tissue as ng per g of tissue, mean ± standard
deviation (n = 5). Left: Distribution to the liver versus tumor as it compares to free HCQ for the
different CQ-HES formulations. Right: Linear regression correlating CQ content to liver levels for
CQ-HES.
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Figure 6.2 – Effect of HCQ content on CQ-HES Eye and Brain Distribution. All CQHES formulations were administered at 5 mg/kg and compared to free HCQ at 24 hours. Tissue
levels were described as total HCQ content within the tissue as ng per g of tissue, mean ± standard
deviation (n = 5).
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Pharmacokinetic (PK) Profile of CQ-HES18%
The effects of CQ-HES on altering the PK profile was first investigated using CQ-HES18%
because of its perceived strong nanoparticle formation. First, effects on blood clearance were
assessed. CQ-HES18% remained in the blood longer than free HCQ, prolonging the half-life from
approximately 12 to 20 hours (Figure 6.3). Next, all major organs were analyzed for HCQ content
including the kidneys and liver, involved in HCQ metabolism and clearance, as well as the spleen
and lungs, which are known to accumulate nanoparticles, and the pancreas (Figure 6.4). The liver
displayed significantly higher levels of HCQ, 95% of which was in the polymeric form while the
other 5% was free HCQ at 6 hours (Figure 6.4). Overall, the total liver levels for CQ-HES were
nearly 10-fold higher than that of free HCQ (Figure 6.5). Kidney and spleen also displayed much
higher distribution with CQ-HES18% compared to HCQ (Figure 6.6). On the other hand, lung
levels were fairly comparable between free and polymeric HCQ at 6 and 24 hours (Figure 6.6).
However, levels at 72 hours remained high in the lungs, approximately 1,300 ng/g, which were
almost entirely in the polymeric form. In fact, in mice administered CQ-HES18%, tissues generally
displayed elevated levels at 72 hours that were mostly polymeric. Samples of remaining drug were
examined to ensure CQ-HES did not degrade prior to administration. It was found that only minute
levels of HCQ were detectable by the free HCQ method validating the integrity of the carbonate
linker and HCQ in the polymeric formulations administered (CQ-HES) was in the polymeric form
(data not shown).

hours were indifferent between groups (data not shown).

± standard deviation (n = 5). Left: Blood analyzed up to 4 hours. Right: zoomed in showing only 2 hours (right). Blood values measured after 4

Figure 6.3 – Blood levels of HCQ after CQ-HES18% administration. CQ-HES was administered at 5 mg/kg and compared to free HCQ, mean
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and no trend lines were applied due to the short timing and limited data points collected.

HCQ (right). Tissue levels reported as ng HCQ per g tissue, mean ± standard deviation (n = 5). Lines represent the connection of moving averages,

Figure 6.4 – Tissue levels of HCQ after CQ-HES18% administration. CQ-HES18% (left) was administered at 5 mg/kg and compared to free
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as ng HCQ per g tissue, mean ± standard deviation (n = 5).

Left: Total levels of HCQ. Right: Levels of Free HCQ. CQ-HES18% was administered at 5 mg/kg and compared to free HCQ. Liver levels reported

Figure 6.5 – Liver levels of HCQ after CQ-HES18% administration.
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as ng HCQ per g tissue, mean ± standard deviation (n = 5).

Top: Total levels of HCQ. Bottom: Levels of Free HCQ. CQ-HES was administered at 5 mg/kg and compared to free HCQ. Tissue levels reported

Figure 6.6 – Spleen, kidney, lung levels of HCQ after CQ-HES18% administration.
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Pharmacokinetic (PK) Profile of CQ-HES6%
Similarly, CQ-HES6% was investigated for its effects on altering the PK profile of HCQ. A more
thorough tissue distribution was explored as this formulation was felt to be more suitable for an in
vivo efficacy study based on the findings presented in the previous sections as well as those of the
pilot study presented in Chapter 4. The following tissue levels were examined in tumor bearing
mice: liver, kidney, spleen, brain, eye, and tumor (Figure 6.7). Furthermore, this study investigated
tissue levels up to seven days after a single injection. Kidney levels were high initially (>10,000
ng/g tissue), but were almost entirely cleared after seven days. Similarly, liver levels were high
initially, and the rate of clearance for the polymeric HCQ was much slower than in the kidneys.
HCQ levels in tumors seemed to follow a similar exponential decrease as seen in the kidneys, but
tumors were much larger at seven days compared to six hours, approximately 69 ± 12 mg v 250 ±
85 mg. Comparing tumor levels at one versus six days, total levels of HCQ in tumors were higher
with free HCQ initially, but levels persisted longer with the polymeric formulation (Figure 6.8).
Retinopathy is an issue with high and prolonged administration of HCQ; thus, total levels of HCQ
in the eyes were examined (Figure 6.8). Free HCQ distributed more readily to the eye. Overall,
CQ-HES6% showed a 50-60% decrease in total HCQ content of the eye. Moreover, both free and
polymeric HCQ displayed levels in the eye that were just as high at day six as they were originally
at 24 hours. This was unique to the eye as all other tissues examined showed decreased levels of at
least free HCQ after extended durations.
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Figure 6.7 – 7-Day tissue and tumor distribution after CQ-HES6% administration.
Top: Tissue levels assessed after single administration of 5 mg/kg and reported as ng HCQ per g
tissue, mean ± standard deviation (n = 3). *Indicates values excluded for calculation of trend line.
Bottom: Tumor levels versus tumor size comparison.
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Figure 6.8 – Tumor and eye levels of HCQ after CQ-HES6% administration.
Left: Tumor levels of total HCQ. Right: Eye levels of total HCQ. Levels reported as ng HCQ per
g tissue, mean ± standard deviation (n = 5).
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Discussion
In a perfect setting, a thorough test of all formulations would be ideal, but PK studies are timeconsuming, expensive, and taxing due to the sheer size and large logistical constraints. Preliminary
in vitro findings presented in Chapter 2 supported stronger nanoparticle formation in the higher
DOS formulations. Further findings presented in Chapter 4 suggested an indiscriminant anticancer
activity in the pilot in vivo study (Figure 4.1). Furthermore, high DOS would deliver a greater
amount of HCQ per molecule to tumors, which could be valuable in the setting of co-administration
with a chemotherapeutic or in combination with radiation. Thus, a higher DOS was chosen to be
studied initially. Since a large amount of compound would be need for a PK study and potentially
a subsequent efficacy study, new batches of CQ-HES were produced. The resulting products were
produced: 3% – CQ-HES3%, 6% – CQ-HES6%, 9% – CQ-HES9%, 18% – CQ-HES18%, and 24%
– CQ-HES24%. As previously described, CQ-HES with HCQ content above 20% wt/wt% were
difficult to prepare for in vivo applications. Thus, CQ-HES18% was believed to be the best
formulation for tumor accumulation that would translate into a better combination when codelivered with a traditional chemotherapeutic like gemcitabine.
Chronologically, CQ-HES18% was tested first. Blood PK showed an improved circulation time,
increasing the blood half-life of free HCQ from 12 to almost 20 hours (Figure 6.3). However, the
levels of total HCQ in the liver were very high and persisted up to 72 hours. Furthermore, many
other tissues demonstrated very high levels that did not change much over the course of 72 hours.
In particular, the kidneys displayed very high levels, which also did not change much over the
course of 72 hours. The pancreatic levels of HCQ were as high as the kidneys at six hours. Strangely
though, these levels declined rapidly as almost 50% was gone at 24 hours and 90% at 72 hours. It
is unclear if the mechanism behind the observed decrease was a result of excretion, metabolism, or
a combination of both. Perhaps the difference in enzymes could explain the discrepancy; esterases
could degrade the linker of CQ-HES, which would then allow the free HCQ to be rapidly cleared
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from tissue. Conversely, the steric hindrance of the starch may prevent enzymatic degradation of
HCQ or the linker, and amylase may facilitate the destruction of the polymeric drug by simply
creating smaller monomers, which are more enzymatically accessible. The pancreas could also be
simply excreting CQ-HES into the digestive tract or the alkaline conditions could be facilitating a
base-dependent passive degradation process of CQ-HES. These mechanisms are simply
speculative, but provide reasonable explanations for why the polymeric drug is cleared so rapidly
and efficiently in this tissue over all the others examined.
The lungs also displayed a relatively high rate of HCQ clearance. Initially, the lungs exhibited
modestly high distribution, but concentrations decreased 70-80% by 72 hours. So while this was
relatively fast compared to other tissues, it was far from the absolute clearance seen in the pancreas.
The spleen was the only tissue to show an increase from 6 to 24 hours, although there was
significant variability at this time point. Thereafter, levels declined by 50% over the next 48 hours.
This seemingly obscure trend is easily explained by the large drug size. Large objects are readily
taken up by macrophages which subsequently become sequestered in the spleen. Nanoparticles are
a prime example of this, and this phenomenon is well-characterized in the literature in regards to
large polymeric drugs and nanoparticles.
Overall, CQ-HES18% distributed to major organs in such high quantities that in some instances,
such as in the liver and kidneys, it appeared as if they were not being degraded to any appreciable
degree over the examined time period. For a number of reasons, gemcitabine or oxaliplatin were
the likely candidates for a combination therapy study of a co-delivered chemotherapeutic.
However, these drugs are known to cause hepatic and renal toxicities. With these findings, there
were concerns that multiple administrations of a CQ-HES18% and one of these two
chemotherapeutics could induce substantial toxicities when given in combination. So it was decided
to screen all currently available formulations in order to ascertain a DOS that would yield the best
balance of tissue distribution for combination treatment.
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Before performing a thorough exploration into the PK profile of an additional CQ-HES
formulation, all five combinations were generally tested for tumor and liver distribution (Figure
6.1). Results from these preliminary PK tests demonstrated that DOS had little bearing on tumor
levels of HCQ between formulations, which seemed to agree with the pilot study in Chapter 4
showing CQ-HES16% and CQ-HES8% were almost equally as efficacious in reducing primary
tumor growth (Figure 4.1). On the other hand, the DOS appeared to directly correlate with the liver
uptake (Figure 6.1). CQ-HES8% from Chapter 4 also demonstrated an ability to reduce liver
metastasis, which was felt to be a combination of reduced dissemination of the primary tumor and
modest liver levels preventing implantation. Therefore, a lower DOS seemed to be more suitable
to balance efficacy and toxicity, and CQ-HES6% was selected for further study.
Looking at the tissue distribution profile of CQ-HES6% (Figure 6.7), liver levels were a third as
high as CQ-HES18%. Moreover, they decreased to nearly half their concentration over the course
of 72 hours as opposed to CQ-HES18%, which only showed a minimal decrease in a similar period.
Levels of HCQ in the kidney, although similarly as high initial, were nearly 50% after three days
and almost entirely cleared after seven days. In addition to displaying a generally lower deposition
in these major organs, CQ-HES6% appeared less stable than CQ-HES18%, though it significantly
improved retention compared to free HCQ. These differences support the idea that a higher DOS
possess stronger cohesive force to assemble into nanoparticles and as a result are more enzymatic
stable due to steric hindrance.
The tumor distribution of CQ-HES6% was also examined (Figure 6.7). Initial levels were fairly
high, ~3,500 ng/g at 6 hours and ~2,300 ng/g at 24 hours, but persistently decreased over the next
few days. In comparison, free HCQ displayed levels of approximately 4,000 ng/g at 24 hours, but
concentrations at 6 days were almost 10 times greater in the CQ-HES6% cohort. The validity of
these results as a longitudinal comparison, like the results presented in other tissues, is somewhat
inaccurate. These tumor studies were started seven days after implantation, and tumors at six hours
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were approximately 0.5 cm and soft in texture with ill-defined borders. Conversely, tumors
harvested at the end of the study were large and hard with well-defined borders. The average size
for tumors harvested at six hours was 69 ± 12 mg compared to seven days at 250 ± 85 mg. Thus,
the growth of the tumor artificially suppressed the quantitated levels of HCQ. Comparing free HCQ
versus CQ-HES6% at these time points may be a fair comparison when speaking in terms of
relativity, but a great deal of caution should be implemented when discussing the values presented
herein, even though they have been normalized on a per gram of tissue basis. Furthermore, the
orthotopic implantation of tumor cells into the pancreas precluded the analysis of pancreatic levels
as the tissue collected was probably not healthy, normal pancreas. Thus, this tissue was not
analyzed.
One of the biggest concerns with high dose or prolonged administration of HCQ is the development
of retinopathy. The pigmented retinal cells of the eye are particularly susceptible to toxic
accumulation of HCQ. Therefore, levels of HCQ in the eye and brain were quantitated and
compared between treatments (Figure 6.8). Levels were approximately 2-3 times greater in free
HCQ administration versus CQ-HES6%. More striking, these levels were just as high at six days
as they were initially quantified 24 hours post-administration. It was unsurprising that levels did
not change in the CQ-HES6% group as the polymeric formulations were generally more stable, but
levels in the eye were unchanged even for free HCQ. The inability to clear HCQ even after 6 days
underscores the fragility of this tissue and the concern for potential cumulative toxicity in subjects,
human or otherwise, receiving multiple doses or chronic therapy.
There are also rare reports of seizures or mental disturbance with HCQ treatment. The brain was
analyzed for levels after both HCQ and CQ-HES6% administration. Neither formulation yielded
any significant levels within the brain (data not shown).
Conclusions
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Overall, higher DOS formulations resulted in higher distribution to the major organs. Moreover, a
higher DOS formulations appeared more stable as tissue levels generally remained stable or
decreased slowly. Thus, it was concluded that off-target tissue distribution of CQ-HES18% would
result in an unfavorable toxicity profile compared to CQ-HES6% when given in combination with
gemcitabine or oxaliplatin. Free HCQ displayed a higher deposition and retention in the eye than
all CQ-HES formulations tested. The results presented herein led to the selection of CQ-HES6%
as the lead candidate in the proceeding in vivo efficacy studies. Moreover, analysis of kidney and
liver function (biomarkers and histopathological analysis) and cumulative tissue levels of HCQ
should accompany subsequent efficacy study in order to thoroughly characterize the therapeutic
window and potential translatability of this polymeric formulation.
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Chapter 7: in vivo Chemosensitization of CQ-HES in PC
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Introduction
Previously, CQ-HES was shown to be synthesized via a carbonate linker (Chapter 2), which didn’t
alter in vitro biological properties, i.e. autophagy inhibition or cytotoxicity (Chapter 3). The higher
degree of substitution (DOS) formulations more readily assembled into nanoparticles, and this
characteristic was assumed to be beneficial for in vivo applications as the enhanced permeability
and retention (EPR) effect of nanoparticles improves tumor distribution. However, preliminary
studies using a xenograft model of pancreatic cancer (PC) suggested a similar efficacy for CQHES16% and CQ-HES8% in reducing primary tumor growth (Chapter 4). The difference in
primary tumor growth was markedly different in mice receiving CQ-HES compared to mice that
did not receive treatment or mice that received free HCQ, while the difference between CQ-HES
formulations was negligible. Both formulations showed reduced rates of liver metastasis with CQHES8% being slightly better, 0% vs 18% compared to 55% in the no treatment group. Because of
the small number of mice in this pilot study, these results were cautiously interpreted. Results from
the pharmacokinetic (PK) evaluation of CQ-HES with different DOS showed CQ-HES18% to
highly distribute to the kidneys and liver (Chapter 6). These concentrations remained high with
very little decrease at 72 hours. Conversely, CQ-HES6% showed high concentrations in the liver
and kidney initially, but they declined quickly. Thus, it was concluded that CQ-HES18% was too
stable and would accumulate to toxic levels in mice given multiple doses.
CQ-HES6% was deemed the most suitable formulation for testing in vivo anticancer efficacy. The
orthotopic syngeneic KPC (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ mutations) mouse model
was selected to perform these studies due to its versatility, low logistical restraints, and ability to
recapitulate the human disease. However, the effects of inhibiting autophagy to reduce cell viability
had not been confirmed in this cell line. Additionally, lower DOS CQ-HES had not been studied in
vitro for its biological effects, and its quicker clearance observed during the PK studies may
generate concerns regarding reduced efficacy. Therefore, the in vitro effects of CQ-HES6% on
autophagy and cell viability, both by itself and in combination with gemcitabine, were assessed
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prior to in vivo evaluation.
Methods
Materials. For all cell culture-related reagents and materials, please refer to Chapter 3. For all
reagents and materials associated with LC-MS/MS, please refer to Chapter 5.
Cell Culture. KPC-derived cancer cells (KPC 8060 & KPC 8069), a kind gift of Dr. Hollingsworth,
were harvested from spontaneous KPC mice and grown in culture until ready for use. Cells were
cultured under previously described conditions found in Chapter 3. Cells were grown to ~50-70%
confluency before using.
Western Blot. Western blot analysis was performed as previously described in Chapter 3.
Cytotoxicity. Cytotoxicity was performed in a similar manner as described in Chapter 3. Briefly,
KPC 8060 or KPC 8069 cells at 50-70% confluency were passaged using 0.05% trypsin. Cells were
plated in 96-well plates at approximately 1,000 cells per well using 100 µL of total cell suspension.
After adhering, medium was replaced with either regular culture medium or medium containing
drug. Cells were allowed to grow for 48-72 hours. CellTiter-Blue solution was used to assess cell
viability.
Orthotopic Syngeneic Mouse Model of PDAC. Mice were purchased from Charles Rivers
Laboratory, and all animal work was approved by the University of Nebraska Medical Center and
conducted according to IACUC protocol 17-020. KPC 8060 cells were orthotopically implanted
into the pancreas of C57/BL6 mice as described in Chapter 6. Definitive tumors were identifiable
on day seven post-implantation via ultrasound. Mice were randomized to treatment groups (n = 20
in the control group and n = 10 in the treatment groups), and treatment was promptly initiated. Drug
treatments were given every four days starting on day seven. HCQ or CQ-HES6% (3 mg/kg HCQ
equivalent, 50 mg/kg total for CQ-HES) was administered IV via tail vein. Gemcitabine (100
mg/kg) was administered via intraperitoneal (IP) injection eight hours after the administration of
HCQ or CQ-HES. Mice were housed under normal conditions and monitored daily for signs of
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toxicity. Weight was measured daily as a surrogate of health, and tumor sizes were followed
longitudinally using ultrasound. If mice displayed signs of severe toxicity (drug-induced, cancerderived, or otherwise) they were withdrawn from the tumor growth study and euthanized.
Symptoms concerning for severe toxicity included: weight loss greater than or equal to 20% body
weight, sudden unexpected weight loss of greater than 10%, severe obtundation, and severe
cachexia. Additionally, if mice displayed tumors greater than 1.5 cm in longest diameter, they were
withdrawn from the study and euthanized. In total, mice were given five treatments, and the study
was stopped once the number of mice in any one group dropped below 70%.
In a follow-up survival study to emulate late stage disease, similar metrics were employed with a
couple exceptions. Treatment was delayed until 12 days. Mice were followed until death or were
prematurely euthanized if: 1) they were in a state of severe obtundation to stupor 352 OR 2) tumors
exceeded 1.5 cm and mice appeared severely cachexic. The study continued until all mice had died
or were euthanized.
Ultrasound. Tumors were monitored every four days using the VisualSonics Vevo 3100 ultrasound
system (Fujifilm, VisualSonics, Toronto, ON) with an MX550D transducer (40 MHz center
frequency, 40 µM axial resolution) fitted on an integrated motor stand. To ensure proper imaging
of tumors, hair was removed from the abdomen of the mice using NairTM hair remover lotion (with
rich cocoa butter and vitamin E to ensure silky smooth, non-irritated skin). Mice were anesthetized
using 1-3% isoflurane and placed in a supine positon on a heated monitoring table fitted with a
nose-cone adapter for regulated isoflurane delivery. Ultrasound gel was generously applied to
ensure contact of the probe. Tumor images were acquired using 3D image capture setting with the
transducer set in B-mode. Vevo Lab software (V 3.1.1) was used to render tumor shapes and
calculate volumes.
Blood Sample Analysis. VETSCAN® HM5 hematology analyzer (Abraxis) was used to perform
a complete blood count (CBC), and VETSCAN® VS2 Chemistry Analyzer (Abraxis) was used
with Preventive Care Profile Plus cartridges to perform a comprehensive metabolic profile (CMP).
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Blood samples were collected and analyzed according to manufacturer specifications. Briefly, 100
µL of blood was collected in potassium EDTA tubes and another 200 µL of blood collected in
lithium-heparin tubes (Fisher Scientific), shaken thoroughly, and read immediately using the HM5
and VS2, respectively. An additional six C57/BL6 mice were obtained and used as a reference
group for what normal values should be in non-tumor bearing mice. As such they are termed
“healthy” mice.
Tissue Collection for cumulative dose analysis. At the termination of the study, euthanized mice
were immediately necropsied. Tumors were removed en bloc, weighed, immediately snap-frozen
using liquid nitrogen, carefully transferred to 50 mL conical tubes, and stored at -80°C. Organs
were inspected for frank signs of metastasis. A portion of the liver, one kidney, and half of the
spleen was removed for pathological inspection of damage. Each tissue was placed in 4%
paraformaldehyde and stored for 24 hours at 4°C. The remaining organs were removed, weighed,
transferred to 2.0 mL Eppendorf tubes, and stored at -80°C. After 24 hours, fixed tissue samples
were transferred to 70% ethanol and sent for paraffin embedding.
Determination of HCQ levels in tissues. PK and LC-MS/MS details are thoroughly descried in
Chapter 6. Briefly, tissues from recently necropsied mice were weighed and stored in 2.0 mL
Eppendorf tubes at -80°C until further use. For tissue homogenization, frozen tissues were removed
from the freezer, appropriate amount of water was added to dilute tissue samples, a 5 mm stainless
steel bead was added to the vial, and samples were shaken for 6 minutes to ensure proper
homogenization on TissueLyser II (Qiagen). Since half of the spleen was used for histopathologic
analysis (see subsequent section), spleen was diluted with 10x water creating a final 11x dilution.
The eyes were done in a similar manner in order to attain enough sample for analysis, while kidney
and liver samples were diluted in 5x water resulting in 6x diluted tissue samples. Samples were
prepared for LC-MS/MS determination of HCQ levels according to the protocol outlined in Chapter
6 using 100 µL of tissue samples.
Histopathologic analysis. Microscopic damage was assessed by a blinded pathologist using H&E
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stained slides and a semi-quantitative scale from no damage to severe damage. In sections of
kidney, acute tubular injury was characterized by retraction of epithelial cells of the collecting ducts
in the kidney cortex and medulla. In sections of liver, minimal damage was characterized by a
patchy increase in microvesicular steatosis throughout the liver parenchyma. As damage severity
increased, micro vesicular steatosis became more diffuse, coupled with the accumulation of
cytoplasmic hyaline bodies. Severely damaged liver tissue was characterized by widespread macroand micro vesicular steatosis, Mallory bodies, and early bridging fibrosis. Finally, the spleen was
assessed for architectural changes and variations in immune cell composition and extra-cellular
hematopoiesis.
Graphing and Statistical Analysis. All data was plotted and statistically analyzed using GraphPad
Prism 7. Difference in tumor growth between groups was assessed using regression analysis.
Additional testing of continuous variables such as final tumor volumes or blood markers were
performed using non-parametric t-testing (Mann-Whitney-Wilcoxon rank-sum test) without
adjustments for pairwise comparisons. Difference in tissue concentrations of HCQ was assessed
using non-parametric t-testing.
Statistical tests were performed in a two-sided manner, and p < 0.05 was considered statistically
significant, while 0.05 < P < 0.10 was considered borderline significant.
Results
CQ-HES Autophagy Inhibition and Cytotoxicity in KPC cells
The effects of HCQ and CQ-HES on autophagy inhibition were tested on two different mousederived cells lines of PDAC, KPC 8060 and KPC 8069 (Figure 7.1). The effects on autophagy in
human cell lines described in Chapter 3 are similarly presented as a comparison. Inhibition of
autophagy appeared slightly more increased in the KPC 8069 cell line over the KPC 8060 cell line,
but the degree of inhibition was comparable between free HCQ and CQ-HES within each cell line.
The cytotoxicity of CQ-HES in KPC 8060 was also compared to free HCQ (Figure 7.2). Overall,
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CQ-HES displayed a similar cytotoxicity profile with an estimated IC 50 of 30 µM. The cytotoxicity
profile of gemcitabine was also tested in KPC 8060 cells with and without HCQ or CQ-HES. The
addition of HCQ or CQ-HES further reduced cell viability. However, the combined effects of either
HCQ or CQ-HES with gemcitabine appeared purely additive, and no synergism was observed with
these drug combinations.

Figure 7.1 – Effects of CQ-HES6% on autophagy in KPC 8060 and 8069 cells.
LC3 levels were assessed as a marker of autophagy for KPC 8060 and KPC 8069 cell lines as
well as three, human cell lines (described in Chapter 3) presented as a comparison.
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Figure 7.2 – Effects of CQ-HES6% on gemcitabine cytotoxicity in KPC 8060 cells.
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In Vivo Efficacy of CQ-HES
To test the in vivo anticancer activity of CQ-HES, an orthotopic model of KPC 8060 was used
(Figure 7.3). Beginning on day 7, tumors were readily identifiable via ultrasound, and combination
treatment was started. On day 25, the number of mice in the control group dropped below the
predetermined 70% threshold for early termination of the study. This ensured enough mice were
available per group in order to reduce selection bias and ensure proper comparisons between groups
could be performed. Compared to the control group, tumor volumes at the conclusion of the study
were reduced by almost thirty percent (72% of control volume) in mice administered gemcitabine.
With the addition of HCQ to gemcitabine, mice experienced a further ten percent decrease in tumor
volume compared to gemcitabine alone (62% of control volume), while the addition of CQ-HES6%
further reduced tumor volumes by 25% over gemcitabine alone (47% of control). Comparing final
tumor volumes between combination groups, CQ-HES6% was 25% smaller than HCQ. This
superior reduction in tumor growth by the addition of CQ-HES with gemcitabine represents a
significant decrease compared to the combination with free HCQ, p < 0.01.
In a subsequent study, the ability of CQ-HES6% to prolong survival in a later stage disease setting
was investigated (Figure 7.6). Instead of initiating treatments on day 7, drug treatments were
initiated on day 12 and were similarly given every fourth day. The no treatment group displayed a
median survival of 27 days, while the gemcitabine and gemcitabine with HCQ demonstrated
median survival between 28 and 33 days. Mice given gemcitabine plus CQ-HES6% experienced a
significantly longer median survival at 40 days, p = 0.03.

Tumor Volume (mm3)
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Figure 7.3 – Effects of the CQ-HES6% gemcitabine combination on tumor growth.
Tumor volumes as calculated using ultrasound. Number of mice within each cohort are described
below graph. Values presented are average volume ± standard error of mean.

Representative ultrasound images are presented, which reflect the average size of each cohort at the conclusion of the study.

Figure 7.4 – Representative ultrasound images.
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treatment, gemcitabine only, gemcitabine plus HCQ, and gemcitabine plus CQ-HES6%.

Tumors were flash frozen using liquid nitrogen, and representative images were taken while tumors were still frozen. From top to bottom row: no

Figure 7.5 – Final tumor volumes.
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Figure 7.6 – Effects of the CQ-HES6% gemcitabine combination on survival. Median

survival times: No treatment – 27 days; Gemcitabine (Gem) – 28 days; Gem + HCQ – 33
days; CQ-Gem + HES – 40 days.
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Evaluation of Multiple Doses on Cumulative Tissue Levels and Toxicity
Cumulative Tissue Levels. In total, mice received five administrations of gemcitabine or
gemcitabine plus HCQ or CQ-HES6%, and 48 hours after the last administration, the study was
terminated. In mice receiving one of the combination therapies, tissues were assessed for their
levels of HCQ (Figure 7.7). In mice administered free HCQ, drug levels in the spleen, liver, and
kidney were all between 50 and 100 ng per gram of tissue, while similar tissues from mice
administered CQ-HES6% were nearly 100 times greater (2.5, 10.6, and 7.5 µg/g respectively).
Comparing these values to those previously performed in the single dose PK evaluation (Figure
6.6), cumulative levels after 5 consecutive doses were about twice as high in the spleen and liver
but not different in the kidneys. In the eye, both formulations were approximately five times greater
at the conclusion of the study compared to what was observed for a single administration (Figure
6.7) with free HCQ resulting in substantially higher doses in the eyes compared to CQ-HES6%, p
= 0.02.
Blood Markers as Indicators of Organ Dysfunction. A CBC and CMP were conducted on mice
at the conclusion of the study to identify any potential indications of toxicity or tissue dysfunction
(Table 7.1). In the CBC, the only discernable difference identified between treatment groups were
white blood cell (WBC) counts (Figure 7.8). Normal, “healthy” mice had median WBC counts of
1.5 (IQR: 1.1 - 2.1), while WBCs were elevated in all tumor bearing mice. The no treatment group
had a median value of 6.1 (IQR: 4.1 - 10.8) versus 3.5 in the treatment groups. Both the HCQ and
CQ-HES6% groups displayed significantly lower WBCs compared to the control tumor-bearing
mice group, p < 0.01 and p = 0.001 respectively. In performing the CMP, only AST showed a
difference between groups (Figure 7.9). AST in the healthy cohort was 111 (IQR: 98.5 – 145.5)
compared to the no treatment group of 163.5 (IQR: 152 - 247.8), p = 0.05. Of note, the median
AST of the gemcitabine only and CQ-HES6% cohorts were also higher, 200.5 (IQR: 165 – 326.8)
and 156.5 (IQR: 61.8 – 270.3), but not statistically different from the healthy group. More
importantly, no differences were observed between treatment groups.
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Figure 7.7 – Cumulative tissue levels after CQ-HES6% multidose administration.
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Figure 7.8 – White blood cell count after CQ-HES6% multidose administration.
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BUN (mg/dL)
CRE (md/dL)
ALP (U/L)
Alb (g/dL)
TP (g/dL)
ALT (U/L)
AST (U/L)
TBIL (mg/dL)
GLU (md/dL)
Glob (g/dL)
Na (mmol/L)
K (mmol/L)
Ca (mg/dL)
Cl (mmol/L)
tCO2 (mmol/L)

Healthy
Median IQR
16.5
(2.0)
0.3
(0.1)
68.0 (52.0)
4.7
(0.1)
5.3
(0.3)
43.5
(8.0)
108.5 (16.0)
0.1
(0.1)
128.5 (10.0)
0.4
(0.7)
147.0 (1.0)
9.2
(1.3)
10.1
(0.7)
110.5 (2.0)
19.0
(5.0)

No Treatment
Median IQR
16.0
(1.5)
0.4
(0.2)
18.0 (28.8)
3.9
(0.3)
5.2
(0.3)
38.5 (10.3)
163.5 (21.3)
0.1
(0.1)
121.0
(9.5)
1.3
(0.3)
149.5
(1.8)
8.2
(0.4)
11.2
(0.7)
111.5
(1.8)
17.5
(2.8)

GEM
Median IQR
15.5
(8.3)
0.2
(0.1)
0.5
(4.0)
4.4
(0.8)
4.5
(0.5)
43.5 (17.5)
200.5 (99.3)
0.0
(0.1)
123.5
(17)
0.0
(0)
148.5
(3.3)
10.2
(2.2)
10.2
(0.5)
113.5
(1.8)
17.5
(2.5)

CQ-HES
Median IQR
14.0
(3.5)
0.2
(0.0)
22.5 (16.5)
4.3
(0.6)
4.9
(0.5)
45.0 (32.8)
156.5 (131)
0.1
(0.1)
117.5
(8.3)
0.8
(0.8)
150.5
(4.0)
9.4
(3.3)
10.6
(0.2)
114.5
(1.8)
16.5
(6.3)

Table 7.1 – Blood markers of toxicity after CQ-HES6% administration.
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Figure 7.9 – AST levels after CQ-HES6% multidose administration.
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Histopathologic analysis. In the kidney, no significant damage to arterioles nor glomeruli were
observed. Acute tubular injury was the principle form of injury identified, but was generally
prevalent in all treatment groups. Thus, the extent of mild kidney damage in mice receiving HCQ
or CQ-HES combinations was indistinguishable from those administered gemcitabine alone. In
sections of liver, minimal damage was characterized by a patchy increase in microvesicular
steatosis throughout the liver parenchyma. As damage severity increased, micro vesicular steatosis
became more diffuse, coupled with the accumulation of cytoplasmic hyaline bodies (Figure 7.10).
Overall, hepatocyte damage and inflammation ranged from normal to severe, but was generally
observed in indistinguishable frequencies across treatment types including the no treatment group
(Table 7.2). In severely damaged liver tissue, there was widespread macro- and micro-vesicular
steatosis, Mallory bodies, and early bridging fibrosis. The only mouse to display severe liver
damage was in the control group. This mouse also displayed concomitant signs of bile duct
obstruction. Cross-referencing necropsy notes, there were also gross indications of bile duct
obstruction at the time of death including a mild appearance of jaundice, yellowing of internal
organs, and enlarged gall bladder. Little cellular damage was observed in all cases of spleen
examined, with the main variable observed being differences in amount of extra-cellular
hematopoiesis.
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No
Treatment

Gem
only

Gem
+ HCQ

Gem
+ CQ-HES

Kidney
Normal
Mild
Moderate
Severe

63.6%
18.2%
9.1%
9.1%

37.5%
50.0%
12.5%
0.0%

20.0%
80.0%
0.0%
0.0%

40.0%
50.0%
10.0%
0.0%

Liver
Normal
Mild
Moderate
Severe

63.6%
18.2%
9.1%
9.1%

37.5%
50.0%
12.5%
0.0%

20.0%
80.0%
0.0%
0.0%

40.0%
50.0%
10.0%
0.0%

Table 7.2 – Pathological assessment of toxicity after CQ-HES6% administration.

Figure 7.10 – Images of liver and kidney after CQ-HES6% multidose administration.
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Discussion
Before CQ-HES could be tested in vivo for its anticancer activity, two assumptions had to first be
verified. First, most of the preliminary work performed was done on a higher DOS formulation of
CQ-HES. Specifically, the in vitro characterization performed in Chapter 3 demonstrated that CQHES with a high DOS behaved very similarly to free HCQ in both its ability to inhibit autophagy
as well as its cytotoxicity. The pilot efficacy study performed in Chapter 4 showed CQ-HES8%
was just as efficacious in vivo in reducing primary tumor growth and liver metastasis. So, it was
assumed that CQ-HES with lower DOS also possessed similar biological activity as a comparable
amount of free HCQ. However, this assumption needed to be tested. Second, an orthotopic
syngeneic KPC model would be used to test efficacy instead of the xenograft model used
previously. However, it was unknown at the time whether this cell line, which is of mouse origin,
would show any response to HCQ, and it needed to be tested for sensitivity towards inhibiting
autophagy. If the use of HCQ or polymeric HCQ did not demonstrate any ability to reduce cell
viability in vitro, then little to no efficacy could be expected in vivo.
To validate these two assumptions, CQ-HES6% was tested for its ability to inhibit autophagy on
two different KPC-derived mouse cell lines, KPC 8060 and KPC 8069. Results from this study
showed that CQ-HES6% behaved similarly to a comparable concentration of free HCQ (Figure
7.1). This is unsurprising as a higher DOS behaved as a polymeric drug, and even if a lower DOS
was less stable, the end result would be the release of free HCQ and HES to the cell. Thus, the cell
would experience the effects of HCQ regardless, as long as the amount given was comparable.
Further cytotoxicity studies also showed a similar degree of cytotoxicity between CQ-HES6% and
free HCQ (Figure 7.2). When given in combination with gemcitabine, CQ-HES6% only reduced
cell viability to a level suggestive of only an additive effect with the two drugs. Again, CQ-HES6%
was similar in its effects to that of free HCQ. This is not unsurprising as gemcitabine acts at the
level of DNA synthesis, while the effects of HCQ are more related to internalization of extracellular
signaling and intracellular re-arrangement of macromolecules and organelles.
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Theoretically, a better drug combination would be with paclitaxel, which ultimately disrupts cell
division via stabilization of microtubules leading to perturbations in mitotic spindle function and
chromosomal segregation. Conversely, the combination with a receptor tyrosine kinase inhibitor
might also prove synergistic as HCQ/CQ-HES could augment disruption in receptor signaling.
However, these drugs are not readily given in the context of PC. So, it was felt that the most
translational approach would be to describe the added benefit of CQ-HES with a drug that is
commonly given clinically. FOLFIRINOX is front line therapy, but performing this combination
in a mouse model would be impossible. Similarly, the toxicity profile is generally unfavorable, and
adding CQ-HES may further exacerbate side effects or death, precluding a meaningful efficacy
assessment. Gemcitabine plus Abraxane, a nanoformulated version of paclitaxel, is the second line
therapy for PC. Ideally, CQ-HES6% would have been tested in combination with Abraxane, the
drug is expensive and given as a thirty-minute infusion, something that was not feasible to perform
in mice. Conversely, gemcitabine has been thoroughly studied in mice, and the efficacy and side
effect profile is well-established. So although it did not demonstrate synergism in vitro, gemcitabine
was the best translational option available to study in vivo given our current technology and
limitations.
Looking at the effects of the polymeric drug in vivo, CQ-HES6% performed reasonably well. All
preliminary in vitro work suggested CQ-HES6% was almost identical in its biological effects as
free HCQ. Moreover, tumor levels of HCQ were actually lower with CQ-HES compared to free
HCQ (Figure 6.1). In fact, tumors levels in mice administered CQ-HES were almost half as much
as free HCQ, regardless of the DOS. But levels appeared to persist for much longer, and at six days,
CQ-HES6% showed levels of HCQ in tumors that were six to ten times greater than free HCQ
(Figure 6.7). The biological stability and resulting prolonged tumors levels of polymeric HCQ of
CQ-HES may have resulted in greater reduction in tumor sizes (Figure 7.3).
In a preliminary study to assess tumor growth and survival, tumors were readily visualizable after
five days, and mice, who were not given any drug, lived approximately 20-25 days on average (data
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not shown). Given these findings, it was determined that twenty mice in the control group would
be required in order to have sufficient numbers at the conclusion of the study to perform tumor
volume assessments. Additionally, the study would conclude at an earlier enough time point that
most, if not all mice, were alive in the treatment groups. This ensured that tissue for each treatment
group would be collected at the same time so that a true assessment of drug levels and tissue damage
could be performed. Conversely, treatments would start when tumors are very small and not wellestablished. This is a large criticism and shortcoming of this approach, and it could be argued that
dense desmoplasia, one of the largest barriers to overcome in treating PC cancer, has yet occurred
in these tumors. This is supported by the size of tumors presented in Chapter 6, where the PK study
was initiated at a similar time point.
Efficacy was also assessed as the ability to prolong survival in a subsequent experiment. In this
study, treatment was delayed by an additional five days in an attempt to emulate later stage disease
and ensure tumors were well-established before treating with drug. Ultrasound was not employed
because the effects of isoflurane may contribute to toxicity, and it was still unknown whether CQHES6% possessed substantial, if any, toxicities. From this small study (n = 7), the difference in
survival was great enough to demonstrate a difference between the gemcitabine combination with
HCQ and CQ-HES6%, p = 0 .03. One may argue that because of two mice dying early at 21 and
23 days, the shape of the curve is skewed, which may be erroneously giving rise to the lower pvalue. However, if one were to take the longest surviving mouse at each step on the gemcitabine
only and gemcitabine plus HCQ curves and then compare that to the CQ-HES6% combination, the
p-value is still 0.04 (data not shown). No other comparisons were performed for this study including
no treatment or CQ-HES6% combination versus gemcitabine only. This may be a criticism of the
study. However, the only comparison this study was intended to describe was the comparison
between the gemcitabine combinations with CQ-HES6% and HCQ and thus was powered
accordingly. This is logical as every proceeding experiment, including ones in previous chapters,
have shown an improvement in anticancer activity with the addition of HCQ.
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Weight monitoring, blood markers, and pathological assessment from the anticancer growth study
illustrated the safety of CQ-HES6%, despite accumulation of high levels in certain tissues. The
average weights of each cohort did not change over the course of the study (Figure 7S1). WBC
count was significantly elevated in the no treatment group compared to healthy mice (Figure 7.10).
Treatment groups also displayed elevations in WBC above the healthy group, though this was
modest and not statistically different. The significance of these findings is unknown. No other
issues in blood counts were observed signifying no myelosuppression for the combination of
gemcitabine with CQ-HES6%. Moreover, AST levels were significantly elevated in the no
treatment group compared to healthy mice, while the median AST levels were also higher but not
statistically different in the combination groups compared to healthy mice (Figure 7.9). Thus, the
elevations in AST were not contributed to the chemotherapeutics but rather to the model, which
showed progressive invasion of the biliary tract leading to obstruction and liver dysfunction.
Inspection of tissue by a practicing pathologist also failed to identify signs of microscopic tissue
damage associated with any one treatment group. In short, the rates of identifiable damage in the
kidneys, liver, and spleen were indistinguishable between treatments. Therefore, CQ-HES6% was
deemed to be safe in the subacute setting in mice.
It should be noted that the weights of some mice did not change compared to baseline despite very
large tumor development. In most instances, large tumors were accompanied by general cachexia
and wasting, which could have offset the weight gain by the large tumor. This phenomenon has
been observed by others in our lab using the same model. It is unclear if this is consistent with other
tumor models or unique to this one; regardless, this phenomenon/discrepancy was worth
mentioning.
Had it been established that CQ-HES6% was generally innocuous and safety was not a concern,
the studies presented in this chapter could have been performed differently. The anticancer growth
study could have used individual survival as criteria for censoring from the tumor size calculations
and continued until all mice had died or were euthanized. In doing so though, cumulative drug
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levels and safety could not have been monitored. Moreover, the size of tumors generally correlated
with survival, and the death of a mouse with a large tumor, and thus exclusion from subsequent
volume calculations, may bias the results as well as undoubtedly and erroneously change the shape
of the tumor growth kinetics. Conversely, tumors could have been monitored for size using
ultrasound in the survival study. However, the study would have required more mice as the
biological variability in tumor size was not insignificant within each cohort. One could also criticize
the fact that performing ultrasound of mice every four days could be burdensome on the health of
the mice, who may already be in a frail state. In such a case, unhealthier mice would die sooner and
potentially create, or even expand, a false difference in survivorship between cohorts. This is
particularly important in the model we used, as liver dysfunction occurs late in the disease and
isoflurane used for anesthesia during ultrasound imaging would further exacerbate the issue or even
precipitate fulminant liver failure. In short, there was no perfect way to assess both the effects on
primary tumor growth as well as overall survival, but the summation of the studies performed
illustrates the safety and efficacy of CQ-HES nonetheless.
Conclusions
Regardless of the DOS, CQ-HES appear to behave similar to free HCQ when assessing the
inhibition of autophagy and cytotoxicity in vitro. The combinations of gemcitabine with HCQ or
CQ-HES show a similar additive effect on in vitro cytotoxicity. However, CQ-HES more robustly
reduces primary tumor growth compared to free HCQ in vivo. This enhanced anticancer activity
translated to an improvement in survival by 20-40%. Analysis of tissue revealed the accumulation
of high levels after multiple doses, but blood markers and histopathological examination failed to
identify any indication of toxicity. Overall, CQ-HES appears safe and well-tolerated, and the
addition of this polymeric formulation to conventional gemcitabine therapy leads to a significant
improvement in tumor reduction and survival.
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Supporting Information
Figure 7S1 – Mouse Weight As A Surrogate of Toxicity

Figure 7S1 – The effects of CQ-HES6% on mouse weight, a surrogate of toxicity. Values
represent the group change in average weight compared to the initial day of treatment, average ±
standard deviation.
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Chapter 8: in vivo Radiosensitization of CQ-HES in PC
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Introduction
To summarize the findings so far, CQ-HES was synthesized via a carbonate linker (Chapter 2),
which did not impact its in vitro biological properties, autophagy inhibition and cytotoxicity
(Chapter 3). The higher degree of substitution (DOS) formulations more readily assembled into
nanoparticles, and this characteristic was assumed to be beneficial for in vivo applications as the
enhanced permeability and retention (EPR) effect of nanoparticles improves tumor distribution.
However, preliminary studies using a xenograft model of pancreatic cancer (PC) suggested a
similar efficacy between CQ-HES16% and CQ-HES8% in reducing primary tumor growth
(Chapter 4). The difference in primary tumor growth was markedly different for mice receiving
CQ-HES compared to the control mice, who did not receive any therapeutic intervention, and
generally better than free HCQ groups. Moreover, the difference between CQ-HES formulations
(CQ-HES8% and CQ-HES16%) was negligible. Both formulations showed reduced rates of liver
metastasis with CQ-HES8% being slightly better, 0% vs 18%. Because of the small number of mice
in this pilot study, these results were cautiously interpreted. Results from the pharmacokinetic (PK)
evaluation of CQ-HES with different DOS showed CQ-HES18% highly distributed to the kidneys
and liver (Chapter 6). These levels remained high with very little decrease at 72 hours. Conversely,
CQ-HES6% showed elevated levels in these tissues, but decreased quickly. Thus, it was concluded
that CQ-HES18% was too stable and would accumulate to toxic levels in mice given multiple
doses.
CQ-HES6% was deemed the most suitable formulation for testing in vivo anticancer efficacy. The
orthotopic syngeneic KPC (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ mutations) mouse model
was selected to perform these studies due to its versatility, low logistical restraints, and ability to
recapitulate the human disease. The effects of inhibiting autophagy to reduce cell viability was first
confirmed in this cell line (KPC 8060) to ensure CQ-HES would be active in vivo. Cell studies
were used to describe the interaction of CQ-HES and gemcitabine on KPC 8060 cells, which was
found to be an additive effect and similar to the combination of HCQ and gemcitabine. In vivo
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testing of CQ-HES6% showed an improved ability to reduce primary tumor growth with the
combination of gemcitabine reducing primary tumor growth by an additional 35% versus HCQ
plus gemcitabine of only 14%. This improved anticancer effect translated to prolonging survival
by 20-40%. Levels of HCQ in the eyes were lower in mice receiving CQ-HES. Testing of blood
markers (a complete blood count and comprehensive metabolic panel) and pathohistological
assessment of tissue revealed no organ dysfunction and no microscopic indications of tissue
damage indicating CQ-HES was safe and well-tolerated.
In this next chapter, the ability of CQ-HES to sensitize cancer to the effects of radiation in vitro
and in vivo will be assessed in PC. Several pre-clinical and clinical studies have demonstrated the
ability of HCQ to augment the effects of radiation therapy in many different types of cancer (see
Chapter 1). However, in vivo studies using HCQ with radiation, specifically stereotactic body
radiation therapy (SBRT), in PC have yet to be performed. Thus, it is unclear if HCQ therapy may
of beneficial in the setting of SBRT for PC. Additionally, CQ-HES shows an improved ability to
reduce migration and invasion in vitro over HCQ (Chapter 3). Thus, CQ-HES may be of benefit in
the setting of SBRT for PC where systemic therapy or reduction of local invasion could improve
survival.
Methods
Materials and Reagents. Fetal bovine serum (FBS) was purchased from Atlanta Biologicals. The
KPC 8060 cell lines were a gracious gift from Dr. Tony Hollingsworth. All other reagents,
chemicals, and cell culture materials were obtained from Fisher Scientific.
Cell Culture. KPC-derived cancer cells (KPC 8060), a kind gift of Dr. Hollingsworth, were
harvested from spontaneous KPC mice and grown in culture until ready for use. Cells were cultured
under previously described conditions found in Chapter 3. Cells were grown to ~50-70%
confluency before using.
In vitro Assessment of Radiosensitivity. Response to radiation was initially assessed using cell
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viability in 96-well plates to select an optimal dose of radiation. Briefly, KPC 8060 cells at 50-70%
confluency were passaged using 0.05% trypsin. Cells were plated in 96-well plates at
approximately 1,000 cells per well using 100 µL of cell suspension. After adhering, medium was
replaced with either regular culture medium or medium containing drug. After approximately eight
hours of incubation, cells were then irradiated with a varying amount of radiation using a Rad
Source RS-2000 Irradiator (160 kGv x-rays at 2.0 Gy/min, Rad Source Technologies). Cells were
then allowed to grow for 48-72 hours. CellTiter-Blue solution was used to assess cell viability.
Surviving fraction was calculated as the fluorescence for each given dose divided by the average
fluorescence of the control group receiving no radiation (0 Gy). Data was plotted in GraphPad
Prism 7 (GraphPad Software Inc., La Jolla, CA, USA), and survival curves were constructed using
a non-linear, quadratic fit (least-squares fit) and 1/Y2 weighting.353
In vitro Assessment of Radiosensitization. KPC 8060 cells were plated in 6-well plates at 200
cells per well. After adherence to the plates, medium was added which contained HCQ, CQHES6%, or vehicle. Cells were incubated for approximately eight hours then subjected to
irradiation. A single dose of 7 Gy was administered using the Rad Source RS-2000 Irradiator,
described above. Cells were then grown under normal conditions, and the cellular radioresponse
was assessed using a standardize colony survival assay (CSA).353 The surviving colonies were
visualized by first fixing using 100% methanol for 10 minutes followed by staining using crystal
violet (0.2%) at room temperature for 10 minutes. Data was plotted in GraphPad Prism 7, and
survival curves were constructed using log (HCQ molar equivalent) vs response.
Orthotopic Syngeneic Mouse Model of PDAC. Mice were purchased from Charles Rivers
Laboratory, and all animal work was approved by the University of Nebraska Medical Center and
conducted according to IACUC protocol 17-055. KPC 8060 cells were orthotopically implanted
into the pancreas of C57/BL6 mice as described in Chapter 6 with one modification. After injection
of the cells, two titanium surgical clips (Weck® HorizonTM Metal Ligation System, Teleflex Inc.)
were carefully placed at either end of the resulting cell suspension bubble to approximate the
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proximal and distal ends of the tumor. Definitive tumors were identifiable on day six postimplantation via ultrasound, and stereotactic body radiation therapy (SBRT) treatment plans were
performed for each mouse according to the procedures outlined in the preceding section. Mice were
randomized to treatment, and SBRT treatment was initiated the following day, day seven posttumor implantation, according to the outlined procedure in the preceding section. HCQ or CQHES6% (3 mg/kg HCQ equivalent, 50 mg/kg total for CQ-HES) was administered IV via tail vein
approximately eight hours before the first and fourth SBRT treatments. Mice were housed under
normal conditions and monitored daily for signs of toxicity. Weight was measured daily as a
surrogate of health, and tumor sizes were followed longitudinally using ultrasound starting postSBRT treatment day 1. Mice were followed until death or were premature euthanized if: 1) they
were in a state of severe obtundation to stupor352 OR 2) tumors exceeded 1.5 cm and mice appeared
severely cachexic. The study continued until all mice had died or were euthanized.
Stereotactic Body Radiation Therapy (SBRT) Treatment Planning. Each mouse was
anaesthetized with a mixture of xylazine/ketamine, as previously described, and restrained on a
styrofoam with a prone position. Planning CT scans were acquired for all the mice with the same
scanning protocol of 0.6mm slice thickness on a Siemens CT simulator (Model: SOMATOM
Definition AS, Siemens Healthineers, Erlangen, Germany). Gross tumor volumes (GTV) were
delineated based on surgical clips in Varian Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA) by an attending radiation oncologist, and the planning target volume
(PTV) was a 3-dimensional expansion of 2mm to the GTV. The prescription dose to the PTV was
35 Gy performed in 5 consecutive fractions. Radiation physicists delineated the organs-at-risks
such as spinal cord and lungs, and generated a 3D stereotactic body radiotherapy (SBRT) plan for
each mouse.
SBRT Treatment. Before the treatment, the simulation position was replicated for each mouse
following anesthesia. Treatment was delivered on a Varian EdgeTM linear accelerator coupled with
a cone-beam CT system and a PerfectPitch 6 Degrees of Freedom (6DoF) couch system.354 Prior
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to the radiation delivery, cone-beam CT (CBCT) was utilized as image guidance. Briefly, a CBCT
scan was acquired for each mouse, and was used to match the planning CT via a 3D-3D image
registration. If necessary, a 6-degree couch shift (lateral, longitudinal, vertical, rotation, pitch, and
roll) was applied according to the CBCT-CT image registration to compensate the possible setup
errors. Individual plans for each mouse were delivered as intended on 5 consecutive days. CBCT
was also performed on all the control mice to account for the additional radiation caused by CBCT.
Results
In vitro Radiosensitization Effects of CQ-HES
Prior to testing the radiosensitization effects of CQ-HES, the KPC 8060 cell line was assessed for
its sensitivity to radiation (Figure 8.1). Using increasing doses of radiation, the cells displayed only
a modest degree of sensitivity towards radiation. This dose response curve was plotted alongside
previously published CSA data from a collaborator using cells (KPC 961) that were selected for a
resistant phenotype to radiation.353 At 7 Gy, KPC 8060 showed a 60% survival, whereas KPC 961
was only 20%. This inherent radioresistant nature was further tested at 7 Gy using CSA. This
secondary method displayed a 66% survival and validated the previous findings. Thus, this
comparison to previously described KPC-derived cell lines thought to be radioresistant illustrates
the superiorly resistant nature of KPC 8060 cells.
With clinical regimens for PC using five consecutive doses of 7 Gy and the cells displaying a fairly
high resistance at this dose, 7 Gy was selected as an appropriate dose to use for testing the
radiosensitization effects of HCQ and CQ-HES using CSA. CSA revealed that 7 Gy of radiation
produced a consistent 30-40% reduction in surviving colonies (Figure 8.2). Further, a reasonable
dose-response curve was observed for both HCQ and CQ-HES using the CSA. Notably, even doses
as low as 1 nM appeared to show effects on the percent of colonies surviving. The addition of
radiation (7 Gy) after HCQ or CQ-HES treatment reduced cell count more than the combined
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effects of either treatment alone. This suggested a possible synergistic relationship between the two
therapies.
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Figure 8.1 – In vitro radioresponse profile of KPC 8060. The effects and radioresponse of

KPC 8060 cells to radiation was assessed using MTT assays (labeled *KPC 8060). Further
colony formation assay at 7 Gy was performed to compare results between the two methods
(labeled KPC 8060). Additionally, data performed by Souchek et al. for the radioresistant
cell line KPC 961 is added as a reference and has been previously published.353

% Surviving

Colonies
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Figure 8.2 – In vitro radiosensitization effects of CQ-HES6%. The effects of HCQ and CQ-

HES sensitization on KPC 8060 cells to radiation (7 Gy) was assessed using colony
formation assay.
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SBRT Treatment Planning
To test the effects of radiosensitization in vivo, SBRT was used. Each mouse was imaged using
CT, and individual radiation plans were developed. For each of the five SBRT treatments, mice
were re-imaged with a cone-beam CT and oriented to align with their initial dosing plan (Figure
8.3 - Left). Generally, alignment stayed fairly consistent as illustrated in Figure 8.3 - Right. The
6DOF system further ensured alignment of the SBRT plan with the clips used a surrogate markers
of the tumors. Upon death of each mouse, necropsy was performed, and the tumors were inspected
to ensure clips remained in place (Figure 8.4). No aberrant clip placement or loose clips were
observed, and all clips were found secured within or fully encapsulated by tumors at time of
necropsy.

Both clips can be visualized and assisted with alignment of the mouse. Spinal cord was outlined in yellow within the vertebra.

and alignment of the daily cone-beam CT with the planning CT ensured proper orientation and selective treatment of the tumor (right).

An outline of the mouse body and placement of marker beads ensured mice were aligned similarly each time. Use of SBRT software

Figure 8.3 – Alignment of mice on SBRT machine and planning software. Mice were anesthetized and restrained on SBRT blocks (left).
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Figure 8.4 – Validation of clip placement at time of necropsy. After mice died, necropsy was

performed on each mouse. Inspection of the tumor showed that clips were within the tumor
and had not come loose.
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In Vivo Radiosensitization Assessment of CQ-HES
In the control group which received no therapy, a median survival of 26 days was observed (Figure
8.5). This was comparable to the median survival of 27 days in the control group from the
combination study with gemcitabine presented in Chapter 7 (Supporting Information – Figure
8S2). The mice treated with RT only and the addition of HCQ were no different displaying median
survivals of 28 and 22 days, respectively. Of note, one mouse in the RT only group survived 42
days, much longer than the rest of the cohort. Mice who received CQ-HES prior to SBRT
demonstrated a median survival of 34 days. This translated to an approximate 20% increase in
survival over SBRT alone, p = 0.06.
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Figure 8.5 – The effects of CQ-HES6% on survival after SBRT. The effects of HCQ and CQ-

HES sensitization assessed in an orthotopic syngeneic model of PC using KPC 8060 cells.
Mice were treated to 35 Gy in 5 consecutive fractions using SBRT.
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Discussion
Typical methods to assess the effects of drug treatment include viability assays such as CellTiter
Blue (CTB) or MTT assays. These are quick, easy, and generally reproducible. Many assessments
can be performed in 96-well plates improving the number per group or number of treatments within
one plate. This facilitates high throughput screening. This methodology was first employed to study
the effects of radiation on the KPC 8060 cells. However, even plating as 1,000 cells per well only
allowed for 72 hour treatments before control groups became nearly confluent. This method was
first employed to study the effects of radiation and HCQ/CQ-HES radiosensitization on KPC 8060
cells (Supporting Information – Figure 8S1). However, this precludes the assessment of longterm effects of radiation treatments. This is of significant importance in radiation studies, where
delayed therapeutic effects occur as a result of instability in DNA and replicative error leading to
induced apoptosis.
Thus, viability assays are not ideal in radiation studies, and CSA was performed. Using CSA, the
effects of RT on KPC 8060 cells were assessed. This was plotted in comparison to a collaborating
group, which through selection after RT, developed a radioresistant cell line, KPC 961 (Figure
8.1). Similarly, a CTB assay performed at 7 Gy was also displayed to illustrate the potential
difference assessed sensitivity. These overall findings describe an inherently, highly resistant cell
line to RT. Even at 7 Gy, the effects of RT were only a 40% reduction, compared to 80% in the
radioresistant cell line KPC 961. Further studies using HCQ or CQ-HES as a sensitizing agent
demonstrated the ability of both compounds to sensitize KPC 8060 cells to the effects of RT
(Figure 8.2). Even at low doses, HCQ and CQ-HES were able to augment the effects of RT,
although this robust effect could be due in part to the low cell number in each replicate. Thus, it
was felt that KPC 8060 cells were ideal to study in the setting of SBRT, and 5 fractions of 7 Gy,
the regimen used in humans, was an appropriate regimen for SBRT.
A couple small pilot studies (n = 5 each) were performed to assess the use of clips as markers for
tumors. It was found that the clips remained on the pancreas and in proximity to the tumor at the
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conclusion of SBRT and at necropsy (data not shown). During SBRT treatments, the clips were
found to shift slightly, and in a couple instances, the clips moved quite a bit. Because of this, there
were fears that the clips were not remaining in place and could come lose. In both small pilot
studies, all clips remained in place, and this was not an issue. In the efficacy study, a substantial
deviation in clip placement was also noted to have occurred a couple times. In one instance, the
shift occurred prior to the 2nd day of treatment. However, the clip was in its original placement at
the beginning of the 3rd treatment. Similarly, the clip placement in a different mouse was different
enough from the initial SBRT plan, that it was thought to have come loose. Necropsy on each
mouse revealed that all clips remained intact and in their original placement. So despite what
appeared to be substantial shifting as seen on conebeam CT, this could be a result of simple internal
organ shifting. Future studies involving SBRT should be aware of this issue and necropsy should
be performed to confirm that clips have remained in their proper location.
Because clips were placed in the pancreas and adjacent to tumors, there may be concern that the
clips could induce a degree of added toxicity. While this is a reasonable concern, a comparison of
the survival between the no treatment group presented in Chapter 7, where no clips were used, and
the no treatment group in this present study, where clips were used, showed almost identical
survival curves (Supporting Information – Figure 8S2). Thus, it was concluded that the clips
induced no substantial toxicity that led to altered survival outcomes. Additionally, the similarities
between control group survivals reaffirmed the reproducibility of the model used.
In assessing survival outcomes within this study, two potential sources of concern were observed.
First, the combination of SBRT and HCQ showed outcomes that were almost worse than the no
treatment, control group. Second, the SBRT only group was very similar to the no treatment, control
group. In vitro assessment of HCQ radiosensitization (Figure 8.2) suggested that there was a
pronounced effect with this combination. This is in contrast to in vivo data describing no benefit to
using this approach. Given that SBRT had little to no impact as well, the implementation of SBRT
was either too late and the cancer had already spread and/or the cancer spread despite treatment
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with SBRT. In all mice treated with SBRT, primary tumors initially halted in their growth
immediately following treatment. After some time, some tumors began to regrow. When this
occurred, mice died shortly thereafter (data not shown). Sensitization with CQ-HES appeared to
delay the recurrence of primary tumor growth compared to the other treatment groups (data not
shown). However, almost all mice in the treatment groups died due to invasion of the small bowel
and/or biliary tract leading to bowel obstruction or liver failure, respectively. Data from Chapter 3
illustrated that CQ-HES is a potent inhibitor of PC migration and invasion. This, coupled with the
ability to sensitize PC cells to RT, might explain the survival benefit observed in mice given the
combination treatment as delayed invasion of the bowel or bile duct would have led to prolonged
survival.
One may also comment that the tumors at the time of SBRT treatments were larger than 2 mm
radial expansion around clips. Thus, not all the tumor was being treated by SBRT and could explain
the continued invasion of localized structures and lack of survival difference between control and
the SBRT only group. Given the findings from the pilot study, this was thought not to be an issue
and 2 mm radial expansion was sufficient. Additionally, delaying treatment until 7 days could allow
for more advanced and established disease, or even disease that has spread beyond the pancreas.
This could also help to explain the lack of efficacy with SBRT. Repeating these studies but
initiating treatment earlier could answer this question. However, this would be difficult for a
number of reasons. First, wounds needed ample time to heal prior to SBRT to ensure treatment was
delivered to only the tumor. Skin wounds would change the shape of the mouse during therapy
which could have impacted the integrity of treatment. Additionally, SBRT required one day of
imaging to plan the SBRT treatments. Thus, treating earlier could have only occurred by one to two
additional days due to these limitations.
Conclusions
Using CQ-HES as a radiosensitizing agent in stereotractic body radiation therapy (SBRT), primary

182

tumor growth was arrested longer than in mice receiving HCQ and SBRT or SBRT alone. This
translated into a 20% improved survival for mice sensitized with CQ-HES. Despite using a highly
aggressive and radioresistant cell line, CQ-HES augmented the effects of SBRT and led to
improvements in survival.
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Supporting Information

Surviving Fraction

Figure 8S1 – Radiosensitization as Assessed by CTB

Figure 8S1 – The effects of CQ-HES6% on radiosensitization using CellTiter Blue. The

effects of HCQ and CQ-HES on radiosensitization assessed using KPC 8060 cells in 96well plates using 1,000 cells per well. Cells were treated to with 1 µM HCQ or CQ-HES
and then irradiated eight hours later.
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Figure 8S2 – A Comparison of Survival Controls between Experiments

Figure 8S2 – A comparison of survival for control groups between studies. Survival of the

control group from Chapter 7 is presented alongside the control of survival study performed
for the radiation studies. The similarity in survival illustrates the reproducibility of the
model.
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Chapter 9: Discussion/Conclusions
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Introduction
In the preceding chapters, the rationale for developing a polymeric HCQ (CQ-HES) was described
(Chapter 1), the chemical synthesis and physical characterization was presented (Chapter 2), the in
vitro biological activity was assessed (Chapter 3), preliminary acute toxicities and in vivo efficacy
was performed (Chapter 4), a method for quantitating tissue levels of CQ-HES was developed
(Chapter 5), the altered PK profile was evaluated (Chapter 6), and in vivo anticancer efficacy of
CQ-HES used in combination with gemcitabine (Chapter 7) or as a radiosensitizing agent for SBRT
(Chapter 8) was investigated. This final chapter will summarize the findings and provide a
perspective on results and translatability of CQ-HES as a potential drug candidate for clinical trials.
The Rationale for CQ-HES: A Multifunctional Drug Delivery Agent
CXCL12/CXCR4 Axis in PC. The CXCL12/CXCR4 axis plays an integral role in the
development of PDAC from the early stages of PanIN lesions to the progression of metastatic
disease. CXCR4 signaling acts mainly through the activation of Akt and ERK, but substantial
crosstalk with several other key pathways leads to survival, chemoresistance, metastasis, and the
overall highly aggressive phenotype of PDAC cells. Through complex signaling of CXCL12
between cancerous and non-cancerous cells, this axis is also an integral factor in establishing and
maintaining the highly atypical TME seen in PC. Patient-based studies validate the clinical
significance of CXCR4 by correlating its expression to poor outcomes. Disrupting the
CXCL12/CXCR4 axis using combination therapies with CXCR4 antagonists has shown great
promise in preclinical models and represents a viable strategy for future drug development.
However, most of these studies investigate the administration of drug treatments early in the disease
course, which is often not reflective of the clinical reality as most PDAC patients present at stage
III and IV. Moreover, animal models of PDAC often fail to recapitulate the complex TME
involving non-cancerous cells such as CAFs, the immune system cells, high acellular content
resulting from the desmoplastic reaction, and the intricate crosstalk between cancer cells, immune
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cells, and non-cancer cells involved in the human disease.
The CXCL12/CXCR4 axis may be playing a role in initiating or sustaining tumorigenesis and
progression of PanIN to PDAC. However, little to no evidence exists to describe the effects of
abolishing this pathway early in the disease progression in order to stop or reverse tumor
establishment. In fact, almost all studies describe the benefits of inhibiting the activity of the
CXCL12/CXCR4 pathway in the context of decreasing invasive and metastatic potential of
established cancer cells or tumors. So, it is unclear if early initiation of treatment may be beneficial.
Furthermore, >80% of clinical PDAC cases arise at Stage III/IV where the cancer has locally
invaded or metastasized, yet the pre-clinical studies also have not investigated treatment initiation
in late-stage disease. Most of these studies would be translatively similar to stage I or at best stage
II. This paucity in data could be due to researchers not finding meaningful results in late-stage
disease and thus not publishing the data due to the current paradigm in science of unpublishable
non-significant findings, and/or knowledge that initiation of treatment earlier in the disease course
yield more significant findings/improvements with therapy and thus are more easily publishable
again due to the current paradigm in science, and/or a lack of understanding of the human disease.
Clinical trials involving CXCR4 antagonists should be established to analyze the survival benefits
they may impart for each stage of PDAC, as those with less advanced disease may benefit more
from these combination therapies. This may be difficult due to the limited incidence of the disease,
which is distributed over a diverse population making stratification to control for factors pertinent
to outcomes infeasible. Moreover, preclinical studies should investigate the utility of CXCR4
antagonists in the setting of early as well as late-stage disease. This will further provide context and
insight as to whether the benefits of a combination therapy with a CXCR4 antagonist will be seen
globally over PC patients or more so in one disease setting versus the other. In conclusion, the
growing evidence supports the notion of targeting the CXCL12/CXCR4 axis, which may help to
overcome the therapeutic barriers we are currently experiencing with PC, but careful attention
should be placed both pre-clinically and clinically on which stage of disease the therapy is intending
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to treat.
Autophagy in PC.
In Chapter 1, the importance of autophagy in PC was discussed and generalized as critically
important to PDAC tumors for maintaining their sustained growth and proliferation. Although
most of the literature supports this notion, recent literature has surfaced contradicting this paradigm
and complicating our understanding of this mechanism. For example, the survival dependency of
PDAC cells on autophagy may be reliant on the mutational status of TP53.268 Findings from a
subsequent group investigating the impact of TP53 and autophagy status on survival contradicted
this study and demonstrated improved survival using HCQ to abolish autophagy. 127 Furthermore,
autophagy in cells neighboring PC cells may help to produce cellular building blocks and energy
molecules that stimulate and support PC cells proliferation.269-273 Thus, autophagy appears to be a
viable therapeutic target for PC, whether that is in the PC cells themselves or nurturing neighboring
“non-cancerous” cells.
CQ-HES as an inhibitor of CXCR4 and autophagy.
The overall rationale for developing CQ-HES was multifaceted and hinged on the previous findings
of the CXCL12/CXCR4 axis and autophagy being critically important in PC. (1) The
CXCL12/CXCR4 axis appears to be playing a significant role in tumorigenesis and maintenance
of tumors that may be disrupted by antagonistic properties of HCQ. (2) HCQ is a modest CXCR4
antagonist, and has a multivalency effect of a polymeric formulation that may augment the
antagonist properties of HCQ. (3) The internalization of polymeric HCQ may serve a dual role via
autophagy inhibition. (4) A polymeric formulation of HCQ may improve distribution to the tumor
while limiting distribution to the eye thus creating a more favorable PK profile and therapeutic
window. (5) The chemical composition of CQ-HES should result in a polymeric formulation that
decomposes to nothing more than HES, a safe a well-tolerated colloidal plasma volume expander,
and HCQ leaving no residual modifications to either compound and thus pose no enhanced
immunogenicity issues.
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Chemical Synthesis and Physical Characterization
Using carbonyl diimidazole, HES was modified with HCQ. The carbonate linker decomposes in an
acid or base-dependent manner much like an ester. However, it would ultimately decompose to
CO2 and the parent compounds leaving no residual modifications as described above. This has
several advantages with the first being the lack of immunogenicity. Secondly, acid environments
like the TME or lysosome after intracellular uptake should facilitate the decomposition process.
The initial assessments of stability presented in Chapter 2 demonstrated a rather high degree of
stability at physiologically relevant pH’s. It was not until very harsh conditions were implemented
that CQ-HES appeared to degrade. This stability was greater than was initially anticipated, but it
was unknown how this translates in vivo as enzymes would most likely facilitate a quicker
degradation.
Additionally, great detail was implemented to fully characterize CQ-HES. This was in part to
ensure the modification to HCQ occurred at the hydroxyl group and no side reactions occurred at
the amines. Given the docking studies outlined in Chapter 1, the hydroxyl had little bearing on
CXCR4 antagonism. Additionally, the hydroxyl group does not impact the effects on autophagy as
CQ and HCQ appear to have equal potency and efficacy. Conversely, the amines are critical for
both functions. Thus, 2D NMR was performed to confirm the bond location and purity of the
compounds.
In vitro Biological Activity
While the physical characterization of CQ-HES indicated HCQ was modified at the hydroxyl
groups and thus no alterations to biological activity should occur, this needed to be tested.
Importantly, modifying HCQ by attaching it to HES, a 200 kDa starch, inadvertently changes one
important property, membrane permeability. This is important, because free HCQ readily
permeates through cellular membranes to get to lysosomes. Conversely, CQ-HES would require
endocytosis and intracellular trafficking to localize to lysosomes. Disruption of several steps during
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this trafficking process could nullify the effects of HCQ in CQ-HES. Thus, cellular trafficking
studies were performed to assess how readily CQ-HES was taken up by cells and if it distributed
to lysosomes. Ultimately, confocal studies showed that CQ-HES was trafficked to lysosomes
(Figure 3.1), but this did not validate that the anti-autophagy properties were preserved. Subsequent
studies evaluating LC3 levels after drug administration demonstrated a comparable increase in both
LC3 I & II. These findings confirmed a retention in the biological activity of HCQ after
conjugation. These findings taken together with the stability studies suggested that CQ-HES is
behaving as a polymeric drug. Later in Chapter 7, the PK profile of CQ-HES was assessed. The
findings that CQ-HES remained as a conjugated species in many tissues, including the liver where
metabolic enzymes are abundant and highly active, further support the notion that CQ-HES is active
and behaves as a polymeric drug.
Cytotoxicity was assessed using CellTiter Blue method. The limitations of this method were
discussed in Chapter 8, where it was concluded that this method is not ideal for studying long-term
effects. Initial cytotoxicity studies using this method are valuable as they are fast, reproducible, and
allow for large numbers for each concentration to perform proper statistics. However, the colony
survival assay (CSA) may have been a better approach to judge toxicity. This is more cumbersome
as it involves many more plates. Using the CSA, a synergistic relationship with RT and HCQ/CQHES was observed, while CellTiter Blue only displayed an additive effect with these combinations.
Perhaps using CSA, a more robust relationship could have been appreciated. This would have taken
more time and resources, and ultimately it would have been of little utility as this data is merely
supportive data for proceeding further with in vivo evaluations as all other subsequent data
performed suggested CQ-HES was a drug candidate worth studying at the in vivo level.
The ability of CQ-HES to inhibit wound healing as a surrogate of abrogating chemotaxis is
complicated by the multiple mechanisms of action HCQ possess. Although HCQ is thought to just
inhibit autophagy, this mechanism also impacts receptor recycling, proliferation, and intracellular
reorganization imperative to cellular mobilization. The culmination of these effects can appear as
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a general ability to inhibit chemotaxis. In the instance of wound healing assays, cell proliferation
at the wound margins would facilitate gap closure. Disrupting cellular receptor recycling and
proliferation can manifest as inhibiting wound gap closure and thus migration. Additionally, cells
migrate into the wound to close the wound and further proliferation by these cells augments this
effect. Disrupting cellular receptor recycling and intracellular reorganization can impact this
process. This would lead to the interpretation of inhibiting migration. So although not necessarily
wrong, the ability of CQ-HES and HCQ to inhibit wound closure as a surrogate for chemotaxis
should be interpreted with meaningful thought as this is a multifaceted process and not just
dependent upon cellular movement.
Likewise, the interpretation of cellular invasion studies presented in Chapter 3 should be done with
a degree of open-mindedness. These studies were performed using both SDF-1/CXCL12 and FBS
as chemoattractants. In the former, one would surmise that CQ-HES inhibits cellular invasion in a
CXCR4-dependent manner because HCQ is a CXCR4 antagonist and CXCL12 is being used as the
chemoattractant. Again, HCQ and CQ-HES also affect autophagy and receptor recycling. Thus,
many possible situations could be occurring. First, HCQ and CQ-HES are strong enough to
completely antagonize CXCR4 and thus block CXCR4-mediated invasion purely through
antagonism of the receptor. Conversely they may only be weakly antagonizing CXCR4, whereas
CXCL12 is still able to activate the receptor. In this situation, the disruption of receptor recycling
could prevent CXCR4 redistribution to the cell surface effectively slowing or fully stopping
chemotaxis due to a loss of surface distribution of the receptor to guide cellular movement.
Moreover, disrupting cellular re-organization could be preventing the cell from moving even
though the cell has recognized the chemoattractant gradient and is wanting to migrate/invade. These
CXCR4 antagonist-independent processes are significant contributors as the disruption in invasion
is very prominent when FBS is given as a chemoattractant. However, the overall effects are clearly
a combination of multiple factors.
Regardless of the which assay or chemoattractant used, HCQ disrupted cellular migration and
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invasion. However, CQ-HES appeared to have a stronger effect on these cellular behaviors
inhibiting migration and invasion to a much more appreciable degree than free HCQ. This is in
contrast to the autophagy studies which suggested a comparable activity. Thus, CQ-HES may be
acting through additional mechanisms, augmenting one or more known mechanisms of action
(MOA) of HCQ, producing a more prolonged effect, or a combination of these explanations. As
described above and in more detail in the previous chapters, the MOA of HCQ is multifaceted, and
their contributions were not assessed individually, but rather cumulatively, in the overall disruption
of chemotaxis and invasion. These additional MOA were outside the scope of this thesis work,
which focused on describing the effects of polymeric formulations on in vivo PK and anticancer
properties. Rather, emphasis was placed on how readily CQ-HES disrupted migration and invasion
as these studies served as supporting evidence for selecting a drug candidate that may perform well
in in vivo studies.
Preliminary In Vivo Studies: Toxicity & Efficacy
Preliminary in vivo studies focused on determining acute and subacute toxicities (Chapter 4). Initial
MTD evaluation suggested the toxicities were more prevalent in the higher chloroquine-containing
formulations. The lower content CQ-HES exceeded 100 mg/kg, while the higher content, i.e. 20%,
displayed toxicities near 40 mg/kg. At 40 mg/kg, the CQ-HES20% would have administered 8
mg/kg of HCQ, while CQ-HES6% at 100 mg/kg would only be 6 mg/k of HCQ. Thus, it is unclear
if the higher content was simply due to more total HCQ administered or if it was due to a difference
in tissue distribution or some other issue.
Because a collaborator needed their personnel trained in orthotopic xenograft model of Colo357,
many tumor bearing mice were available for testing subacute toxicity after multiple drug
administrations. It was concluded that there were enough mice to perform a small efficacy trial to
compare HCQ to CQ-HES for two different doses. CQ-HES16% was chosen as it the highest
content containing polymeric formulation that did not pose solubility issues and its ability to readily
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form nanoparticles may help it to be more stable in the body. CQ-HES8% was selected as it was
conveniently half the content of CQ-HES16%. A dose reduction of 25% was selected for CQHES16% such that 30 mg/kg would be administered, equating to 4.8 or ~5 mg/kg of HCQ. A similar
overall dose of 30 mg/kg was chosen for CQ-HES8%, although the corresponding HCQ dose was
only 2.4 mg/kg. Similarly, corresponding dose of HCQ could have been administered resulting in
60 mg/kg of total compound. However, it was felt that any difference in efficacy could be a result
of a difference in tissue distribution due to a different DOS.
As controls, two different concentrations of HCQ were used, 2.4 and 4.8 mg/kg to compare 30
mg/kg of CQ-HES16% or CQ-HES8%. Surprisingly, CQ-HES8% performed similarly as well in
reducing primary tumor growth, while CQ-HES8% appeared to perform even better and
reducing/preventing liver metastases. Metastasis was measured in a bivariate manner, either
presence or absence. In this setting, it is unclear if the CQ-HES prevented tumor cells from escaping
the primary, prevented implantation of the liver by circulating cancer cells, reduced the number of
established tumor sites in the liver, or a combination of these. Given the design of the study and
small primary tumor sizes, it is likely the former could be the prevailing rationale behind low liver
metastasis.
Additionally, this tumor model lacks a key component of the human disease, TME interactions
centering upon infiltrative immune cells. In humans, infiltrative immune cells can substantially
impact growth and proliferation as outlined in Chapter 1. This xenograft model uses athymic mice
lacking immune cells capable of recapitulating this process. Additionally, dense stromal deposition
is another hurdle to drug delivery, and this model fails to reproduce this critical feature as well.
This may explain the significant reduction in primary tumor volume with just HCQ alone. Other
reports have illustrated marked tumor responses with HCQ as a single agent as well.238 Thus, this
model may overestimate the anticancer effects of drugs and a more suitable model to study drug
delivery and efficacy should be used like the orthotopic KPC model used in subsequent studies.
During this pilot study, the subacute toxicities from a multidose regimen were investigated. This
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assessment was largely subjective as there were little means to determine toxicities, i.e. no available
histology or instrumentation to evaluate blood samples. Overall though, morbidity was similar to
control mice with comparable tumor sizes, and it was concluded that the mice in the treatment
groups did not appear to incur any side effects above baseline. Furthermore, less mortality was
realized in the treatment groups, which was probably a reflection of the smaller tumor sizes and
mitigated liver involvement. So, CQ-HES was felt to be reasonably safe at five consecutive doses.
Of course this was speculative, and future studies would and did include assessment of blood
markers for liver and kidney dysfunction as well as histological tissue assessment of microscopic
damage. However, given the difference in outcomes between CQ-HES16% and CQ-HES8%, a full
PK evaluation of the effects of DOS on tissue distribution and tumor uptake was felt to be the more
appropriate next step so as to ensure the most optimal formulation would be selected for future in
vivo efficacy studies.
Pharmacokinetics
Because of the results from the pilot efficacy study, a range of CQ-HES was selected, 3-24%. From
Figure 6.1, it appears that a higher liver distribution is seen with the higher CQ-HES content
polymers, while all formulations appeared to have similar tumor uptake. Another way to
conceptualize what occurred is to transform the values into total CQ-HES in the tissues. In doing
so, the liver levels of total compound did not change much between the polymeric formulations
suggesting the distribution to the liver is largely due to the large size of HES (Figure 9.1).
Conversely, the lower doses appear to have substantially higher levels of total compound within
the tumor, although the total HCQ content is not different. This assumes what HCQ was in these
tissues was almost entirely polymeric formulation, which is an oversimplification but may be a
reasonable way to approximate tissue levels as long as the relative amount of polymeric versus total
HCQ was similar between formulations.

polymer in tissue (Left) compared to total HCQ levels presented in Figure 6.1 (Right).

Figure 9.1 – Levels of total polymeric formation in tumor and liver. The different polymeric formulations were reassessed for total
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HES is thought to be inert and not contribute to the anticancer activity of CQ-HES, whereas most
of the biological activity is derived from the actions of HCQ in CQ-HES. This may be a fair
assumption in vitro. However, HES possesses osmotic activity as it is a colloidal agent. Thus in
vivo, it may increase the capillary pressure shifting the osmotic gradient in tumors to facilitate drug
uptake. This becomes relevant in the setting of PC where dense stroma and hypoperfusion in tumors
reduce drug uptake, and increasing the osmotic capillary pressure make help to facilitate the
delivery of a co-administered chemotherapeutic. Thus, CQ-HES may further bolster the activity
when used in combination with something simply through a more passive process of increasing the
osmotic capillary pressure in tumors. So while HES may be an inert component in vitro, it may
have significant effects in vivo.
CQ-HES24% represented the highest content tested, but it proved difficult to dissolve. In moving
forward, this would not be an ideal drug candidate for an efficacy study because of this issue. Thus,
18% was chosen as the highest content to fully quantitate. Blood levels showed marked increase in
half-life. In evaluating the tissue distribution, CQ-HES18% appeared to highly preference the liver
and kidneys. Total levels did not change much over 72 hours in the liver suggesting reasonable
stability. Moreover, free levels at 6 hours were similar between free and polymeric formulations,
while at 72 hours, levels were almost non-existent compared to 33% between free and polymeric
formulations. This difference over the same time course suggests that CQ-HES18% is slowly being
degraded into free HCQ and HES. The sample of CQ-HES18% administered was later assessed
and was found to not be degraded but rather still present in the polymeric form. This data coupled
with the fact that levels are present at reasonable high at 6 hours post administration indicated that
a significant portion of CQ-HES may be degraded while circulating in the blood.
Because of the slow metabolism and clearance from normal tissue, i.e. liver and kidney, CQHES18% was perceived as high risk for the development of side effects when used in a multidose
study as levels would accumulate. Conversely, it was found that CQ-HES6% was cleared from
tissues much faster than CQ-HES18%. Additionally, lower DOS was thought to potentially be
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beneficial in helping to establish a more favorable pressure gradient in tumors, which would aid in
drug uptake. CQ-HES6% was further studied to assess how high and long tumor levels would
remain over 7 days. These studies described a rather quick clearance of CQ-HES6% from tumors.
However, the tumors grew substantially over the 7 days complicating the interpretations of the
results. Despite this complexity, levels within the tumors were much higher in the CQ-HES cohort
compared to HCQ. Levels of HCQ in the eye were lower for CQ-HES compared to administering
free HCQ, while both formulations showed relatively stable levels over 6 days.
Overall, these findings illustrate that CQ-HES alters the PK profile of HCQ, and although the
polymeric formulation does not result in higher HCQ levels compared to free drug, CQ-HES
persists in the tumor much longer and the effects on the osmotic pressure gradient may lead to
meaningful improvements when used in combination with a chemotherapeutic. Additionally, CQHES reduces eye exposure and may help to prevent retinopathy, one of the biggest issues with high
and prolonged dosing of HCQ.
In vivo Chemosensitization
CQ-HES displayed improvements in reducing primary tumor growth and improving survival. In
this experiment, an orthotopic syngeneic model of pancreatic cancer was used, and treatments were
initiated at day 7 for tumor growth studies and day 12, emulating later stage disease, for the survival
study. Mice who were administered gemcitabine alone displayed an approximate 30% reduction in
primary tumor growth but only a modest improvement in survival. The addition of CQ-HES6%
reduced tumor growth and prolonged survival by 30%. While this only appeared to be a modest
improvement, two things should be considered. First, the studies were performed in a very
aggressive model. The median survival was only 25-30 days, and the tumors displayed exponential
growth patterns rapid invasion and hematologic spread to the liver (data not shown). This is in stark
contrast to most other publications, where a less aggressive model is used and control groups often
live much longer. Second, the initiation of drug treatment was rather late in the disease course.
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Even in the tumor growth study, treatment was started at seven days at which point tumors were
established. This is in comparison to other studies which start drug treatment only a few days after
orthotopic implantation of cells. This was done intentionally as many pancreatic cancer patients
experience aggressive and drug-resistance disease. From a translative standpoint, this approach was
ideal, but in comparison to other results published in the literature, these improvements may appear
too modest to have translational potential.
CQ-HES may have some ability to increase intratumoral levels of gemcitabine due to increased
intracapillary pressure reducing the pressure gradient within the tumor. This may explain the
improvements in mice treated with the combination of CQ-HES over HCQ. To test this,
gemcitabine levels could be assessed. Similarly, the use of matrix-assisted laser desorption
ionization (MALDI) tandem mass spectrometry could be highly beneficial. Tumors were frozen,
and it was initially thought that MALDI-MS/MS was available to us through a collaborator. The
use of MALDI-MS/MS could have demonstrated the tumor penetration characteristics of CQ-HES
in comparison to free HCQ as well as any potential difference in intratumoral distribution of
gemcitabine. This is important as CQ-HES may facilitate gemcitabine penetration into tumors via
the pressure gradient mechanism described above. Additionally, CQ-HES could have impacted the
TME, which could have resulted in fewer tumor-associated immune cells or reduced desmoplasia
leading to a reduced penetrance barrier for drug delivery.
The use of MALDI-MS/MS on the tumor samples could have also expanded the understanding of
how CQ-HES was altering the intratumoral metabolism/clearance of HCQ. From the single
administration PK studies presented in Chapter 6, CQ-HES appeared to remain within the tumors
much longer. It is unclear how multiple administration may impact intratumoral levels of HCQ as
these samples are stored and still have neither been analyzed by MALDI-MS/MS nor LC-MS/MS.
Additionally, these bits of data could help explain how CQ-HES is eliciting tumor response despite
lower levels of overall HCQ distributing to the tumors. Does free HCQ penetrate into the tumor
further than CQ-HES because it is a small molecule? Does CQ-HES lead to much larger
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concentrations at the border of the tumor facilitating reduced growth via a difference in tumor
distribution? Does the multidose regimen of CQ-HES lead to cumulative tumor levels like in other
tissues? These are just a few questions that MALDI-MS/MS could answer, which would help
explain the improved tumor response of the CQ-HES combination over the combination with HCQ.
Additionally, metastasis was not assessed in these studies. It was concluded that assessing
cumulative drug levels and pathologic signs of toxicity were more important than inspecting the
tissue for signs of metastasis. Thus, a follow-up study looking at the ability of CQ-HES to impede
metastasis would be highly impactful, especially given the preliminary findings that CQ-HES
reduced liver metastasis in the xenograft model of PC. If this were to be explored, two studies
should be conducted due to the nature of CQ-HES. First, mice should be administered the drug then
given cells. This would test the ability of CQ-HES to prevent implantation of circulating cancer
cells into the liver. CQ-HES highly distributes to the liver where it is slowly cleared. Thus, the liver
may act as a reservoir for the drug and create an inhospitable niche preventing implantation. Thus,
PC patients could be given this drug early in the disease to prevent spread to the liver. Second, CQHES should be administered to mice harboring PC metastasis in the liver. This would illustrate if
CQ-HES has the potential to treat metastasis in the liver. Given the large distribution to the liver,
it is not unreasonable that CQ-HES may accumulative to high enough concentrations to be
tumoristatic or even tumoricidal. In both studies, a liver metastasis model should be used where
injection of the spleen leads to hepatic metastasis via hematogenous spread of the splenic vein. This
has been established in our lab, but due to time constraints, these studies were not performed.
Another beneficial study that could not be performed is assessing the impact of eye distribution on
functionality of the eye. High levels of HCQ or CQ-HES would undoubtedly lead to impaired
vision, but what acute and chronic levels would be required to precipitate injury to the retina? These
physiological function studies would help us understand at what level of each drug would start to
impart real damage. Additionally, this effect is often described as transient for HCQ. So further
assessment in the reversibility of eye dysfunction could be beneficial. Perhaps, vision is disturbed
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at a lower concentration with CQ-HES than with HCQ. Maybe the impairment in vision occurs at
a similar concentration as HCQ but the extent of impairment is greater with CQ-HES. Or the
changes in vision with CQ-HES last longer or are permanent compared to HCQ, which are transient
or nonexistent at a similar tissue concentration. These are toxicity effects that should be evaluated
but cannot with our current level of technology.
Ultimately, it was concluded that the combination with gemcitabine should be studied.
FOLFIRINOX is front line therapy, but performing this combination in a mouse model would be
impossible. Similarly, the toxicity profile is generally unfavorable, and adding CQ-HES may
further exacerbate side effects or death, precluding a meaningful efficacy assessment. Single agent
of FOLFIRINOX like oxaliplatin (OX) could have been performed. In fact, the combination of CQHES with OX showed substantial synergy (Figure 9.2). This was abandoned and not pursued due
to potential toxicity. OX and HCQ have been shown to cause substantial nephrotoxicity when
administered in combination. Given the PK findings from Chapter 6 showing high distribution to
the kidneys, a combination of OX with CQ-HES could be very nephrotoxic. However, the
polymeric formulation could also create a differential distribution in the kidney such that limited
toxicity may occur. So although CQ-HES was perceivably nephrotoxic, it may be altered the intrarenal distribution of HCQ leading to reduced toxicity. However, the combination was ultimately
never tested in vivo.
Another likely combination with CQ-HES was with Abraxane, a nanoformulated version of
paclitaxel (PTX). Abraxane with gemcitabine is the second line therapy for PC, and this would
have been a good drug combination as PTX disrupts cell division via stabilization of microtubules
leading to perturbations in mitotic spindle function and chromosomal segregation. Thus, the
combination of PTX and HCQ disrupting intracellular re-organization could have led to strong
synergism. However, Abraxane is expensive and given as a thirty-minute infusion, something that
was not feasible to perform in mice. Alternatively, the combination with a receptor tyrosine kinase
inhibitor might have also proved to be more synergistic as HCQ/CQ-HES could augment disruption
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in receptor signaling. However, these drugs are not readily given in the context of PC. So, it was
felt that the most translational approach would be to describe the added benefit of CQ-HES with a
drug that is commonly given clinically. Ultimately gemcitabine was selected because it has been
thoroughly studied in mice, and the efficacy and side effect profile is well-established. So although
it did not demonstrate synergism in vitro, it was the best translational option available to study in
vivo given our current technology.
Several lines of evidence showed that CQ-HES behaved similar to HCQ when administered in
vitro, and that combinations with gemcitabine were only additive. This is in contrast to the in vivo
finding demonstrating that CQ-HES was much better than HCQ. The combination of CQ-HES and
gemcitabine displayed higher reduction in primary tumor growth and had improved survival over
the combination with HCQ. This improvement was thought to arise from a difference in PKs. CQHES was cleared more slowly by tissue, and tissue levels appeared to accumulate more favorably
with CQ-HES. However, there are several studies that could be performed as described above, such
as MALDI-MS/MS, that could help elucidate the exact mechanism of how CQ-HES was imparting
a better anti-cancer activity. Regardless, the data presented herein illustrates the large discrepancy
that exists between findings at the in vitro and in vivo level of drug evaluations. These difference
may arise from our inability to predict how drugs will behave in the body and the alterations on
critical aspects of oncology like TME, which cannot be simulated in vitro or predicted a priori.
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Figure 9.2 – Cytotoxicity of CQ-HES in combination with OX. Cytotoxicity as assessed by

CTB in KPC 8060 cells for OX and the combinations with HCQ or CQ-HES.
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Radiosensitization
Typical methods to assess the effects of drug treatment include viability assays such as CTB or
MTT assays. These are quick, easy, and generally reproducible. However, these methods were not
ideal for studying the effects of RT (see Chapter 8 Discussion) as they preclude the assessment of
long-term effects of radiation treatments. This is of significant importance in radiation studies,
where delayed therapeutic effects occur as a result of instability in DNA and replicative error
leading to induced apoptosis. Thus, CSA was performed instead of viability assays. Using CSA,
the effects of RT on KPC 8060 cells were assessed, which found KPC 8060 cells to be highly
radioresistant compared to those from a collaborating group, who developed a radioresistant cell
line, KPC 961 (Figure 8.1). Even at 7 Gy, the effects of RT were only a 40% reduction, compared
to 80% in the radioresistant cell line KPC 961. Further studies using HCQ or CQ-HES as a
sensitizing agent demonstrated the ability of both compounds to sensitize KPC 8060 cells to the
effects of RT (Figure 8.2). Even at low doses, HCQ and CQ-HES were able to augment the effects
of RT, although this robust effect could be due in part to the low cell number in each replicate.
Thus, it was felt that KPC 8060 cells were ideal to study in the setting of stereotactic body radiation
therapy (SBRT), and 5 fractions of 7 Gy, the regimen used in humans, was an appropriate regimen
for SBRT.
Mice are too small to visualize a pancreas or even the smaller pancreatic tumors using CT,
especially with the less sensitive conebeam CT that is used prior to each SBRT treatment to align
the mouse and ensure radiation is only delivered to a tumor. So, two small clips were placed at
either end of the injected cell material. Before a large-scale study, a couple of small pilot studies (n
= 5 each) were performed to assess the use of clips as markers for tumors. It was found that the
clips remained on the pancreas and in proximity to the tumor at the conclusion of SBRT and at
necropsy (data not shown). During SBRT treatments, the clips shifted slightly, and in a couple
instances, the clips moved quite a bit. Additionally, there were concerns that the clips came lose
altogether. In both small pilot studies, all clips remained in place, and this was not an issue. In the
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efficacy study, a substantial deviation in clip placement was also noted to have occurred a couple
times. Using the 6DOF table, mice were re-aligned accordingly, and it was felt that treatment to
the planned area was given accurately. The shifting of the clips could have led to inaccurate SBRT
treatments and may explain some variability within or between groups. Necropsy on each mouse
revealed that all clips remained intact and in their original placement. So despite what appeared to
be substantial shifting as seen on conebeam CT, this could be a result of simple internal organ
shifting. However, this still may have impacted the dose to the cancerous mass. Future studies
involving SBRT should be aware of this issue, necropsy should be performed to confirm that clips
have remained in their proper location, and perhaps a method developed to reduce clip movement
altogether.
Because clips were placed in the pancreas and adjacent to tumors, there may be concern that the
clips could induce a degree of added toxicity. While this is a reasonable concern, a comparison of
the survival between the no treatment group presented in Chapter 7, where no clips were used, and
the no treatment group in this present study, where clips were used, showed almost identical
survival curves (Supporting Information – Figure 8S2). Thus, it was concluded that the clips
induced no substantial toxicity that led to altered survival outcomes. Additionally, the similarities
between control group survivals reaffirmed the reproducibility of the model used. Because we
administered radiation, the clips could have caused differences in radiation exposure to adjacent
areas. In doing so, a slightly different dose to a tumor could have occurred. Given that the pancreas
cannot be visualized without the use of clips, there is no way to circumvent this issue, and this is a
limitation of the model.
In assessing survival outcomes within this study, two potential sources of concern were observed.
First, the SBRT only group was very similar to the no treatment, control group. Given that SBRT
had little to no impact as well, the implementation of SBRT was either too late and the cancer
spread and/or the cancer spread despite treatment with SBRT. In vitro showed a highly
radioresistant phenotype with 7 Gy reducing colony count by 40%. This was performed on only
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200 cells and in culture. Conversely, tumors consisted of hundreds of thousands of cells in a
complex TME with other cell types and a continuous supply of nutrients. Thus, the complexity of
a tumor cannot be recapitulated ex vivo using cell culture. So the inherent resistance could be a
result of the model used. Conversely, primary tumors were initially halted in their growth
immediately following SBRT, regardless of HCQ or CQ-HES sensitization. After varying amounts
of time, some tumors began to regrow in size. When this occurred, mice died shortly thereafter.
Sensitization with CQ-HES appeared to delay the recurrence of primary tumor growth compared
to the other treatment groups. However, the cancer ultimately invaded into the small bowel and/or
biliary tract lead to bowel obstruction or liver failure, respectively. Data from Chapter 3 illustrated
that CQ-HES is a potent inhibitor of PC migration and invasion. This, coupled with the ability to
sensitize PC cells to RT, might explain the survival benefit observed in mice given the combination
treatment as delayed invasion of the bowel and/or bile duct would have led to prolonged survival.
Additionally, the TME plays a substantial role in tumor progression, and RT is highly dependent
upon immune cell response. Thus, HCQ therapy could actually be a hindrance to RT therapy, which
may explain the slightly worse outcomes with the combination of SBRT and HCQ. This complexity
may even be variable between mice and on an individual basis. In short, sensitization with HCQ
may augment the initial effects of RT, but the alterations to immune response may be detrimental
in the long run. Thus, free HCQ therapy may not be ideal in this setting even though it may improve
initial response.
One may also comment that the tumors at the initiation of SBRT treatments were larger than a 2
mm radial expansion around the clips. Thus, not all the tumor was treated by SBRT and could
explain the continued invasion of localized structures and lack of survival difference between
control and the SBRT only group. Given the findings from the pilot study, this was thought not to
be an issue and 2 mm radial expansion was sufficient. Additionally, delaying treatment until 7 days
could allow for more advanced and established disease, or even disease that has spread beyond the
pancreas. This could also help to explain the lack of efficacy with SBRT. Repeating these studies
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but performing treatment early could answer this question. However, this would be difficult for a
number of reasons. First, wounds needed ample time to heal prior to SBRT to ensure treatment was
delivered to only the tumor. Skin wounds would change the shape of the mouse during therapy
which could have impacted the integrity of treatment. Additionally, SBRT required one day of
imaging to plan the SBRT treatments. Thus, treating earlier could have only occurred by one to two
additional days due to these limitations.
Additionally, it was very difficult to plan SBRT treatments. Because this was the instrument used
for patients, treatment on mice occurred at night after all patients were treated. Since six days were
required (one for planning and five for the actual treatments), this took extensive planning to
coordinate times when the SBRT instrument was available, when the radiation oncologist was
available, when two medical physicists were available, when treatment of mice could occur, etc. In
short, there were several logistical constraints in performing such a large experiment. Given the
outcomes, a shorter study involving only two SBRT treatments could be reasonable since the
response to SBRT in mice sensitize with CQ-HES was much more profound than the other groups.
Reducing the number of treatments needed to attain a similar response to SBRT could be a
promising approach to the translation of CQ-HES to the clinical setting. Gemcitabine is also a
radiosensitizing agent, and the combined effects of CQ-HES and gemcitabine led to dramatic
improvements (see Chapter 7). Thus, testing the effects of gemcitabine with and without CQ-HES
for sensitization of SBRT could be a promising study.
Overall, sensitization with CQ-HES delayed primary tumor regrowth and prolonged survival.
Given the safe nature of CQ-HES (see Chapter 6 & 7) and the highly aggressive and resistant nature
of the PC cells this polymeric formulation was tested on, CQ-HES improves the effects of RT.
Concluding Remarks
By using simple CDI chemistry, we have created a polymeric formulation of HCQ (CQ-HES) using
the safe and FDA approved material HES. CQ-HES demonstrated similar in vitro biological
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activity as HCQ, specifically the inhibition of autophagy. However, the effects of CQ-HES on
cellular behaviors such as invasion and migration were much more pronounced. When assessing
its in vivo properties using a highly aggressive and resistant cell line, KPC 8060, CQ-HES showed
the ability to improve the anticancer effects of gemcitabine and SBRT, reducing primary tumor
growth as well as prolonging survival. This may be a result of the altered PK profile of CQ-HES,
which is cleared more slowly from tumor tissue. Moreover, CQ-HES reduced exposure to the eyes,
one major concern when using HCQ-based therapies, and multiple administrations did not result in
any organ dysfunction or microscopic indications of tissue toxicity. What still remains to be
determined is if differing the DOS results in different PK profiles, how dose affects response (i.e.
if giving more CQ-HES produces a higher tumor response/reduces metastatic spread), if giving
earlier in tumorigenesis is beneficial for combination therapy with a chemotherapeutic or with
SBRT, or if there are any unobserved, masked, or long-term toxicities with CQ-HES. The work
presented herein aimed to comprehensively evaluate the polymeric formulation, but ultimately
some questions remain unanswered. Overall, CQ-HES appears safe, effective in augmenting the
effects of chemotherapeutics and radiation, and is a reasonable drug candidate for further evaluation
in the treatment of PC.
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